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The immune system 
The immune system is a complex cascade of cellular and protein interactions that 
protects the individual against pathogens. It consists of different types of cells, tissues 
and molecules that mediate the immune response. The first non-specific line of 
defence is provided by the innate immune system which includes the epithelial barrier, 
cells that phagocytize such as neutrophils and macrophages, dendritic cells that 
capture and present antigens, cells that release inflammatory mediators such as mast 
cells and natural killer cells1,2. The molecules that are involved in this early immune 
response are cytokines and plasma proteins such as complement factors and acute-
phase proteins3. The innate immune response also stimulates the second line of 
defence, the antigen-specific acquired or adaptive immune response4,5. Adaptive 
immune responses are initiated when antigen-receptors on lymphocytes recognize 
antigen. T-lymphocytes mediate cellular immunity and B-lymphocytes mediate 
humoral or antibody-mediated immunity. The adaptive immune system has an 
immunological memory, which implicates that the response to a recurrent infection by 
the same antigen can be more vigorously.   
Cellular immunity 
T-lymphocytes are triggered by antigens produced by intracellular microbes. The T-cell 
receptor (TCR) on T-lymphocytes recognizes MHC associated peptide antigens 
presented by antigen-presenting cells (APCs)6. Co-stimulatory signals are needed to 
establish stable TCR-APC contact. CD4 and CD8 co-receptors recognize the MHC, 
adhesion molecules strengthen the binding and co-stimulators recognize secondary 
signals provided by the APC. When these secondary signals are not present this will 
lead to a state of anergy or tolerance7. In response to antigen and co-stimulators, 
T-lymphocytes secrete cytokines such as IL2 which stimulate the T-cell to proliferate 
and differentiate into effector T-cells. CD4-positive (+) T-cells differentiate into 
T-helper cells that activate phagocytic cells and stimulate B-lymphocytes8. CD8+ T-cells 
differentiate into cytotoxic T-cells that are able to kill infected cells9. At the same time, 
some T-lymphocytes become memory cells that remain inactive until re-exposure to 
the antigen10.  
Humoral immunity 
B-lymphocytes and antibody production 
B-lymphocytes have membrane bound antibodies on their surface that act as B-cell 
receptors (BCR) for extracellular antigens11. The immature B-cell (B1) expresses IgM as 
BCR and produces natural IgM antibodies; the antibodies are poly-reactive and 
recognize carbohydrate antigens of bacterial origin and auto-antigens. In most cases, 
these natural antibodies have a relative low affinity. Mature but naive B-cells (B2) co-
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express IgM and IgD antibodies as BCR. These antibodies recognize and bind antigens 
of protein, carbohydrate or lipid origin. Similar as for the TCR, secondary signals are 
needed, the IgM and IgD receptors only recognize the antigen, the signal transduction 
to the B-cell is provided by two non-covalently attached proteins, Igα and Igβ. B-cells 
also have a receptor for a complement protein on their surface that provides the 
activation signal. Upon activation by antigen, they proliferate in a process called clonal 
expansion and differentiate into effector plasma cells. When the activating antigen is a 
protein, B-cells interact with T-helper cells through their CD86 co-stimulatory 
molecules that subsequently stimulate B-cell proliferation and differentiation12. Plasma 
cells actively secrete IgM and IgD antibodies. During differentiation, a process called 
heavy chain isotype or class switching takes place, which means that some B-cells start 
to produce antibodies of a different class that mediate other effector functions13. 
Repeated exposure to the same antigen promotes the affinity and amount of the 
antibodies produced. A fraction of B2-cells do not differentiate into antibody secreting 
plasma cells but become B-memory cells that use IgG, IgA or IgE as BCR and are able to 
respond rapidly when the antigen is encountered again14.  
Antibody structure 
Antibodies consist of four polypeptide chains, two heavy chains and two light chains 
that are held together by disulfide bonds. Each chain has a variable N terminal (V) and 
a constant C terminal (C). The V regions of the light and heavy chain form the two 
antigen-binding arms (Fab2) that attach antigen through three hypervariable 
complementarity-determining regions15. The C regions of the heavy chain form the Fc 
region which specifies the immunoglobuline (Ig) class and subclass. There are five Ig 
isotypes or classes: IgA, IgD, IgE, IgG and IgM, four subclasses of IgG and two 
subclasses of IgA. These classes and subclasses differ in physical appearance and 
function16. IgD, IgE and IgG are bivalent monomeric units, IgA is a tetravalent dimer 
and IgM is a decavalent pentamer. Each type of antibody can be produced as a free 
circulating molecule or as a membrane-bound BCR17. 
Antibody function 
IgA that is secreted into the gastrointestinal and respiratory tract neutralizes microbes 
and their toxins. IgD and IgM are the BCR of naieve B-lymphocytes. IgE defends the 
body against parasites and activates mast cells to provoke immediate hypersensitivity 
reactions. IgM, IgG1 and IgG3 can activate complement through the classical pathway, 
which initiates a cascade of events ultimately leading to the formation of a membrane-
attack complex that lyses infected cells. IgG neutralizes microbes and their toxins, it 
coats microbes to promote their ingestion by phagocytes in a process called 
opsonization, it also binds to infected cells which allows NK cells to kill them through 
antibody-dependent cellular cytotoxicity. Furthermore, IgG is involved in neonatal 
immunity and feedback inhibition of B-cell activation18.    
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Human Leukocyte Antigen (HLA) system 
The Human Leukocyte Antigen (HLA) complex is part of the Major Histocompatibility 
Complex (MHC) and was first described in the 1950’s. It was demonstrated that blood 
transfusions and pregnancies can induce the production of antibodies that reacted 
with HLA antigens present on human leukocytes19-21. It is now known that these HLA 
molecules are involved in the recognition and presentation of self and foreign 
antigens22. In clinical transplantation, they play an important role in the allo-immune 
response leading to graft acceptance or graft rejection23. The HLA complex is located 
on the short arm of chromosome 6 (6p21)24 and represents the most polymorphic 
genes of the human genome. The HLA genes involved in the immune response are 
divided into HLA class I and class II genes based on structure, expression and function 
of the molecules they encode. The class III genes are not related to the class I and II 
genes structurally or functionally, they encode complement factors, heat shock 
proteins and tumor necrosis factor (Figure 1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Localisation of the HLA complex on chromosome 6. 
 The HLA complex is located on the short arm of chromosome 6 (6p21)24 and represents the 
most polymorphic genes of the human genome. The HLA genes involved in the immune 
response are divided into HLA class I and class II genes based on structure, expression and 
function of the molecules they encode. 
HLA molecules 
HLA class I molecules are encoded by the HLA class I genes, HLA-A, -B and –C. They are 
expressed on all nucleated cells and on platelets. Class I molecules consist of two 
polypeptide chains, a membrane-anchored HLA chain and a non-covalently associated 
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chain, β2–microglobulin (β2m). β2m is encoded by a non-polymorphic gene located on 
chromosome 15 and it is required for the formation of a stable class I complex. The 
HLA chain is composed of three polymorphic extracellular domains, α1, α2 and α3, 
which form the peptide binding groove25 (Figure 1.2). HLA class I molecules present 
endogenously synthesized proteins, mostly of viral origin and self proteins, to cytotoxic 
CD8+ T-cells26. The latest WHO nomenclature update described 1001 HLA-A alleles, 
1605 HLA-B alleles, 690 HLA-C alleles27, (http://www.ebi.ac.uk/imgt/hla/allele.html, 
release 3.0.0 April 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Class I molecule. 
 Class I molecules consist of two polypeptide chains, the membrane-anchored HLA chain and 
a non-covalently associated chain, β2–microglobulin (β2m). The HLA chain is composed of 
three polymorphic extracellular domains, α1, α2 and α3, which form the peptide binding 
groove. 
 
HLA class II molecules are the products of the HLA class II genes, HLA-DR, -DQ and –DP. 
They are present on the cell surface of professional antigen-presenting cells, like 
B-lymphocytes, macrophages, dendritic cells and activated T- lymphocytes. They can 
be upregulated on endothelial cells and renal tubular cells in the presence of stress-
induced cytokines. Class II molecules consist of two non-covalently bound 
transmembrane chains, the α- and β-chain. Both chains have two extracellular 
immunoglobulin-like domains, α1 and α2 for the α-chain and β1 and β2 for the 
β-chain. The peptide binding groove is formed by the highly polymorphic α1 and β1 
domains28 (Figure 1.3). HLA class II molecules present extracellular proteins to CD4+ 
T-helper cells.  
 
The physiological function of the HLA molecule is to present self and foreign peptides 
to lymphocytes and therefore HLA molecules play an important role in the distinction 
between self and non-self and the proper functioning of the immune system. HLA 
molecules are highly polymorphic, this means that many different gene variants of 
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each locus are present in the human population. This is illustrated by the number of 
alleles identified for each locus: 878 HLA-DR alleles, 35 HLA-DQA alleles, 108 HLA-DQB 
alleles, 28 HLA-DPA alleles and 138 HLA-DPB alleles27 (http://www.ebi.ac.uk/imgt/hla/ 
allele.html, release 3.0.0 April 2010). The most polymorphic residues of the HLA 
molecules are found in or around the peptide binding groove. This polymorphism 
provides diversity in peptide binding specificity and antigen presentation necessary to 
overcome infections caused by bacteria, viruses, fungi and parasites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Class II molecule. 
 Class II molecules consist of two non-covalently bound transmembrane chains, the α- and β-
chain. Both chains have two extracellular immunoglobulin-like domains, α1 and α2 for the α-
chain and β1 and β2 for the β-chain. The peptide binding groove is formed by the highly 
polymorphic α1 and β1 domains. 
Typing for HLA 
HLA antigens have been defined by serological methods based on complement-
dependent cytotoxicity (CDC) since 50 years. A variant known as the NIH 
microlymphocytotoxitity test was developed and standardised by Terasaki. It has been 
widely used for HLA typing in clinical transplantation29. Serological typing 
demonstrates the expressed molecule on the cell surface. In the CDC typing assay 
lymphocytes and antisera of known HLA specificity are incubated. Rabbit complement 
is then added and activated by the binding of HLA specific antibodies to the surface 
HLA antigens. As a result, a membrane attack complex is formed that lyses the cell 
membrane which becomes permeable. When a dye is added thereafter, it penetrates 
the membrane of the lysed cells, which can now be discriminated from living cells. 
Although used for many years, the CDC assay has some distinct disadvantages such as 
labour intensiveness, requirement of viable cells and the lack of available monospecific 
alloantisera or monoclonal antibodies.  
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In the 1980’s, molecular cloning made the identification of gene structures possible. 
Together with the introduction of the polymerase chain reaction (PCR), this lead to the 
development of a variety of DNA based typing methods that enable detection of the 
HLA polymorphism at the genetic level. Several molecular methods were developed to 
type the HLA genes. The most commonly used techniques are based on PCR: Sequence 
specific primers (SSP), Sequence specific oligonucleotide probes (SSOP) and Sequence 
based typing (SBT). In the PCR-SSP method, the target DNA is amplified with primers 
specific for alleles or groups of alleles. For the PCR-SSOP method, the HLA gene to be 
typed is amplified and hybridized with probes specific for alleles or allele groups. The 
SBT technique is based on direct DNA sequencing to determine the nucleotide 
sequence  of the HLA alleles present. It detects all polymorphism in the sequenced part 
of the gene and therefore enables high resolution typing and identification of new 
alleles. A more detailed description of these techniques is given in30.   
HLA antibodies 
HLA antibodies do not occur naturally. They are produced after contact with foreign 
HLA antigens. Antibody formation is initiated by the uptake and processing of foreign 
antigen by antigen-presenting cells that present it to the CD4+ T cell. At the same time, 
antigen specific B2-cells recognize, bind, internalize and process these antigens 
through their BCR. Clonal expansion of B-cells is induced when a co-stimulatory signal 
is present. As a result B-cells will differentiate, secrete IgG and memory B-cells will be 
developed7. The antigenic stimuli leading to HLA antibody formation in recipients are 
pregnancy21, blood transfusion19,31 and previous transplants32. Recently it has become 
clear that they sometimes arise  in response to HLA-unrelated immune stimulation33,34 
and that their response is increased by stimuli such as infection35,36 or even 
vaccination37. 
 
In about 25 percent of pregnancies, women develop antibodies against paternal 
antigens present on the foetal cells that enter the maternal circulation38,39. The 
frequency of sensitization increases with the number of pregnancies38. The level of 
immunization may decrease over time, but can also increase and may acquire a wider 
spectrum after a new antigenic challenge such as blood transfusion or renal 
transplantation40.  
 
Before the introduction of erythropoietin, blood transfusions were frequently given to 
patients with end-stage renal disease. In the past, they were also given to reduce the 
allo-immune response to the prospective graft41. Before the introduction of 
calcineurine inhibitors (CNI) as immunosuppressive agent, several studies showed that 
untransfused patients underwent more rejection episodes and presented with worse 
graft survival than transfused recipients42,43. Clinical studies showed that previously 
undetected historical anti-HLA antibodies from pregnancies may reappear after blood 
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transfusion44. Since the introduction of CNI however, the beneficial effect of pre-
transplant blood transfusions has become less clear and transfusions are also 
associated with primary sensitization45. Today in the Netherlands, after the results of a 
multicenter study demonstrated that donor-specific transfusions induce primary 
sensitization and have no beneficial effect on transplant outcome, donor-specific 
transfusions to induce tolerance and transfusions given with the intention to detect 
historical sensitization, are no longer in practice46.  
 
The part of the HLA molecule that is recognized by the antibody is called epitope or 
determinant47. Epitopes or determinants can be “public” which means they are shared 
between HLA alleles, or “private” if they are specific for a certain allele48-50. HLA 
antigens have multiple epitopes that can be recognized by specific antibodies. 
Originally, epitopes were described on the basis of serological cross-reactivity, i.e. 
antibodies produced against one particular antigen may bind to other structurally 
similar antigens. Today, it has been shown that these epitopes correspond to distinct 
amino acid sequences in the HLA molecules. Epitopes may be recognized based on 
linear amino acid sequence or based on conformational shapes. Terasaki et al. have 
empirically identified 103 class I and 83 class II epitopes defined by polymorphic amino 
acid residues using extensive analyses of antibody reactivity patterns51-55. Duquesnoy’s 
HLAMatchmaker-strategy of determining HLA epitopes is based on antibody-antigen 
complexes. An eplet, i.e. a conformational epitope has a so-called patch of highly 
energetic residues that determine the strength and specificity of the antibody 
binding56-61. Information about the HLA type of the antibody producer and the 
immunizing antigen permits the distinction between self and non-self amino acid 
residues. Each eplet has at least one non-self residue, on the molecular surface. 
Recently, the correlation between Terasaki’s epitopes and HLAMatchmaker-defined 
eplets has been extensively studied and described62. About 90 percent of Terasaki’s 
epitopes correspond to HLA Matchmaker-defined eplets.  
HLA and transplantation 
Renal transplantation remains the preferred treatment for suitable patients with end-
stage renal disease. Organ replacement is preferred over dialysis because it provides 
patients with a higher quality of life63,64 and is associated with lower mortality 
rates65,66. In 2009, 811 patients received a kidney from a living (417) or a deceased 
(394) donor in the Netherlands67.  
 
The relevance of bloodgroup ABO compatibility in renal transplantation had already 
been recognized by the early 1960’s. Another system, the MHC, was discovered and 
shown to be important in renal transplantation. The first renal transplantation with 
long-term success (graft and patient survival >1 year) was performed in 1954 by 
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Murray68. The donor was the monozygotic twin brother of the recipient. By then, it 
was known that tissues were freely interchangeable between identical twins. Attempts 
to use unrelated or deceased donors were usually unsuccessful because the allografts 
were recognised as foreign by the recipient´s immune system and were rejected. This 
situation stimulated the search for immunosuppressive therapy69-71. The introduction 
of immunosuppressive reagents made it possible to transplant patients with a donor 
other than a monozygotic twin72,73. However, rejection rates remained high and side 
effects of the immunosuppression such as nephrotoxicity, infections, metabolic 
disorders and cancer, were observed frequently. Further improvement in transplant 
outcome had to be found in immunological selection of the recipient-donor pairs.  
 
In transplantation, the recognition of the donor’s HLA molecules by the recipient’s 
immune system generates a strong response that is a barrier to successful 
transplantation74,75. When a patient receives a renal transplant from a genetically 
different individual, his immune system comes into contact with foreign HLA antigens 
present on the donor cells. The subsequent immune response, allorecognition, may 
cause rejection of the transplant76. Presentation of the donor’s HLA antigens can take 
place through two distinctive pathways: direct and indirect allorecognition. In the 
direct pathway, T-cells recognise intact allo-HLA on the surface of donor antigen-
presenting cells. In the indirect pathway, donor-HLA is shed from the graft, which is 
then processed into allo-peptides presented by the recipients own antigen-presenting 
cells77,78. These two pathways are not sufficient for full activation of the recipient’s 
immune system. A co-stimulatory signal is needed for stabilisation of the cell-cell 
contact. When this secondary signal is absent this will lead to a state of anergy or 
tolerance. The effector mechanisms in transplant rejection and the co-stimulatory 
signals have been reviewed by Rocha et al.7. 
Transplant rejection  
Recognition of donor-HLA by T-cells and antibodies can lead to graft rejection79-81. 
Rejection is suspected when there is a decrease in renal function. Needle core biopsy is 
needed to confirm clinical rejection. Based on time of occurrence, not on mechanism, 
different types of rejection can be discriminated: hyperacute, acute and chronic 
rejection. Preformed HLA antibodies are deleterious to the renal graft82,83. Antibodies 
produced de novo after renal transplantation are a risk factor for acute and chronic 
rejection84,85.  
 
Preformed donor-specific HLA antibodies cause hyperacute rejection by binding to 
blood vessels and activating the complement system which initiates a cascade of 
events leading to coagulation of platelets and immediate circulation blockage and loss 
of graft function within minutes to hours after reperfusion. Hyperacute rejection is 
observed in up to 80% of the kidneys transplanted into recipients with preformed 
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donor-specific HLA antibodies detected in the complement-dependent cytotoxicity 
crossmatch82,86. 
 
Acute rejection can occur at any time after transplantation, ranging from days to years. 
It is most commonly seen within the first three to six months after transplantation. For 
several decades, T-cells have been regarded to be the central regulatory and effector 
cells in acute rejection. Consequently, most current immunosuppressive therapies 
generally target T-cell function. Despite the use of these drugs, episodes of acute 
rejection can still occur. Recent evidence shows that circulating antibodies and 
complement deposition are involved in a substantial proportion of these remaining 
rejection episodes, particularly in those that involve total graft failure87-89. The binding 
of anti-donor antibodies to the endothelium of the graft activates complement, which 
triggers the recruitement of cellular infiltrates, neutrophils and macrophages in the 
capillaries. In 1991, transplant clinicians, pathologists, surgeons, immunologists and 
researchers first participated in a consensus meeting on renal allograft pathology in 
order to standardize the histological definition of different types of rejection, held in 
Banff, Canada. Originally, Banff type I acute rejection was defined as a manifestation of 
cell-mediated immunity, type III as strongly suggestive of an antibody-mediated 
process and Banff type II as a mixture of both cell- and antibody-mediated immunity. 
Based on the anatomical target of the immune reaction rejection was subclassified into 
two major categories: tubular/interstitial rejection and vascular rejection. This so-
called Banff classification is regularly updated and redefined on the basis of new 
developments and evaluation studies, the last update took place in 2009, with special 
attention to diagnostic markers for antibody-mediated rejection such as circulating 
donor-specific antibody and C4d staining90,91. Antibody-mediated acute rejection, also 
known as humoral or acute vascular rejection, is often resistant to therapy with 
steroids or T-cell specific drugs92. Both cellular and antibody-mediated acute rejection 
episodes are more frequent in sensitized patients than in patients without circulating 
antibodies93.   
 
Chronic rejection or chronic allograft nephropathy, more than any other condition, 
limits the long-term success of renal transplantation. It occurs in a later stage after 
transplantation and is caused by a number of processes, particularly by repeated 
inflammation and injury from both immunological and non-immune-mediated 
reactions. The non-immunological causes for deteriorated graft function and graft loss 
like drug toxicity, ischemia and aging are extensively reviewed elsewhere94. Chronic 
rejection is histopathologically characterized by obliterative vasculopathy, infiltration 
of leukocytes and luminal occlusion of the arteries95. As mentioned earlier, the chronic 
immune injury is believed to be caused by indirect presentation of allogeneic peptides 
by recipient antigen-presenting cells. Many studies on the role of HLA antibody in 
chronic rejection have been published, albeit without consensus on the frequency. 
According to Terasaki, up to 60% of chronic rejections are supposed to be caused by 
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donor-specific HLA antibodies96. Piazza et al. found that circulating donor-specific 
HLA antibodies correlate strongly with chronic rejection97. Lee et al. described that de 
novo anti-HLA antibodies are always present before the loss of a graft from chronic 
rejection98. Whether (donor-specific) antibodies actually cause chronic rejection or 
reflect a response to a damaged graft caused by other factors has yet to be 
determined.  
HLA matching 
Allogeneic donor-HLA can stimulate B cells to produce alloantibodies, which are 
involved in the humoral immune responses against grafts, therefore the degree of 
HLA matching between donor and recipient greatly influences transplant outcome99. 
Only grafts from monozygotic twins are successful without immunosuppression. Zero 
mismatched transplants have a superior outcome than grafts with one or more 
HLA mismatches (Figure 1.4)100-102.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The influence of HLA matching on graft survival within eurotransplant. 
Allogeneic donor-HLA can stimulate B cells to produce alloantibodies, which are involved in 
the humoral immune responses against grafts, therefore the degree of HLA matching 
between donor and recipient greatly influences transplant outcome99. Only grafts from 
monozygotic twins are successful without immunosuppression. Zero mismatched transplants 
have a superior outcome than grafts with one or more HLA mismatches 
 
 
Due to the extreme polymorphism of the HLA system, it is not feasible to find an 
HLA identical donor for all renal transplant recipients. To increase the donorpool and 
therefore the chance of providing recipients with a suitable donor, Eurotransplant was 
founded, the first organ exchange organisation in the world. Since then many other 
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organisations e.g. Scandiatransplant, France-transplant, UK transplant and UNOS have 
been founded. Today, 7 countries allocate their organs through Eurotransplant on the 
basis of several parameters that generate transplantation points, such as degree of 
HLA match, waiting time, cold ischemia time, and match prognostic index which means 
that sensitized patients and patients with rare HLA phenotypes receive extra points103. 
 
The effect of HLA class I and II mismatches varies over time after transplantation. 
According to Thorogood et al., the effect of an HLA-DR mismatch is strongest in the 
first five months following transplantation and therefore is associated with increased 
risk of acute rejection and early graft loss, whereas HLA-A and HLA-B mismatches are 
associated with later graft loss104.  
Traditionally, the degree of HLA compatibility between recipient and donor is 
determined by counting the number of mismatched HLA-A, -B and –DR antigens of the 
donor. Another way to asses compatibility is structurally based HLA matching. Based 
on this concept, Duquesnoy56,58,105,106 created HLA Matchmaker, a matching algorithm 
that views each HLA antigen as a string of short linear sequences (triplets) involving 
amino acid residues in antibody-accessible positions. These triplets are considered the 
key elements of epitopes that can induce the formation of specific antibodies. These 
epitopes have two distinct characteristics, namely antigenicity, its reactivity with 
antibody, and immunogenicity, its ability to induce an antibody response107. The 
immunogenicity of an epitope depends on the structural difference between the 
immunizing protein and the antibody responder’s homologous proteins. It has been 
shown that the effect of HLA matching on transplant success varies depending on 
donor and recipient risk factors. In the USA especially, many clinicians even argue that 
current immunosuppressive regimens obviate the benefits of HLA matching, therefore 
HLA-A and –B matching has been eliminated from the UNOS allocation algorithm. 
Many organizations still find a high correlation between the degree of matching and 
sensitization particularly after previous graft failure107. Therefore a poor HLA match 
decreases the chance of finding a second crossmatch-negative donor, prolonging 
waiting times for retransplantation108. In our center, minimal matching requirements 
are set at 1B and 1DR or 2 DR match between donor and recipient. For living donation, 
matching is less stringent, because of the superior quality of the donor kidney, and 
patients can be transplanted pre-emptive109-111. But even in the case of a living donor, 
well matched transplants have superior outcome.  
Crossmatching 
In 1969 the clinical relevance of preformed cytotoxic antibodies directed against donor 
lymphocytes was first demonstrated by Patel and Terasaki82. In their landmark study, 
using the complement-dependent cytotoxicity crossmatch (CDCXm) 80% of recipients 
transplanted with a positive CDCXm lost their graft due to hyperacute rejection, 
whereas less than 5% of recipients with a negative CDCXm had a bad outcome. Since 
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then, the CDCXm, with and without DTT to abolish IgM antibodies, has been routinely 
used to detect preformed donor-specific antibodies and hyperacute rejection has 
become a rare event in renal transplantation. Within Eurotransplant, the CDCXm is the 
mandatory crossmatch assay, being the only one generally accepted to be clinically 
relevant. The fact that in Patel’s study, 20% of the recipients with a positive CDCXm 
had an uneventful post-transplant course and 5% of recipienst with a negative CDCXm 
experienced early graft loss, suggests that the CDCXm is limited in specificity and 
sensitivity. In order to increase the sensitivity, variations of the standard CDCXm have 
been used, such as the addition of antiglobulin and wash steps, prolongation of 
incubation time and modification of incubation temperature. In 1983, the flow 
cytometry crossmatch (FCXm) was introduced as a more sensitive method for the 
detection of preformed donor-specific HLA antibodies in renal transplant recipients112. 
The main advantages of this method are increased sensitivity, differentiation between 
cell types and detection of non-complement-binding antibodies. Many groups 
reported a higher sensitivity in detecting clinically relevant antibodies, and therefore 
the FCXm was adopted as the standard crossmatch assay in many transplant centres in 
the UK and US. In our centre, FCXm was not found to be superior to the standard 
CDCXm with regard to clinical outcome113. In fact, transplantation with a mandatory 
negative FCXm would have excluded 28% of the recipients who are presently doing 
well after transplantation. T- and B-lymphocytes carry many different antigens on their 
surface, which can bind clinically irrelevant antibodies leading to false positive results. 
Solid-phase crossmatches that make use of soluble donor-HLA antigens coated to 
plates have also been investigated114-117. These crossmatches have never been used in 
clinical practice because of technical problems. The clinical relevance of crossmatching 
techniques with higher sensitivity than the standard CDC crossmatch is still subject of 
debate. In 2007, a bead-based solid-phase crossmatch was introduced. The technique 
and its clinical relevance are described in this thesis.  
Screening for HLA antibodies 
There is abundant evidence that preformed HLA antibodies have a deleterious effect 
on renal graft outcome as reflected by increased rejection rates and lower graft 
survival in sensitized recipients118. To prevent positive pretransplant crossmatches, all 
sera from recipients on the waiting list are tested for the presence and specificity of 
HLA antibodies. The specificities detected in the serum are then listed as non-
acceptable mismatches (NAM). Anti-HLA antibodies are a product of the adaptive 
immune system which means that they can vary in quality and quantity over time. 
Therefore recipient serum is tested every three months and after every sensitizing 
event such as blood transfusion or previous transplant. The degree of sensitization is 
traditionally defined as percentage of panel reactive antibody (PRA). The traditional 
definition of PRA is based on the percentage of positive cells of the cell panel used for 
antibody detection. Patients with a PRA over 5% are called sensitized, those with a PRA 
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that exceeds 85% highly sensitized. The PRA should ideally be an index of the chance 
to find a suitable donor with whom the recipient will have a negative crossmatch. 
Therefore, PRA is better based on the exact antibody specificities detected in the 
serum combined with the frequency of those antigens in the donor population. The 
PRA thus calculated is called the virtual PRA and its use is currently more 
promoted119,120.  
 
Most of the HLA antibodies detected in the serum of renal patients are complement-
binding IgG (IgG1 and IgG3) antibodies. They have been proven clinically relevant and 
deleterious to the graft. However, IgG2 and IgG4 HLA antibodies are found in up to 
50% of patients with previous failed grafts121. The clinical relevance of these non-
complement-binding antibodies is still unresolved, mainly due to the fact that they are 
not detected using standard antibody detection techniques122. IgM antibodies are 
usually irrelevant natural or auto-antibodies, but can also be directed against HLA. A 
recent study showed that 17% of retransplant candidates have IgM antibodies against 
HLA and that in 88% of cases these are directed against donor-HLA antigens123. The 
effect of the IgM antibodies is still a matter of debate, some authors believe they have 
a protective effect on the graft but a number of case reports show that they can 
negatively influence graft outcome124-128. A beneficial effect on graft survival has been 
reported for IgA antibodies123,129,130. IgA HLA antibodies are found in about 16% of 
eluates from explanted renal allografts131. 
Special allocation programs within Eurotransplant 
The Acceptable Mismatch program was introduced within Eurotransplant to increase 
the chance of finding a crossmatch-negative donor for highly sensitized recipients with 
a historical or current CDC-PRA ≥85%. For these patients, the HLA antigens are defined 
towards which the recipient has not made antibodies. These antigens are then entered 
in the database as Acceptable Mismatches (AM)132-134. If an ABO compatible donor 
becomes available, matching with the combined recipient’s own and AM HLA, the graft 
is mandatory allocated to this patient. Patients enrolled in this program receive the 
highest priority within the allocation program.  Recipients transplanted in the AM 
program have shorter waiting times and show graft survival that is identical to that of 
non-sensitized recipients135,136. 
 
The Eurotransplant Senior Program (ESP) aims to achieve a more efficient use of 
kidneys from elderly donors and promotes their transplantation in elderly recipients. 
ABO compatible kidneys obtained from donors over 65 years of age are allocated to 
recipients older than 65 years, regardless of HLA matching. Risk factors such as delayed 
graft function (DGF) and acute rejection (AR) are reduced by only including non-
immunized recipients undergoing their first transplant. Cold ischemia time (CIT) is 
reduced by preferably allocating these kidneys locally. In this program, waiting time, 
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DGF and CIT are reduced. Graft survival is identical and AR rates are only 5 to 10% 
higher than kidneys that are allocated with matching requirements137-139. Recently, a 
new research program was introduced, the Eurotransplant Senior DR-compatible 
Program (ESDP), which aims to allocate older donor kidneys on the basis of the ESP 
principle in combination with DR-compatibility to further reduce the need for rejection 
treatment and the accompanying risk of infectious complications. This approach will be 
validated in a study where paired kidneys will be allocated through ESP and ESPD to 
recipients receiving a standardized immunosuppressive regimen. 
 
Cross-over transplantation is a variant of living donation for donor-recipients pairs that 
are ABO and/or antibody (positive crossmatch) incompatible. The donor of the first 
couple donates his or her kidney to the recipient of the second couple and vice 
versa140. 
Aim of thesis 
In the last 40 years, our understanding of sensitization in renal patients, the clinical 
relevance of HLA antibodies and the available antibody detection techniques have 
evolved considerably. Recently, the new bead-based antibody detection technology 
has significantly increased the sensitivity and specificity of HLA antibody detection. 
Therefore, interpretation has become an important factor in discriminating clinically 
relevant from non-clinically relevant antibodies detected by this technology.  
 
The aim of this thesis is to study the use of the Luminex Single antigen and Luminex 
crossmatch assays on antibody profiles of renal transplant patients and to compare 
their profiles to the ones obtained with standard antibody detection techniques. 
Results are correlated to clinical outcome. Chapter 1 introduces relevance of HLA and 
HLA antibodies in renal transplantation by giving an overview of what is known from 
the literature up to now. In Chapter 2, the different techniques for antibody detection 
that have been used over the years are described, in particular the Luminex 
technology. Antibody detection by LSA is compared to the standard CDC assay by 
testing a large panel of well-known CDC typing sera. In Chapter 3, the clinical relevance 
of preformed DSA detected by LSA only is studied in a group of highly sensitized 
recipients transplanted in the AM-program. All recipients were transplanted on the 
basis of negative CDC crossmatches, their sera had been tested for HLA antibodies by 
CDC and were now retested with LSA. Chapter 4 describes the appearance, 
persistence, specificity and effect on graft survival of DSA produced after 
transplantation. Multiple serum samples of a consecutive cohort of recipients without 
pre-transplant DSA, at least one year of renal function and a long follow-up period, 
were tested with LSA. In Chapter 5 DSA appearance in post-transplant sera of 56 
recipients who underwent transplantectomy at different time points after 
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transplantation was monitored. All recipients were DSA negative before 
transplantation. Production of DSA, time of appearance and antibody class were 
analyzed and correlated with matching grade and donor- and patient characteristics. 
The incidence of HLA-DP antibodies in renal patients before and after transplantation 
is analyzed in Chapter 6. The epitope-specificity of the donor and the correlation 
between development of DSA and non-DSA were examined by comparing the HLA-DP 
types of patient and donor. Chapter 7 reports on the Luminex crossmatch. Pre- and 
post-transplant sera of 18 patients transplanted between 1997 and 1999 with a 
negative CDC crossmatch were tested with a new crossmatch technique, the results of 
which were compared to flow cytometric results obtained for the same donor-
recipient combinations and to LSA antibody screening results. In Chapter 8, the clinical 
significance of the Luminex crossmatch is evaluated over a 4-year period in a group of 
renal transplant recipients, all transplanted on the basis of a negative CDC crossmatch. 
Luminex crossmatches with the sera of 165 patients drawn at the time of 
transplantation, were performed and correlated to acute rejection and graft survival. 
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Complement-dependent cytotoxicity test 
For over 40 years the complement-dependent cytotoxicity assay (CDC) has been the 
standard HLA antibody detection assay. Patient serum is incubated with cells of a 
selected HLA-typed panel to allow the formation of immune complexes. Subsequently 
rabbit complement is added, that binds to the immune complexes. The formation of a 
membrane-attack complex is induced, that lyses the cell membrane. Lysed cells are 
stained using a fluorescent dye. Positive and negative reactions are discriminated using 
an inverted microscope1,2. The reaction pattern shows the specificity of the antibodies 
present in the serum, using the best correlation of positive reactions with the 
HLA antigens of the panel cells. The results are expressed as a panel reactive antibody 
(PRA) value, defined as the percentage of cells in the panel to which the serum reacts. 
The composition of the cell panel is crucial, it has to take into account cross-reactivity 
and linkage disequilibrium of the HLA system. The size of the panel is usually 50-60 
selected cells with HLA types that include most common and some rare alleles. The 
distribution of alleles in the cell panel should reflect the frequencies of these alleles in 
the local patient and donor population. 
 
The detection and assignment of class I antibodies is generally trouble free in patients 
with low PRA values, in contrast to the assignment in highly sensitized recipients. 
Class II antibodies are far more difficult to detect, because the class II antigens are 
expressed on B-lymphocytes, which represent only 10 to 15% of the peripheral blood 
cells. Modifications in cell concentration and incubation time partly surpass this 
shortcoming3. The fact that B-lymphocytes present with both class I and II 
HLA antigens on their surface is another reason for the more complicated detection of 
class II antibodies4-6.  
 
The CDC assay detects complement-binding IgG and IgM antibodies. Most 
HLA antibodies are IgG, while IgM antibodies are usually but not exclusively auto-
antibodies. The clinical role of IgM HLA antibodies is doubtful, therefore sera are 
pretreated with dithiothreitol (DTT) to abolish the IgM antibodies in the serum. DTT 
disrupts the sulphide-bonds of the IgM molecules, thereby degrading the antibodies7,8. 
Modifications to increase sensitivity and allow identification of non complement-
binding IgG and low titered antibodies have been proposed. Extended incubation 
times, that permit binding of low-avidity antibodies, wash steps that remove low-
affinity antibodies and inhibitory factors and addition of anti-human globulin (AHG), 
that allows detection of low-level or non-complement-binding antibodies, are 
examples of these modifications9-11. 
 
Technical problems of the CDC assay include labour intensiveness, need of viable panel 
cells and the interference of certain agents present in the test-serum as ATG for 
example12. Nevertheless extensive experience exists with this technique. The major 
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advantage of the assay is that it reflects more than any other test the situation in vivo, 
the HLA antigens used as antibody-target are unaltered and have not been 
manipulated. And most importantly, the clinical relevance of CDC-detected antibodies 
has been clearly established13,14. 
 
Many of the problems involved using cell-based assays, such as need for viable cells, 
presence of auto-antibodies and difficulty to distinguish class I from class II antibodies, 
were resolved when solid-phase antibody detection assays became available. The 
assays are more sensitive, require only small amounts of serum and reading is 
objective and can be automated15,16. The tests use soluble or recombinant 
HLA molecules adhered to trays (ELISA) or microspheres as antibody target17. The 
latter bead-based assays are run on a flow cytometer (FlowPRA)18 or are multiplexed 
on a Luminex platform (LABScreen)19. They are more sensitive in detecting low-titer 
antibody than the ELISA assay20.  
Enzyme-linked immuno-sorbent assay   
The first solid-phase assay for clinical use was introduced in 199317. The ELISA assay 
uses soluble or recombinant HLA molecules, adhered to plastic plates as antibody 
target. The HLA molecules are immuno-precipitated from platelets or Epstein-Barr 
virus (EBV) transformed B-lymphocyte cell lines. When serum is added to the plate, 
only HLA antibodies will bind. Enzyme-conjugated antibody to human IgG is added to 
detect bound IgG antibody. If HLA antibodies are present in the serum, the resulting 
optical density values will reflect this. Two types of assays are commercially available. 
One consisting of wells containing a pool of class I or class II antigens that gives a 
negative or positive result. In the second one HLA molecules of one individual are 
present per well, thus allowing PRA value determination as well as determination of 
HLA specificity. Class I and II antibodies are easily distinguished and isotype-detection 
is limited to one immunoglobulin class, usually IgG17,21,22. By changing the isotype of 
the secondary anti-human antibody in the assay, one can detect other isotypes, for 
instance IgM23. The assay is more sensitive than CDC, it detects complement-binding 
antibodies and non-complement-binding antibodies simultaneously.  
 
A possible drawback of the method is that the HLA molecules on the plates, are 
manipulated before being bound to the artificial surface, thus the natural 
conformation of the molecule may be altered, which can result in false-positive and 
false-negative reactions of the test.  
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Bead-based assays 
The need to measure and quantify multiple analytes at the same time lead to the 
development of particle or bead-based flow cytometric assays. Small cell-sized 
polysterene or latex microbeads were already used to calibrate first commercial flow 
cytometers in the early 1980’s. Shortly thereafter latex, polysterene, polyacrylamide or 
glass microspheres were being used as the solid support for a variety of molecular 
reactions that were analyzed by a flow cytometer. The first beads used to quantify 
soluble analytes were FITC labelled latex beads or fluorescent beads. Conventional 
flow cytometers with the appropriate lasers for the fluorochromes could aquire the 
microbead emission data24. In the late 1990’s, the Luminex corporation developed the 
FlowMetrix system. This system consisted of 64 beads impregnated with a distinct 
proportion of red and orange fluorescent dyes. The unique properties of these beads 
were their size, stability, uniformity and their capacity to absorb and retain fluorescent 
dye. Different assays that make use of these beads were developed, for instance an 
assay to quantify multiple cytokines simultaneously at the protein level. Data 
acquisition for these assays was done on a conventional flow cytometer connected to 
a digital signal processor. The microbeads were excited at 488 nm by an argon laser. 
The orange and red fluorescence of the internal dyes of the beads is detected by the 
FL2 and FL3 detectors of the flow cytometer. The green reporter dye, which is a 
measure for the amount of analyte bound to the surface of each bead is detected on 
the FL1 detector. The dyes emit light at 580 and 660 nm, the reporter dye emits light at 
519 nm. A disadvantage of this system was the need to compensate for the spectral 
overlap between the FL1 and FL2/FL3 detectors25. To resolve this problem, the 
Luminex 100 flow analyzer (Luminex©, Austin,Tx) and xMAP microbeads were 
developed. This system provided a high signal-to-noise ratio for detection of low-level 
fluorescence. The Luminex xMAP technology was designed to measure soluble 
analytes. The system is based on flow cytometry and can simultaneously analyze up to 
100 analytes in a single test sample. Luminex xMAP microspheres or beads are highly 
uniform, polystyrene particles, 5.6 micron in size, that are internally dyed with varying 
amounts of red and infrared fluorochromes. In this way, 100 microspheres were 
created with a unique spectral signature determined by their red/infrared mixture 
(Figure 2.1). The surface of the beads allows simple chemical coupling of capture 
reagents such as cytokines, DNA probes, antibodies and antigens. The Luminex flow 
analyzer is equipped with a digital signal processor and two lasers. The 532 nm YAG 
laser excites the R-phycoerythrin (PE) reporter molecule, which is a measure for the 
amount of analyte bound to the bead, upon excitation it emits light at 578 nm. The 
635 nm red diode laser excites the two classification dyes imbedded in the beads, 
upon excitation by the laser they emit light at 658 and 712 nm (Figure 2.2). In this 
system, there is no overlap between the beads and the reporter molecules. Automated 
sample acquisition is made possible by the X-Y platform for reading 96-well microtiter 
plates26-28. X-map beads to develop in-house assays as well as an array of commercial 
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assays became available. The different commercial assays to detect HLA antibodies are 
described below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Luminex xMAP microspheres. 
 Luminex xMAP microspheres are highly uniform, polystyrene particles, 5.6 micron in size, 
internally dyed with varying amounts of red and infrared fluorochromes. This way, 100 
microspheres were created with a unique spectral signature determined by their red/infrared 
mixture. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 The Luminex flow analyzer. 
 The Luminex flow analyzer has two lasers. The 635 nm red diode laser excites two classification 
dyes imbedded in the beads, they emit light at 658 and 712 nm. The 532 nm green YAG laser 
excites the R-phycoerythrin (PE) reporter molecule, which is a measure for the amount of 
analyte bound to the bead, upon excitation it emits light at 578 nm. 
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FlowPRA 
In the late 1990’s the bead-based flow cytometric assays (FlowPRA) (Onelambda©, 
Canoga Park, CA) were introduced, one to determine the PRA value of the test serum 
and another to define the antibody specificity29,30. For these assays, HLA antigens are 
purified from EBV transformed cell lines by cell lysis and affinity chromatography with 
monomorphic monoclonal antibodies specific for class I and II HLA antigens. They are 
directly linked to uniform latex beads. In the FlowPRA screening assay, a pool of 
30 class I antigens are bound to non-fluorescent beads and a second pool of 30 class II 
antigens to fluorescent beads. The specific class I and class II assays consist of 4 groups 
of 8 microbeads with different fluorescent properties, each coated with purified 
HLA antigens from individual cell lines which allow analysis of the antibody 
specificities. The FlowPRA specific assay is performed by incubating serum with beads 
to allow HLA-specific antibodies to adhere to the molecules on the bead’s surface. 
After washing, FITC-conjugated F(ab)2 fragments of goat anti-human IgG are added, 
which bind to the IgG HLA antibodies. Upon excitation of the beads, the fluorescence is 
analysed using a flow cytometer. Each of the eight beads has a unique PE fluorescence 
that emits light at 580 nm and is measured by the FL2 detector. The fluorescent signal 
of the FITC is emitted at 519 nm and  is detected on the FL1 detector. Positive bead 
reactions show a FL1 channel shift on the FL1 versus FL2 dot blot when compared to 
the negative control serum and the control bead. A detailed description of the assay is 
given by Pei et al.30. 
 
For patients with high PRA, it is difficult to determine the exact specificities present in 
the serum with these assays, because one single reaction may be caused by multiple 
HLA molecules present in the beads. As described by Pei et al., the search for so called 
Single antigens that can be used for antibody testing has been ongoing since 1979. 
Monoclonal antibodies and an E. Coli expression system have been used with limited 
success until 2002, when a new mammalian cell expression system of HLA-transfected 
cells was developed using recombinant DNA technology. HLA antigens purified from 
these transfectants by cell lysis and affinity chromotography were then coated onto 
FlowPRA beads. The Single antigen panel allows the identification of formerly masked 
specificities in patients with broad sensitisation31. 
 
An important limitation of the commercially available FlowPRA assays is that only 
4 groups of 8 (maximum 11) beads can be separated due to the spectral overlap 
between PE (beads, FL2) and FITC (FL1), As mentioned before this problem was 
overcome by the development of the Luminex xMAP technology.  
LABScreen  assays 
The LABScreen assays (Onelambda©, Canoga Park, CA) use beads coated with purified 
HLA molecules as target for antibody detection. By using the Luminex multi-analyte 
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sytem, up to one hundred beads are combined in a single test sample. The LABScan 
100 flow analyser is used for data acquisition and analysis. There are 3 variants of the 
test presently available: the Mixed, the PRA and the Single antigen assay. The Mixed 
assay consists of beads with a large number of class I or class II HLA molecules bound 
to their surface which detect the presence of HLA antibodies and provides a negative 
or positive test result. The PRA test determines the specificity of the HLA antibodies 
using beads coated with the fenotype equivalent of one cell, thus two HLA molecules 
present for each locus. In the Single antigen assay the beads are coated with single 
recombinant antigens from transfected human cell lines, which allow accurate 
definition of the HLA antibody specificities present in the serum. To date, the Single 
antigen panel contains all of the most frequently observed HLA alleles, 98 class I alleles 
(31 A, 51 B and 16 Cw) and 65 class II (34 DR, 14 DQ and 17 DP) are included 
(http://www.onelambda.com).  
 
All assays are performed in a 96-well plate, which allows simultaneous testing of 
95 patient sera and one negative control serum. Patient sera, stored frozen at -30°C, 
are centifugated at 10.000g for 10 minutes prior to testing. Five µl of the appropriate 
beadmixture are vortexed and incubated with 20 µl of patient serum for 30 minutes to 
allow the binding of HLA antibody to the HLA molecule on the bead. After three 
washes with 200 µl of diluted wash buffer to remove unbound antibody, the beads are 
incubated for 30 min with 100 µl of antihuman-IgG-conjugated phyco-erythrine 
(anti-IgG-PE), diluted 1:100 with wash buffer. After another two washes to remove 
unbound anti-IgG-PE, 80 µl of phosphate-buffer solution is added (Figure 2.3). 
Incubations are performed on a gently rotating platform in the dark at room 
temperature. All beadmixtures contain a positive control bead coated with IgG and a 
negative control bead without HLA molecules. A negative control serum is run with 
every assay, it is used to establish the background value for each bead in the mixture. 
The LABScan 100 flow analyser (Luminex©, Austin, TX) and HLA-Visual software (One 
Lambda©) are used for data acquisition and analysis. 
 
The Luminex 100 analyzer is a flow cytometer with an excitation system that comprises 
two solid-state lasers that illuminate the beads as they flow through it in a single file. 
The red classification laser exites both the internal red and infrared dyes of the bead, 
allowing classification of the microbead. The green reporter laser excites the 
fluorescence of the PE molecules bound to the HLA antibodies on each of the beads. 
The fluorescent signal of the PE label, which is a measure for the amount of antibody 
bound to the bead, is expressed as median fluorescence intensity (MFI) value per bead. 
The results of the analysis of each sample are incorporated in data-files (CSV). CSV files 
contain data on the number of events for each bead and the MFI value for each event. 
These files are then interpreted by the HLA-Visual software that generates graphs of 
the results per serum. On the X-axis all beads and the HLA molecules on their surface 
are listed. On the Y-axis, the MFI per bead can be read.  
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Figure 2.3 LABScreen Single antigen assay. 
 Single antigen beads are incubated with patient serum to allow the binding of HLA antibody to 
the HLA molecule on the bead. After three washes to remove unbound antibody, the 
anti-human-IgG antibody labelled with fluorescent phyco-erythrine (PE) label is added. 
Unbound secondary antibody is removed by washing.  
 
 
A serum’s reactivity can be assessed by the fluorescent signal for each HLA coated 
bead (MFI) after correction for non-specific binding to the negative control bead. All 
data are then normalized to the results obtained with the negative control serum. For 
the Mixed assay, the normalized MFI value equals the MFI value of the class I or class II 
coated beads minus the MFI value of the negative control bead. For the PRA and Single 
antigen assay, the normalized MFI value for each bead equals the MFI value of the 
bead divided by the MFI value of the negative control bead. The value obtained is then 
divided by the normalized MFI value for each bead obtained with the negative control 
serum, which equals the MFI value of the bead with the negative serum divided by the 
MFI value of the negative control bead when tested with the negative serum. This 
normalized background ratio is then used to assign the strength of each bead reaction 
and to divide the beads in groups with strength 8, 6, 4, 2 or 0. Which of these scores is 
assigned as positive or negative is defined by the user. 
 
The LABScan 100 flow analyzer has to be calibrated before every use with calibration 
and control beads. For all assays, the bead count for each kind of bead should be over 
50. The MFI value of the negative control bead should be lower than 500 or 1500 for 
high-background sera and less than half of the MFI value of the positive control bead. 
The MFI of the positive control bead should be over 500 and at least twice the 
MFI value of the negative control bead. 
Benefits, limitations and modification of bead-based assays 
The Luminex technology is shown to be more sensitive in detecting HLA antibodies 
than CDC and ELISA assays32-34. Because bead-based assays make use of total IgG as 
SA bead with HLA-A2
Anti-HLA-A2 ab
Anti-IgG with PE label
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secondary antibody, they do not discriminate between complement-binding and non-
complement-binding antibodies. Because the clinical relevance of non-complement-
binding antibodies is still unclear, several modifications of the assays have been tested 
to solely detect complement-binding antibodies. Wahrmann et al. adapted the 
FlowPRA assay by using human serum as the source of complement C4d, which binds 
to the beads in the presence of complement-binding antibodies. A FITC-labeled 
anti-C4d antibody was used for detection35. Smith et al. also modified the Single 
antigen assay, they used human serum as the source of complement again but used a 
mouse anti-human C4d monoclonal antibody and a PE- donkey anti-mouse IgG for 
detection of complement-binding antibodies36. Several other investigators replaced 
the total IgG with the individual isotypes, i.e. IgG1,2,3 or 4 37,38.  
 
The major advantage of the Single antigen assay is that it allows accurate evaluation of 
sera containing complex mixtures of antibodies. Class I and class II antibodies are 
clearly discriminated. Furthermore, antibodies directed against HLA-DRB3,4,5, HLA-DQ 
and HLA-DP are discriminated from reactivity against HLA-DR. Beads containing 
different HLA-C, HLA-DQA, -DPA, -DPB alleles are available, as well as beads for 
detection of antibodies against MHC class I chain-related (MICA) molecules39-41. Even 
antibodies directed against some allelic specificities can now be detected42-45. Using 
the Single antigen assay, it has become clear that many sera with multiple specificities 
reacted with epitopes shared by several HLA molecules46-49. Based on the specificities 
found using these assays, a so-called virtual PRA can be calculated. This virtual 
PRA value is based on the antigen frequencies in the local donor population to which 
the recipient has antibodies50,51. The virtual PRA predicts the chance to find a positive 
crossmatch and results in a so-called “virtual” crossmatch52-56. The strength of the 
antibody detected can be measured by converting MFI values in molecular equivalent 
fluorescent (MESF) values using specific calibration beads57. 
 
When bead-based assays were first introduced and their results compared to those of 
cell-based assays, some discrepancies were encountered. Bray et al.58 describe a serum 
with a positive FCXm but negative FlowPRA screening. They hypothesized that this 
discrepancy was caused by an epitope that is recognized by antibody on the intact cell 
membrane, but not on bead-bound protein. According to them this could be due to 
separation of the HLA from the β2m chain which could lead to an altered class I 
morphology; either alteration of epitopes during bead preparation or altered 
conformation of the protein once adhered to the bead. Gebel et al.59 describe a similar 
case, they assume the discrepancy to be due to allelic variation or lesser density of 
HLA antigens expressed on beads than on living cells. Bray also describes a serum with 
a negative FC-Xm but a positive FlowPRA screening, which might be caused by 
antibody binding to epitopes that are inaccessible on the cell membrane but become 
accessible on the bead58. Recently, it was shown that IgM antibodies present in 
recipient serum can sterically hinder IgG antibody detection because they are 
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pentamers and thus larger than IgG antibodies. This inhibition can be removed by 
either hypotonic dialysis or DTT treatment of the sera60-62.  
Comparison of LSA and CDC assays 
The cut-off point for positivity of the Luminex Single antigen assay has to be defined by 
the user and therefore may differ considerably between laboratories. To clarify how 
the results of the assay compare to those of the CDC assay, we decided to test a 
number of well-known HLA sera in both techniques. The sera used for this validation 
were CDC HLA typing sera that have been used in our lab as well as in many others all 
over the world for over 20 years. Both CDC specificity and reaction strength of each 
serum were well-defined. The main strong specificity as well as occasional extra 
reacting weak specificities are given in Table 2.1. 
 
A total of 103 well-known HLA typing sera were used, 73 for class I and 26 for class II. 
They were tested with the LSA class I and II test respectively. The normalized MFI 
values obtained were divided in 5 areas: values less than 2000 (score 0), 2000-4000 
(score 2), 4000-8000 (score 3), 8000-12000 (score 4) and values over 12000 (score 5). 
For each serum the main CDC specificity and the extra specificities if present, were 
categorized according to their MFI value in one of these areas.  
 
For the HLA class I typing sera, all main specificities were detected to have a score 3 or 
higher, most of them score 4 and 5. None were found with an MFI value below 4000. 
For the weaker extra specificities 98% reacted with score 3 or higher (132/135), 2% of 
the reactions were found in the score 2 area, none had values under 2000 MFI. 
Altogether 99 % of all class I CDC specificities had an MFI value of 4000 or more in the 
LSA assay.  
 
For the HLA class II typing sera, 94% of the main specificities were found to have a 
score 3, 4 or 5, 6% were found with MFI values between 2000-4000. From the extra 
reactions 88% reacted with score 3 or higher. Thus in total, 92 % of all class II 
CDC specificities showed an MFI value of 4000 or more when tested with LSA. The 
results for all sera are summarized in Table 2.2.  
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Table 2.1A Main and extra CDC specificities of 73 HLA class I typing sera. 
Serum CDC specificities  Serum CDC specificities  
ID Main Extra ID Main Extra 
ms 135 A1,36  ms 187 B55,42 B7,54,56,67 
ms 145 A1,36,80  ms 003 B27 B7,42,47,61,67 
ms 023 A25,26,34,66 B7 ms 045 B27,47 B13 
ms 124 A25,26,66 A11, 34 B7, 60, 61 ms 050 B27,47 B44,5,53,17,59 
ms 133 A25,26,34,66,11 A25,26,34,66,11 ms 025 B35,50,70 B53,56,62,75 
ms 084 A26,66 A25,34 ms 093 B35,50,56,62,75 B55,70,76,77,8 
ms 166 A25  ms 152 B13,60,61,81 B47,48 
ms 027 A11  ms 160 B48,60,61,81 B13,47 
ms 066 A11,66 A26,34 ms 042 B51 B52,53 A1 
ms 070 A29,30,31,33 B60 ms 071 B49,51,52,63,77,78 B53,57,58 
ms 125 A29  ms 162 B51 B52,53,77,78 
ms 062 A2,203,28  ms 172 B51,52 B49,53,63,77 
ms 092 A2,203 A28 ms 033 B35,51,52,53,75,77,78 B18,49,62,63 
ms 096 A2,203 A28 ms 037 B35,51,52,53,78 B18,49,75,77 
ms 105 A2,203,28 B57,58 ms 103 B35,51,52,53,78 B70 
ms 110 A28  A2 ms 137 B35,51,53  
ms 142 A28 A2 ms 059 B7,27,42,55,56,67,81 B54 
ms 142 A28  ms 076 B7,42,48,60,67,73,81 B27,22,61 
ms 188 A3  ms 079 B7,42,67,81 B13,22,61,73 
ms 195 A3 B7,27 ms 085 B7,27,81 B13,47,73 
ms 009 A23,24 A32 B51 ms 104 B7,27,42,48,60,67,73,81 B55,56,41,61 
ms 109 A23,24 2403  ms 120 B7,81 B42,67,73 
ms 119 A23,24,2403  ms 044 B73  
   ms 112 B73  
ms 017 B44,45 B13,49,52,57 ms 146 B73 Cw7  
ms 127 B44,45  ms 018 B8 B60 
ms 134 B44,57,58,49  ms 069 B8  
ms 158 B44,45 B13,60,61,41 ms 089 B8 B14 
ms 144 B44  ms 108 B8,14 B59 
ms 072 B13  ms 030 Bw6 (not B46)  
ms 173 B13     
ms 026 B62,75,76,77 B63 ms 156 Cw9,10 B46 B62,63,75 
ms 002 B57,58,63,59 B49 A24 ms 080 Cw4  
ms 032 B57,58 B63 ms 150 Cw5,8  
ms 091 B57,58,63  ms 040 Cw6,NM(18) Cw4 
ms 078 B18     
ms 010 B49 B50,51,52,53,57,58,63    
ms 167 B49,50,52,53 B62,63,77    
ms 115 B55,42,67 B56,7 A2    
ms 176 B54,55,56,42,67 B7,81    
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Table 2.1B Main and accompanying weak extra CDC specificities of 26 HLA class II typing sera. 
Serum CDC specificities  Serum CDC specificities  
ID Main Extra ID Main Extra 
msd 046 DR1  msd 014 DQ5,6  
msd 102 DR1  msd 021 DQ5,6  
msd 002 DR15 DR16 msd 029 DQ5,6  
msd 075 DR16 DR15 msd 068 DQ5,6  
msd 003 DR17,18  msd 020 DQ2 DR7 
msd 060 DR4  msd 023 DQ7,8,9 DR4 
msd 097 DR4  msd 085 DQ7,8,9 DQ4 DR13 
msd 050 DR11 DR12,13 msd 065 DQ7,8,9,2,4  
msd 057 DR11,13,8     
msd 018 DR11,14,4 DR12,13,3    
msd 024 DR11,13 DR12,14,3    
msd 095 DR12,13,9 DR14,3,7    
msd 004 DR15,51     
msd 030 DR51     
msd 051 DR53     
msd 077 DR53,7     
msd 001 DR7     
msd  096 DR11,8     
 
 
Table 2.2A Classification of main and weak extra class I CDC specificities according to their MFI value in 
the LSA class I assay. 
CDC specificities Single antigen Score  (MFI) 
 5 4 3 2 0 
 >12000 12000-8000 8000-4000 4000-2000 <2000 
Main  (n=184)   98 (53%)   72 (39%) 141 (44%) 0 0 
Extra (n=135)   31 (23%)   69 (51%)   32 (24%) 3 (2%) 0 
Total (n=319) 129 (41%) 141 (44%)   46 (14%) 3 (1%) 0 
 
 
Table 2.2B Classification of main and weak extra class II CDC specificities according to their MFI value in 
the LSA class II assay. 
CDC specificities Single antigen Score  (MFI) 
 5 4 3 2 0 
 >12000 12000-8000 8000-4000 4000-2000 <2000 
Main  (n=49) 28 (57%) 16 (33%) 2 (4%) 3 (6%) 0 
Extra (n=17)   3 (18%)   5 (29%)   7 (41%)   2 (12%) 0 
Total (n=66) 31 (47%) 21 (32%)   9 (14%) 5 (7%) 0 
 
 
The median MFI values for main and extra class I specificities was 12.382 (5.786-
17.931) and 9.449 (2.553-15.478) respectively. For the main and weak extra class II 
specificities, the median values were 11.037 (2.914-17.659) and 7.797 (2.369-16.559) 
(Table 2.3).  
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Table 2.3A MFI values of main and weak extra class I CDC specificities in the LSA class I assay.   
CDC specificities median MFI range of MFI values 
Main 12382 5786-17931 
Extra   9449 2553-15478 
Total 11249 2553-17931 
 
 
Table 2.3B MFI values of main and weak extra class II CDC specificities in the LSA class II assay.   
CDC specificities median MFI range of MFI values 
Main 11037 2914-17659 
Extra   7797 2369-16559 
Total 10069 2369-17659 
 
 
The increased sensitivity of the LSA obviously results in a much larger number of 
specific HLA antibodies than those detected in CDC. The numbers of these additional 
specificities demonstrated in the sera using LSA are given in Table 2.4. The majority of 
the antibodies are most likely non-complement binding antibodies, they are mainly 
found in the score 3 area. Some of them are directed against less common HLA alleles, 
which means that they might have been missed by the CDC test. On average 
11 additional LSA specificities per serum were found for class I, while only one was 
detected for class II. 
 
Table 2.4 Number of HLA specificities only detected by the LSA.  
 Single Antigen Score (MFI) 
   5     4     3 
 >12000 12000-8000 8000-4000 
Class I (73 sera) 45 237 505 
Class II  (26 sera)   6   25   11 
 
Together with the transplantation clinicians we decided that in our centre, the cut-off 
point for positivity of the LSA would be 4000 MFI for clinical transplant purposes, 
based on the results obtained with the typing sera. This means that a number of 
CDC undetected, non-complement binding antibodies are excluded for a given patient 
but we feel confident that with this cut-off point all specificities detected by CDC are 
covered and listed as not acceptable antigens for a transplant recipient.   
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Abstract 
Background 
Highly sensitized (HS) patients (>85% panel-reactive antibodies) have a lower chance of receiving a donor 
kidney. Within Eurotransplant the Acceptable Mismatch (AM) program was developed to increase the 
chances of HS patients to receive a crossmatch negative donor kidney. The standard crossmatch in the 
AM program is based on complement-dependent cytotoxicity.  
 
Methods 
In this study we wanted to determine the clinical relevance of human leukocyte antigen donor-directed 
antibodies (DDA) detected by the Single antigen (SA) bead technique, in the pretransplant sera of 
HS patients transplanted in our center through the Eurotransplant AM program.  
 
Results 
From 34 AM patients, 27 were transplanted with 1 to 5 mismatches and 7 received a 0- mismatched graft. 
From the mismatched patients, retrospectively, 13 proved to possess pretransplant DDA by SA whereas 14 
did not. No antibodies were found in the 0-mismatched group. Comparison of the DDA+ and DDA- patients 
in the human leukocyte antigen-mismatched donor/recipient combinations revealed a trend to an earlier 
and higher number of rejection episodes in DDA+ patients (P=0.08). No detrimental effect of DDA on 
graft survival was observed. 
  
Conclusions 
This single-centre study showed that in the AM program DDA detected by SA and not by less- sensitive 
methods, may be related to acute rejection episodes but is not detrimental to long-term graft outcome. 
These findings question the increasing use of more-sensitive screening techniques for the allocation of 
organs. 
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Introduction 
Patients with a sensitization of 85% or more panel reactive antibodies (PRA) are 
generally considered to be highly sensitized (HS). They have a lower chance of 
receiving a donor-kidney offer than other patients on the waiting list. The sensitization 
is caused by pregnancies, blood-transfusions, or previous transplants.  
 
There are two strategies to facilitate transplantation in HS patients. One is increasing 
the chance of finding a crossmatch-negative donor, for example, by determination of 
acceptable human leukocyte antigen (HLA) mismatches, and the other removal of 
HLA antibodies by desensitization, for example, with intravenous immunoglobulin-
based protocols. Within Eurotransplant (ET) the Acceptable Mismatch (AM) program 
consists of a special HS waiting list that allows patients with a current or historical 
sensitization of 85% or more PRA to enter1,2. Acceptable mismatches are defined as 
those mismatches against which the recipient has never made antibodies and are 
considered to be acceptable as mismatch on the potential donor organ. A blood group 
compatible deceased donor that becomes available and is HLA-A,-B,-DR matched with 
the recipient’s antigens, including the AM antigens, is first offered to the HS patient 
waiting list. The standard crossmatch performed in the AM program is the 
complement-dependent cytotoxicity (CDC) crossmatch. Patients transplanted in the 
program have a 1-year graft survival similar to that of nonsensitized patients within 
ET3.  
 
Screening techniques of higher sensitivity than CDC and enzyme-linked 
immunosorbent assay (ELISA), such as the Single antigen (SA) bead assay have been 
introduced recently4,5. In this assay, color-coded microspheres coated with single 
HLA antigens are used to identify HLA class I and II antibodies in patient sera. The test 
detects both complement-binding and non-complement-binding HLA antibodies using 
anti-human IgG as secondary antibody. More and more laboratories rely on the 
detection of specificities demonstrated by these types of assays, and use the 
information obtained for allocation of donor organs. The clinical relevance, however, 
has not been studied systematically, nor has it been proven.  
 
In this study we wanted to determine the presence or absence of HLA donor-directed 
antibodies (DDAs) by the SA Luminex bead technique in the pretransplant sera in a 
cohort of highly immunized patients that entered the ET AM program and were 
transplanted in our center. These patients were transplanted on the basis of a negative 
CDC crossmatch. Their post-transplant course was studied to evaluate the clinical 
relevance of the DDA specificities detected. 
54⏐Chapter 3 
Materials and Methods 
Patients and donor 
Thirty-four patients with PRA greater than 85% from the Maastricht Transplant Center 
entered the ET AM program and were transplanted between 1989 and 2006. 
Acceptable mismatches were determined by means of crossmatches with selected 
donors or by extensive screening protocols. Since 2001, also the HLA matchmaker 
algorithm has been used in the determination of acceptable mismatches6. From 
34 patients seven were transplanted with a 0-mismatched donor, the remaining 27 
with 1 to 5 mismatches. There were 12 first and 15 retransplants.  
Organ donors were offered through the ET organ exchange organization, and typed or 
retyped by the Maastricht laboratory. All relevant crossmatches with current and 
historical patient sera were performed in the recipient center. All grafts were from 
heart-beating donors, except two from non-heart-beating donors. 
Immunosuppression 
The immunosuppressive regimen was calcineurin inhibitor-based triple drug therapy 
for all recipients. Calcineurin inhibitor was cyclosporine (CsA; n=14) until 1994 and 
tacrolimus (TAC; n=20) thereafter. Additional immunosuppression was prednisone in 
all, azathioprine in 8, mycophenolate mofetil in 15, sirolimus in 2 and FK778 in 
2 recipients. None of the patients received induction therapy with antilymphocyte 
globuline or IL2-receptor antagonist. CsA levels were determined in whole blood by 
enzyme monoclonal immuno test (Dade Behring, Newark, DE) or high performance 
liquid chromotography-MS/MS. In the first 3 months after transplantation, target CsA 
trough levels were 0.10 to 0.15 mg/l, afterwards decreasing to 0.05 to 0.10 mg/l. TAC 
trough levels were measured in whole blood by Imx (Abbott, Abbott Park, IL) or high 
performance liquid chromotography-MS/MS; target levels were 15 to 20 ng/ml for 
weeks 1+2 and 10 to 15 ng/ml for weeks 3+4, thereafter tapering to 5 to 7 ng/ml. 
Clinical outcome parameters  
A biopsy was taken during surgery 1 hour after reperfusion for every transplant. 
Rejection was defined as any rejection treatment within 3 months after grafting. All 
rejection episodes were proven by needle core biopsy. No fresh frozen material for 
C4d staining was available because of the retrospective design of the study. Rejection 
treatment consisted of three doses of methylprednisolone (0.5-1.0 g/dose) or a 10-day 
course of antithymocyte globulin for vascular rejections. Graft failure was defined as 
failure of graft, but also included death with functioning graft. 
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Center policy of tissue typing 
During the study period all patients were typed for HLA-A, -B, -DR and -DQ. Typings 
were initially performed by serology; from 1994, class II was DNA typed by polymerase 
chain reaction-sequence-specific primers and from 2004 class I as well. Recently, all 
recipient and donor typings have been repeated with molecular techniques (SSO 
Luminex) to ascertain the exact number of mismatches. HLA antigens were considered 
unacceptable for a patient, if antibodies against the specificity had ever been 
demonstrated, either at the time of transplantation or in the past. Mismatches from 
previous transplants were excluded, as were the paternally inherited antigens of 
children in female patients. CDC crossmatches of peak and current patient sera had to 
be negative with and without DTT in order for the transplant to be performed. 
Screening for human leukocyte antigen antibodies 
All recipient sera had been screened before transplantation for the presence of class I 
and class II antibodies.  The routine antibody detection technique during the whole 
period, 1989 to 2006, was CDC. Both class I and class II DR antibodies were determined 
using the two-color fluorescence technique on unseparated PBLs. Reading was 
performed with automated Leitz inverted fluorescence microscopes. In 2002 a generic 
ELISA test (LAT-M, One Lambda, Inc., Canoga Park, CA) as well as ELISA identification 
test (Quick-ID, GTI Diagnostics, Brookfield, WI and LAT-M, One Lambda) for class II 
DR-antibodies was added to our screening strategy. The generic test was used as a 
prescreening test, the identification tests for better definition of class II DR antibodies. 
For all recipients, acceptable mismatches were defined by performing 
CDC crossmatches with selected panel cells, differing for only one antigen with the 
patient, or by determining the negative antigens in relevant sera by extensive CDC, and 
since 2002, also by Elisa screening. For this study all historical relevant sera and the 
current serum have now been retested with class I and II SA Luminex beads (One 
Lambda) according to the manufacturer’s protocol.  
Statistical analysis  
All statistical analyses were performed by using Statistical Package for the Social 
Sciences software (SPSS, Cary, NC; version 12.0.1 for Windows). Groups were 
compared by non- parametric tests. Kaplan-Meier survival analysis was performed to 
analyze differences in rejection-free survival and graft survival (log-rank statistic). 
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Results 
Mismatches and antibodies 
From 34 recipients, 27 were transplanted with 1 to 5 AM mismatches, the remaining 7 
received a 0-mismatched graft. Their pretransplant characteristics are given in 
Table 3.1. The relevant sera of all patients in the study were retested by Luminex class I 
and II SA bead assay. Patients who received a 0-mismatched graft never showed the 
presence of donor-directed HLA antibodies in their relevant pretransplant serum. From 
the 27 mismatched patients, 13 presented with DDA in the relevant pretransplant 
serum and 14 had no detectable antibodies.  The positive patients showed a class I or II 
antibody in 11 and 2 patients, respectively. The two groups of mismatched patients 
were compared; the 0-mismatched patients were excluded from the analysis. The 
number of mismatches, the actual mismatched antigens, the DDAs found, and 
PRA values for peak and current serum are given in Table 3.2. 
 
Table 3.1 Pretransplant recipient characteristics (n=27). 
 
DDA+ groupa 
(n=13) 
DDA- group 
(n=14) 
Median recipient age, yrs (range) 51 (30-69) 51,5 (29-65) 
Gender, male/female 5/8 5/9 
Female recipients with pregnancies 7 7 
Transplant number, 1/2/3/4 7/5/1/0 5/6/2/1 
Median donorage, yrs (range) 45 (23-63) 43,5 (7-63) 
Donor type, HB/non-HB 13/0 12/2 
a DDA positivity was based on reactivity of the peak pretransplant serum 
 
 
Rejection and Graft Survival 
In total 8 of 27 patients were treated for an acute rejection. For the peak sera, more 
rejections were seen in the DDA+ than in the DDA- group (six vs. two). The rejections in 
the DDA+ group occurred earlier after transplantation (days 5-21) than in the 
DDA-group (days 35-44). In three patients the rejection was treated with 
antithymocyte globulin; two were on TAC and one on CsA, two were DDA+ and one 
was DDA- (Table 3.2). However, rejection-free survival was 83% for the DDA- and 54% 
for the DDA+ group. The difference in actuarial rejection-free survival did not reach 
statistical significance (Kaplan-Meier survival analysis; log-rank statistic: 3.1, 1df, 
P=0.08; Figure 3.1). For the current sera three patients were shown to have lost their 
DDA, one patient from the DDA- group was shown to possess DDA at the time of 
transplant. Analysis of the current pretransplant sera in both groups showed 
comparable rejection-free survival (DDA+ vs. DDA-, P=0.14). 
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Figure 3.1 Rejection-free survival according to DDA positivity by SA of 27 highly sensitized patients 
transplanted in the Acceptable Mismatch program. Kaplan-Meier curve of acute rejection-free 
survival for DDA- (solid line) and DDA+ (dotted line) patients. P=0.08 
 
Graft failure occurred in 4 of 27 patients in the early post-transplant period (up to 
day 45). There were no histological signs of rejection in any of them. Two primary 
non-function failures were in the DDA- group. Both patients received a graft from an 
older donor, one had persistent hypotension. The other two failures were in the 
DDA+group. By Kaplan Meier survival analysis, it was found that graft survival up to 
8 years did not differ significantly between the DDA groups (log-rank statistic: 0.27, 
1df, P=0.60; Figure 3.2). Graft survival was not different when the analysis was 
performed for current serum (P=0.75).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Graft survival according to DDA positivity by SA of 27 highly sensitized patients transplanted in 
the Acceptable Mismatch program. Kaplan-Meier curve of graft survival for DDA- (solid line) 
and DDA+ (dotted line) patients. P=0.60 
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Discussion 
From 34 HS patients from the Maastricht Transplant Center transplanted in the ET 
AM program, 27 were transplanted with 1 to 5 mismatches, whereas seven received a 
0-mismatched organ. From the mismatched patients 13 proved to possess 
pretransplant DDA when tested retrospectively with the SA Luminex beads, whereas 
14 did not. No antibodies were found in the 0 mm group. Comparison of the two 
mismatched groups revealed a trend to an earlier and higher number of rejection 
episodes in the DDA+ group; however, DDA positivity did not have a detrimental effect 
on graft survival. The difference in rejection rate did not reach statistical significance 
with the limited size of the patient groups.  The results were similar when the current 
pretransplant serum was used for DDA definition.  
 
The SA Luminex bead assay is a very sensitive and specific screening method for 
HLA class I and II antibodies. The antibodies detected are both complement-binding 
and non complement-binding. One can not differentiate between these antibodies, 
because the secondary antibody in the test is anti-human total IgG. The clinical impact 
of cytotoxic complement-binding DDA is well known.  The DDA detected here were 
mainly class I, only 2 of 13 patients showed class II antibody. Rejection episodes 
showed the same distribution; five in class I-positive and one in class II-positive 
patients. The antibody specificities detected were against antigens common in the 
Dutch population.  In this study we were not able to prove a clear clinical impact of the 
DDA detected by the SA Luminex test. Although there might be an effect on the 
occurrence of rejection episodes, it is obvious that the DDA detected are not 
detrimental to long-term graft outcome. This poses questions to the clinical relevance 
of antibodies detected by Luminex bead- based screening tests but not in CDC.  
 
In this single-center study, the AM program without induction therapy results in long-
term graft survival, which is identical to the results obtained by the Dutch transplant 
registry for deceased heart-beating donors. Donor-directed antibodies detected by 
SA Luminex beads and not by less- sensitive methods, might be related to acute 
rejection episodes but seemed not to be detrimental to long-term graft outcome. 
These findings question the ongoing use of more and more sensitive techniques in 
allocation of organs. Although this single-center study comprises only a relatively small 
number of patients and confirmation of the findings in a larger patient group is 
necessary, these findings are important in view of the fact that presently a lot of effort 
and money is spent on desensitization protocols to remove DDA, detected in these 
sensitive assays, in patients before transplantation. 
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Abstract 
Prevalence, time of appearance, and HLA class of DSA were studied in 140 consecutive renal transplant 
patients. Pre-transplant DSA-negative recipients with at least one year renal function and a follow-up time of 
up to 14 years was monitored for the production of DSA in 1107 sera by the Single antigen assay. Presence 
of DSA was shown in 224 sera of 35 recipients (class I/II/I+II in 11/20/4). In 17 patients transient DSA were 
found, present for a short period of time and not reappearing during follow-up (class I/II/I+II in 9/7/1). 
Median fluorescence intensity values (MFI) differed considerably for persistent and transient DSA (median 
12.000 versus 3.000). In multivariate analysis class II DSA persisting or appearing after the first year post-
transplant was the only independent risk factor for graft failure (OR=3.2). For transient DSA patients both 
class I and II positivity showed a comparable risk of graft failure as DSA-negative recipients. Thus, class II 
DSA positivity was predictive of graft failure if present after the first year post-transplant. The presence of 
transient DSA did not affect graft failure. Persistent DSA was shown to have 4 times higher MFI values, 
nevertheless many DSA positive patients had grafts with stable function. 
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Introduction 
Despite the improvement of current immunosuppressive regimens, HLA antibodies 
continue to be a risk factor for kidney transplant failure. Until recently it has been 
difficult to study the development of HLA antibodies in recipients because the 
methods available for their detection were insensitive and cumbersome. However the 
new detection technologies provide the possibility to define more specific their 
significance in patients before and after transplantation. 
 
The presence of pre-transplant cytotoxic donor-specific HLA antibodies (DSA) is a 
major cause of graft loss1,2. The development of DSA after renal transplantation is 
associated with acute and chronic rejection, and a decline in graft survival3-6. The 
results from a collaborative prospective international study showed that patients with 
HLA antibodies had graft failure at a significantly higher rate than patients without 
graft failure7. Many authors have described similar results8,9,10 and HLA antibodies 
therefore are considered to be a major cause of kidney allograft failure. This has led 
many laboratories to post-transplant HLA antibody testing of their recipients, in order 
to predict graft failure11,12. In many of the studies described, the patient population 
included recipients with pre-transplant DSA or was restricted to recipients who 
rejected their graft12,13. The number of serum samples tested per patient was limited, 
the methods used were of intermediate sensitivity (ELISA), and clinical follow-up time 
was short. 
 
The present paper is a detailed analysis of the frequency and features of HLA DSA, 
particularly whether and when the presence of post-transplant anti-HLA class I and/or 
II DSA leads to graft failure. This study differs from most other studies in that it 
includes a cohort of consecutive renal transplant recipients, some of whom have lost 
their graft but most still have functioning transplants. The presence of DSA is 
monitored from the moment of transplantation up to 15 years thereafter. All patients 
were proven DSA negative before transplantation, had at least 1 year of renal function 
and an average of 8 serum samples was tested per patient. Sera were collected before 
and after transplantation up to graft failure and DSA were determined with the 
Luminex Single antigen assay. The time of appearance, persistence, specificity, and 
antibody class of DSA were analyzed, as well as their effect on graft survival. 
Materials and Methods 
Patients 
The patients included in the study were 140 consecutive kidney transplant recipients 
with at least one year of renal function. All were DSA negative before transplantation 
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as assessed by the Luminex Single antigen assay. They were transplanted at the 
University hospital of Maastricht from January 1995 until January 1999 and clinical 
follow-up was continued through January 2010. Hundred-twenty were first transplants 
and 20 were re-transplants. Patient, donor and transplant characteristics are listed in 
Table 4.1. Serum samples were collected at the time of transplantation and at regular 
intervals thereafter. Multiple serum samples were available for the recipients included 
in the study: a sample immediate pre-transplant, at month 3, month 6, year 1, and 
preferably one for every year thereafter up to July 2009, graft failure or death. As not 
every patient had a yearly follow-up in the transplant center, the serum samples could 
not be obtained every year for all patients in the study. Two patients were lost to 
follow-up at three and four years. A total of 1107 sera were tested for the presence of 
DSA. Testing of at least 5 sera per patient was mandatory, 4 in the first year including 
the pre-transplant sample and at least 1 serum thereafter. On average, eight serum 
samples per patient were examined. Collection, storage and use of tissue and patient 
data have been performed in agreement with the Code for “Proper Secondary Use of 
Human Tissue”, put forward by “The Federation of Dutch medical scientific societies” 
(www. Federa.org), therefore no IRB approval is needed. 
 
Table 4.1 Patient, donor and transplant characteristics (n=140). 
Parameter  
Recipient age, years* 51 (16-76) 
Male gender 96/44 
Donor type (HB/DCD/L) 83/35/22 
Donor age, years* 47 (4-70) 
HLA-A mismatch 0/1/2 41/68/31 
HLA-B mismatch 0/1/2 41/68/31 
HLA-DR mismatch 0/1/2 53/80/7 
HLA-DQ mismatch 0/1/2 85/55/0 
Pre-transplant CDC PRA 0-5% 132 
 6-85% 8 
Serum creatinine level at year 1** 158.02 
First transplants/ re-transplant 120/20 
Acute rejection yes/no 47/93 
Delayed graft function yes/no 53/87 
Cold ischemia time, hours** 22.4 
Data are given as numbers or in case of * as median (range), ** mean 
 
Immunosuppression 
The immunosuppressive regimen at the time of transplantation was prednisone (PRED) 
in combination with a calcineurine inhibitor (CNI) in all recipients: cyclosporine (CSA) in 
60, and tacrolimus (TAC) in 80 recipients. In addition to CSA and PRED, azathioprine 
(AZA) was added in 15 recipients. Additional immunosuppression to TAC and PRED, 
was AZA in 5 recipients and mycophenolate mofetil (MMF) in 26 recipients. None of 
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the recipients received induction therapy at the time of transplantation. CSA levels 
were determined in whole blood by Enzyme Monoclonal Immuno Test (EMIT, Dade 
Behring, Newark, DE, USA) or HPLC-MS/MS. In the first 3 months after transplantation, 
target CSA trough-levels for CSA+PRED treated recipients were 0.15-0.20 mg/l and for 
CSA+PRED+AZA treated recipients 0.10-0.15 mg/l. TAC trough-levels were measured in 
whole blood by lmx (Abbott) or HPLC-MS/MS, target levels were 15–20 ng/ml for week 
1+2 and 10–15 ng/ml for week 3+4, thereafter tapering to 5–7 ng/ml. The 
immunosuppressive regimen one year after transplantation was CNI-based in all but 
one recipient who received MMF in combination with PRED. Fifty-two recipients 
received CSA, 8 recipients were on CSA monotherapy, 28 on CSA+PRED, 15 on 
CSA+PRED+AZA(14)/MMF(1), 1 received CSA+AZA. Eighty-seven recipients received 
TAC, 48 recipients were on TAC monotherapy, 27 on TAC+PRED, 3 on TAC+PRED+AZA, 
2 on TAC+PRED+MMF, and 7 on TAC+MMF. The immunosuppressive regimen was 
solely based on pre-transplant immunological status (PRA and HLA match) and post-
transplant clinical course (acute rejections) and not on HLA antibody screening post-
transplant. 
Clinical outcome parameters 
Acute rejection was defined as any rejection treatment within 3 months after grafting. 
Rejection episodes were proven by needle core biopsy. Rejection treatment consisted 
of three doses of methylprednisolone (0.5–1.0 g/dose). For steroid-resistant rejections, 
second line therapy consisted of anti-thymocyte globulin (ATG). Delayed graft function 
(DGF) was defined as the need for renal replacement therapy in the first week after 
transplantation. Graft failure was defined as return to dialysis and was censored for 
recipient death with functioning graft. 
Center policy of tissue typing 
All patients and donors were typed at the time of transplant for HLA class I (HLA-A and 
–B) by serology and for HLA class II (HLA-DR and –DQ) by molecular methods 
(PCR-SSP). Donor typing for Cw and DP was not performed and DSA against these 
specificities were not included. All transplants were performed under the auspices of 
Eurotransplant and were ABO compatible. Crossmatches before transplantation were 
the standard NIH crossmatch with and without dithiothreitol (DTT), and the two-color 
fluorescence crossmatch. Crossmatch-sera used were the pre-transplant serum drawn 
at the time of transplantation and all relevant positive historical samples (peak sera). A 
negative class I CDC crossmatch was mandatory for transplantation. Pre-transplant 
CDC-screening was performed with and without DTT and included a selected 60-cell 
panel, in which most common HLA specificities were included. Reading was performed 
using a Leitz Patimed automated microscope and positivity was defined as at least 
10% of cell death in the patient serum over the negative controls. Of the 140 recipients 
in this cohort, 132 were non-immunized (CDC-PRA 0-5%) and 8 were immunized (CDC-
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PRA 6-85%). HLA class I and II antigens were considered unacceptable for a patient, if 
antibodies against the specificity had ever been demonstrated either at the time of 
transplantation or in the past. Mismatches from previous transplants were excluded, 
as were the paternally inherited antigens of children in female patients. Non-
transfused male recipients and female recipients not immunized by pregnancy 
received at least one leukocyte-poor blood transfusion before transplantation 
according to the local transfusion protocol at that time14. 
Single antigen Bead Assay 
Patient sera were screened for HLA antibody at the Terasaki Foundation Laboratory 
using the HLA class I and class II Single antigen assay (LABScreen beads: LS1A04 and 
LS2A01, One Lambda Inc, Canoga Park, CA). The beads detect HLA-A, -B, Cw, -DR, -DQ 
and -DP antibodies. All assays were performed according to the manufacturer’s 
protocol. Briefly, 20 µl of test serum was added to 5 µl of SA beads, incubated in the 
dark for 30 minutes at room temperature (RT), and then washed with the provided 
wash buffer. One hundred µl of goat anti-human IgG antibody conjugated with 
R-phycoerythrin(PE) was added to the beads, incubated for 30 minutes in the dark 
at RT, then washed and read on the LABScan 100 flow cytometer (One Lambda Inc., 
Canoga Park, CA). With every assay a negative control serum (One Lambda Inc, Canoga 
Park, CA) was run to determine the background due to non-specific binding. All beads 
with normalized median fluorescence intensity value (i.e. raw MFI value of the test 
bead – MFI value of the negative control bead) >2000 were considered positive. This 
cut-off point was established based on the results from a previous study15. 
Statistical analysis 
All statistical analyses were performed using Statistical Package for the Social Sciences 
software (SPSS, Cary, NC). Graft survival was analyzed with the proportional hazards 
regression analysis (Cox regression) using stepwise forward selection and backward 
elimination techniques for a basic model including suspected patient, donor, 
transplant and clinical risk factors: “age of recipient (years)”, “gender recipient 
(male vs. female)”, “type of CNI at the time of transplantation (TAC vs. CSA)”, “type of 
CNI at year 1 after transplantation (TAC vs. CSA)”, “PRED at year 1 after transplantation 
(yes vs. no)” “CDC PRA% current serum (non-immunized <6% vs. immunized ≥6%)”, 
“serum creatinine μmol/l at year 1 grouped into quartiles (<110 μmol/l vs. 
110-140 μmol/l vs. 140-180 μmol/l vs. >180 μmol/l)”, “age of donor (years)”, “donor 
type (living vs. heartbeating vs. donation after cardiac death)”, “transplant number 
(first transplant vs. re-transplantation)”, “mismatch HLA-A, -B, -DR, -DQ (0 vs. ≥1)”, 
“cold ischemia time (hours)”, “Acute rejection (no vs. yes)”, “Delayed graft function 
(immediate graft function vs. delayed graft function”. Results of DSA testing and 
interaction factors were then entered into the model that included the statistically 
significant risk factors from the basic model. Non-parametric tests (Pearson chi-square, 
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Kruskall-Wallis) were performed when indicated, a P-value <0.05 was considered to be 
statistically significant. 
Results 
DSA prevalence 
A total of 1107 sera of 140 renal transplant recipients (all pre-transplant DSA negative) 
with at least one year graft function were retrospectively tested for DSA using the 
Luminex Single antigen assay. The number of sera per patient was 5 to 17 (median 8). 
Median time of follow-up post-transplant was 11.4 years (range 1.1-14.7). During the 
follow-up period, 38 recipients lost their graft, 29 died with a functioning graft, and 73 
continued to function. After transplantation DSA were shown in 35 out of the 
140 recipients (25%). DSA were HLA class I in 11 recipients (5 A, 6 B) and class II in 20 (2 
DR, 13 DQ, 5 DR+DQ). Four recipients had both class I and II (2 A+B+DQ, 1 A+DQ, 1 
A+DR) (Table 4.2). DSA were detected in 83 out of 224 samples of the 35 positive 
recipients (mean per patient 6.4), none were shown at any time after transplantation 
in 883 samples of 105 negative recipients (mean per patient 8.4). 
Time of DSA detection 
DSA were detected early -in the first year after transplantation-, or late -after the first 
year post-transplant (Table 4.2). Early DSA were shown in 23 recipients (ID 1-23), in 16 
for the first time at month 3 (70%), in three at month 6 (13%) and in four at year 1 
post-transplant (17%). Nine had class I, 12 class II, and two both I and II. Late DSA was 
shown in 12 recipients (ID 24-35) between year 2 and 10; two class I, 8 class II and two 
both I and II.  
 
From the early DSA group (n=23) six patients showed DSA positivity throughout the 
follow-up period (ID1-6), in four the antibodies disappeared and reappeared several 
years later (ID7-10). The remaining 13 patients presented with DSA in one or two sera 
and stayed negative thereafter (ID11-23). In the late DSA group 8 of 12 recipients had 
antibodies present throughout the follow-up period (ID 24-31), the remaining four 
showed antibody presence only in one or two sera and were negative thereafter 
(ID32-35).  
 
The DSA specificities in the positive patients were consistent. With the exception of 
ID1, all patients maintained the locus specificities in all positive sera tested, as shown 
in Table 4.2. Only ID1, who presented with anti-DQ7 in all DSA-positive sera, showed 
the additional presence of A24 and B35 in one sample (month 6). 
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Transient DSA 
A group of 17 recipients developed DSA for a short period of time but the antibodies 
disappeared and were not detected again during the follow up period. The time during 
which the DSA were present varied between 3 months and 2 years. These so-called 
“transient” DSA were seen both in the early (n=13, ID11-23), and late (n=4, ID32-35) 
group. Transient early DSA was class I in 8, II in 4 and both in one recipient, transient 
late was class I in one and II in 3 patients. 
 
Median Fluorescence Intensity (MFI) values obtained when testing transient DSA 
ranged from 2000-11500 MFI, with a median value of 3000 MFI. There was no 
difference between DSA class I (median 2750, range 2000-11500) and class II 
(median 3000, range 2000-7000). In contrast median MFI value in persistent positive 
patients was 12000 (range 2000-24000), while MFI values for DSA class II were 
considerably higher (median 14000, range 2000-24000) than those for class I (median 
2400, range 2000-15500) (P=0.01). 
Clinical outcome   
From the 140 patients included in the study, 38 lost their graft function during the 
follow-up period; they were re-transplanted or returned to renal replacement therapy. 
Overall actuarial graft survival at the end of the follow-up period was 72.9%. Of the 
38 recipients who lost their graft, 16 (42%) were DSA-positive, compared to 19 (18%) 
in 102 recipients who died with functioning graft or are still functioning (X2=8.39, 
P=0.004). The grafts of the persistent positive patients had functioned in the presence 
of DSA from 1.3-13.5 years. From the DSA positive patients (n=35), 17 grafts (49%) 
failed, whereas from the DSA-negative (n=105) 21 grafts (20%) failed (X2=10.84, 
P=0.001).  
 
To test for donor-, recipient-, and transplant risk factors involved in death censored 
graft loss, multivariate analysis by Cox regression analysis was performed. First we 
analyzed a basic model without the inclusion of the DSA result. From the risk factors 
tested for in the basic model, delayed graft function (DGF) was the only significant one 
contributing to graft survival (Table 4.3). All other factors tested had a P-value from 
0.14–0.99: CIT P=0.99, HLA mm B P=0.96, age recipient P=0.95, donor type (living vs. 
heart-beating (HB) vs. donation after cardiac death (DCB)) P=0.93, gender recipient 
P=0.91, CDC immunization  (non-sensitized vs. sensitized) P=0.90, IS PRED at year one 
P=0.84, age donor P=0.68, IS CNI at year one P=0.58, HLA mm DQ P=0.50, HLA mm A 
(0 mm vs. >=1) P=0.50, IS CNI at time of transplant (TAC vs. CSA) p=0.47, acute 
rejection (no vs. yes) P=0.40, first TX vs. reTX P=0.22, serum creatinine at year one 
(quartiles) P=0.14, HLA mm DR P=0.14. Subsequently DSA positivity was introduced as 
risk factor to the model. DSA class II positivity persisting or appearing after year 1 
significantly improved the model that predicts long-term graft survival. Recipients with 
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class II DSA after the first year post-transplant are 3.2 times (CI 1.68-6.46) more at risk 
for graft failure, even when taking into account DGF, the other factor that influenced 
graft survival. DGF and DSA class II positivity were not associated (P=0.71). Class I DSA 
persistent or appearing after the first year post-transplant was a significant factor if 
introduced in the basic model (OR=3.31, CI 1.16-1.49, P=0.03), but did not remain 
significant in the multivariate analysis when introduced together with DSA class II 
positivity. Actuarial 5-year graft survival (Kaplan Meier) in class II DSA positive 
recipients after year 1 (n=19) was 68% vs. 91% in DSA negative recipients, 10-year graft 
survival was 57% vs. 80% (Figure 4.1).  
 
 
Table 4.3 Cox regression analysis of graft survival censored for death with functioning graft: significant 
risk factors in basic model (chi-square=18.58, df=2 P=0.000) and entry of DSA results. 
Basic model Odds Ratio 95% CI df P-value 
Delayed graft function 2.04 1.08 - 3.87 1  0.028 
Entry of DSA results in basic model      
   1 DSA class I positive before Y1 1.15 0.41 - 3.26 1  0.79 
   2 DSA class II positive before Y1 1.67 0.69 - 4.01 1  0.25 
   3 DSA class I positive after Y1 3.31 1.16 - 9.45 1  0.03* 
   4 DSA class II positivity after Y1 3.23 1.68 - 6.46 1  0.001** 
Interaction between DGF and 4 0.78 0.71   
*  Disappears after addition of class II; ** Change from basic model chi-square=10.70 df=1 P=0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Graft survival according to DSA class II positivity after the first year post-transplant. 
 Kaplan-Meier curve of graft-survival for DSA class II negative (solid line, n=121) and positive 
(after the first year post-transplant) recipients (dotted line, n=19). 
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The graft survival of patients with transient DSA class II was comparable to the graft 
survival of transient DSA class I positive and DSA-negative patients (P=0.51). Positivity 
in recipients with “transient” DSA was not related to clinical parameters such as 
rejection episodes, rise in serum creatinine, proteinuria or change in 
immunosuppressive regimen (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Graft survival in transient class I and class II DSA-positive patients compared to DSA-negative 
patients. 
 Kaplan-Meier curve of graft survival in DSA negative recipients (bold line), recipients with 
transient class I DSA (dotted line) and transient class II DSA (solid line). 
Discussion 
This single center study analyzed the frequency and nature of HLA DSA after kidney 
transplantation. The presence of DSA was monitored from the time of transplantation 
up to 15 years thereafter. All patients were DSA negative before transplantation, had 
at least 1 year of renal function and an average of 8 serum samples was tested per 
patient. The class and specificity of the antibodies was determined by the Single 
antigen assay. We concentrated on “de novo” donor specific antibody formation, non-
DSA were not included in the analysis. The inclusion of as many serum samples as 
possible in the study enabled us to detect changes in DSA if any, over the post-
transplant years. The strength of the present study is the screening for “de novo” DSA 
during a follow-up period of up to 15 years in a cohort of consecutive renal transplant 
recipients. 
 
DSA developed after transplantation in 25% of a consecutive series of kidney 
transplant recipients. The DSA were more often class II (60%) than class I, the high 
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number of patients with anti-DQ antibodies was remarkable. Only few patients had 
both classes of antibody (10%). From the patients who lost their graft, 42% was 
DSA positive compared to 18% of the remaining patients, showing that the presence of 
antibodies is associated with graft survival, but does not necessarily lead to an 
immediate deleterious effect on graft-function. The absence of graft-dysfunction in the 
presence of DSA is possibly the result of accommodation, a phenomenon mainly 
known from ABO incompatible transplants16. 
 
The DSA were detected in the majority of the patients within one year after grafting 
(66%), the remaining appeared after the first year post-transplant at different time 
points during the follow-up period. From 18 persistent DSA positive patients, 13 lost 
their graft after having been DSA positive for 0.6 up to 13.5 years. In general DSA were 
persistent once detected, as was the specificity of the antibodies detected. Only one 
patient (ID 1) showed next to the persistent DQ7 antibody in his serum samples, the 
additional presence of 2 class I donor specific antibodies in one sample, however the 
class I antibodies disappeared after 6 months.  
 
A distinct group of 17 patients presented with DSA during a short period of time only, 
thereafter the antibodies disappeared. We called them patients with “transient” DSA. 
Patients with transient DSA were found both early (ID 11-23) and late (ID 32-35) after 
transplantation, the DSA were more often class I than class II. Of the 17 transient 
DSA-positive recipients only three lost their graft during the follow-up period, patients 
with transient DSA seemed to have the same risk of graft failure as DSA negative 
recipients. Transient DSA could not be shown to have an effect on graft survival. To our 
knowledge transient antibodies have not been described previously in studies on 
chronic rejection, but studies as the present one with long-term follow-up of sera and 
patients, are rare. In the transient DSA patients no difference in graft survival was 
found between DSA class I and II, however the numbers in the analysis were small and 
the number of patients with DSA class II after year-1 is only 3.  
 
The strength of the antibodies detected in the Luminex Single antigen assay is 
expressed as MFI. When the MFI values for the persistent and transient DSA were 
compared, the transient DSA proved to have significantly lower MFI values. MFI values 
for transient DSA had a median value of 3000, compared to 12000 MFI for persistent 
DSA. For persistent DSA a difference was also shown between class I and II, median 
MFI for class I was 2400 and for class II 14000. This is a puzzling finding, although 
class II DSA are found more often than class I, the difference in MFI value is 
unexpected. The one patient (ID 1) who presented with persistent class II DSA and 
transient class I fitted the persistent/transient MFI profile. 
 
These findings again point to the fact that defining the cut off point for positivity in the 
Single antigen assay is not easy. Where the blessing of the technique is the clear and 
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sensitive determination of the distinct HLA antibody specificities, the question remains 
whether all the HLA antibodies whose presence is determined, are also clinically 
relevant. In a previous paper we already showed that DDA detected by SA and not by 
less sensitive methods may be related to acute rejection episodes, but are not 
detrimental to long-term graft outcome17 This is consistent with our findings in the 
analysis of 103 cytotoxic typing sera. All cytotoxic class I and II antibodies had MFI 
values >4000 in 99% of the class I and 92% of the class II sera (data not published). On 
the basis of these results, for our transplant center the decision was taken that only 
antibody in pre-transplant sera with an MFI value >4000, would be considered positive 
for clinical purposes. Although lower MFI values may represent harmful DSA in 
occasional patients, we believe this to be a small minority.  
 
DSA was strongly associated with graft survival (P=0.001) in univariate analysis. Risk 
factors reported to be associated with long-term graft survival were included in 
multivariate Cox regression analysis. DSA class II positivity persistent or appearing after 
year 1 proved to be significantly associated with long-term graft survival. Recipients 
with class II DSA after the first year post-transplant are 3.2 times more at risk for graft 
failure, even when taking into account other factors that influence graft survival such 
as DGF. Class I DSA after the first year post-transplant were not an independent 
significant factor in the multivariate analysis in addition to class II DSA, nor were either 
class I or II when only present in the first year post-transplant. From our data it is not 
possible to conclude whether it is the specificity or the MFI value that is more related 
to a worse clinical course, because the higher MFI values are predominantly found for 
the class II DSA. 
 
Interesting are the nine patients, who were DSA class II positive both before and after 
year 1 post transplant. Although in five of them the MFI values of the positive sera in 
the first year post-transplant were 19.500-22.300, this was not correlated with an 
immediate clinical event at that time. One patient still has a functioning graft after 
15 years, one died with functioning graft after 8.8 years, while the others had graft 
failure at 3.6, 9.0, and 11.8 years. From the seven patients, who were positive only 
after the first year post-transplant, one still has a functioning graft after 15 year, while 
the other six had graft failure at 3.6, 3.8, 4.2, 4.8, 11.0 and 11.3 year. Although these 
are small numbers, the results are suggestive of worse graft survival for patients with 
persistent DSA class II appearing after year I. This is in contrast with the findings by Lee 
et al., that development of HLA antibodies within the first year post-transplant 
markedly lowered allograft survival compared with later antibody development12. 
 
Actuarial 5-year graft survival (Kaplan-Meier) in class II DSA positive recipients after 
year 1 was 68% versus 91% in DSA negative recipients, 10-year graft survival was 
57% versus 80%. Actuarial 10-year graft survival for transient DSA positive (class I and 
class II) and DSA negative recipients was comparable (± 80%).  
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The role of class II antibodies in graft survival has been described before. Lachmann et 
al. tested patients with a minimum of 6 months stable kidney function, at a median of 
5 years post-transplant for the presence of DSA in one serum sample. The patients 
were antibody negative by CDC and ELISA at the time of transplant. DSA were mainly 
against HLA class II antigens, especially HLA-DQ. They concluded that class II DSA, even 
when produced late after transplantation, are detrimental to graft outcome18, which is 
in accordance with our present findings. Campos et al. studied recipients with a 
minimum of 3 years stable kidney function once for the presence of HLA antibodies at 
a median 4.4 years post-transplant19. The presence of HLA class II antibodies was a risk 
factor for graft loss even before a decline in renal function was shown; the detection 
technique however was ELISA. Hidalgo et al. tested for DSA in sera drawn at the time 
of clinically indicated biopsies (7 days-31 years). De novo DSA at the time of a late 
biopsy is primarily against class II, and is associated with histopathological changes in 
the biopsy and subsequent graft failure13. 
 
Gill et al. tested for DSA using FlowPRA in the first year post-transplant. No difference 
in graft loss could be shown between recipients with and without de novo 
HLA antibodies during the first year post-transplant. These findings support our 
analysis that DSA, developed in the first year post-transplantation and not persisting 
after the first year, have no effect on graft loss20.  
 
In a recent case-controlled study, Lee et al. looked at DSA and non-DSA in a selected 
patient group. Antibodies developed within the first year after transplantation resulted 
in graft failure after a mean of 5 years, while 80% of the recipients who developed 
HLA antibodies after one year had a graft survival of 10 years. Their conclusion that 
HLA antibody development within the first year post-transplant decreases graft 
survival, compared to later antibody development, was not supported by our findings. 
However, this study differs essentially from the one described here, because the 
patients were selected and patients with pre-transplant DSA were included12. 
 
In conclusion, our study shows that post-transplant DSA is detected in 25% of 
recipients, slightly more class II than I. DSA presence is associated with graft survival, 
but does not necessarily lead to an immediate loss of graft function. Only class II DSA, 
persistent or appearing more than one year after transplantation, turned out to result 
in worse clinical outcome. Patients with DSA had a functioning graft in the presence of 
DSA for 1.3 to 13.5 years. Most of the DSA found are persistent throughout the 
follow-up period, but in a number of patients the DSA are transient, characterized by 
lower MFI values than the persistent ones, and presence of transient DSA is not related 
to graft survival.  
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Abstract 
Background 
Donor-directed antibodies (DDA) have been shown to result in poor graft survival. This study was designed 
to analyze antibody appearance and patient and graft characteristics related to antibody formation in 
patients who lost their graft at different time points after transplantation. 
 
Methods 
Pre- and post-transplant sera of 56 DDA negative first transplant patients were screened for human 
leukocyte antigen (HLA) class I and II DDA by the Luminex Single antigen assay (LSA). All patients were 
treated with calcineurine inhibitor-based immunosuppression. 
 
Results 
Three of 56 patients proved DDA positive by LSA before transplantation. Eighty-one percent of the remaining 
53 patients became DDA class I or II positive or both; 16% before and 84% after transplantectomy. Class I 
antibodies were produced in 84% and class II in 77% of the recipients. Based on time of transplantectomy, 
three groups were created as follows: less or equal to 1 month, 1 to 6 months and more than 6 months. The 
groups proved to be significantly different for HLA class II mismatch and acute rejection. All recipients in 
group 1 to 6 months proved to be DDA positive. Logistic regression analysis showed that DDA positivity for 
class I was related to higher donor age and donor type (non-heart-beating), class II to higher donor age and 
class II mismatch. 
 
Conclusions 
Donor-directed HLA antibodies after transplantation were demonstrated in 81% of first transplant recipients, 
all of whom were DDA negative by LSA before transplantation. The majority of the antibodies were found 
after transplantectomy. These findings may have to be taken into consideration in the allocation of organs of 
marginal donors such as older or non-heart-beating kidneys. 
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Introduction 
Donor-directed human leukocyte (HLA) antibodies (DDA) newly formed after 
transplantation have been shown to result in poor graft outcome1-4. HLA antibodies 
have been demonstrated even before transplant rejection5,6. The results of these 
studies led to the suggestion that demonstrable HLA antibodies in recipients after 
transplantation are predictive of graft outcome and present a useful tool in monitoring 
of graft function. 
 
DDA detected by Luminex bead-based assays were demonstrated in post-transplant 
sera and also on transplant eluates7-10. DDA fixed to the transplant can lead to a 
possible underestimation of HLA antibodies in post-transplant sera of recipients with 
their graft in situ. The high number of recipients that remained antibody negative after 
transplantation, but turned positive after transplantectomy, arose our interest. We 
wondered whether in addition to post-transplant events, also patient and graft 
characteristics might be related to DDA positivity. The results on patients with a 
transplantectomy within 1 month after grafting were reported previously11. 
 
In contrast to many reports in the literature, we have not been able to demonstrate 
HLA antibodies before graft failure in earlier studies using conventional screening 
methods. The present study was designed with the hypothesis that antibodies before 
transplant failure would be detectable when using more advanced and sensitive 
methods. At present, the most sensitive antibody screening technique is the Luminex 
Single antigen assay (LSA). Only patients with no DDA before their first transplantation 
were included. Production of DDA, time of appearance, and antibody class were 
analyzed. Antibody production was correlated with matching grade, donor and patient 
characteristics. 
Materials and Methods 
Patients 
From 541 patients transplanted with a first kidney graft between January 1992 and 
January 2005 at the University Hospital of Maastricht, 483 were HLA antibody negative 
in complement-dependent cytotoxicity (CDC) and ELISA before transplantation. Ninety-
six of them underwent transplantectomy before 2005. When tested by flow cytometric 
(FC) screening, another 27 proved HLA antibody positive before transplantation. From 
13 recipients no serum samples were available. Therefore 56 patients were included in 
the study. They were analyzed taking into account the time of transplantectomy and 
divided into groups I (transplantectomy <1 month), II (1-6 months) and III (>6 months). 
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Pretransplant patient characteristics are given in Table 5.1. Clinical follow-up was 
continued until 6 months after transplantectomy. 
 
Table 5.1 Patient characteristics: All patients and time of transplantectomy groups. 
Parameter All patients 
 
(n=53) 
Group I 
<1mo 
(n=23) 
Group II 
1-6mo 
(n=13) 
Group III 
>6mo 
(n=17) 
Median recipient age (years [range]) 52 (17-72) 47 (17-71) 57 (24-72) 52 (19-66) 
Male gender 32 (60%) 14 (60%) 7 (54%) 11 (65%) 
Female recipients with pregnancies 11/21 5/9 4/6 2/6 
Donor type (L/HB/non-HB %)a 17/43/40% 26/30/44% 15/31/54% 6/71/23% 
Median donor age (years [range]) 52 (1-90) 47 (1-74) 60 (17-90) 51 (2-65) 
HLA-A, B mismatch (mean) 1.81 1.78 1.92 1.65 
HLA-DR mismatch (mean)a 0.77 0.82 1.07 0.47 
Median day of tect 50 (2-3619) 5 (2-22) 89 (32-150) 428 (187-3619) 
Acute rejection * 30% 9% 77% 24% 
aNonparametric test for differences between group I, II, and III P<0.05; HLA, human leukocyte antigen. 
 
Immunosuppression 
The immunosuppressive regimen was calcineurine inhibitor-based in all recipients; 
tacrolimus (TAC) in 38 recipients and cyclosporine A (CsA) in 18. Additional 
immunosuppression to TAC was prednisone (PRED) in 34, mycophenolate mofetil 
(MMF) in 12, daclizumab in one and rapamycine (RAPA) in nine patients. In addition to 
CsA, PRED was added in 18 and azathioprine in two recipients. CsA levels were 
determined in whole blood by enzyme monoclonal immuno test (Dade Behring, 
Newark, DE) or high performance liquid chromotography-MS/MS. In the first 3 months 
after transplantation, target CsA trough-levels for CsA+PRED treated recipients were 
0.15 to 0.20 mg/l and for CsA+PRED+azathioprine-treated recipients 0.10 to 0.15 mg/l. 
TAC trough levels were measured in whole blood by Imx (Abbott, Abott Park, IL) or 
high performance liquid chromotography-MS/MS, target levels were 15 to 20 ng/ml 
for weeks 1 and 2, 10 to 15 ng/ml for weeks 3 and 4, thereafter tapering to 
5 to 7 ng/ml. Immunosupression was cessated after removal of the graft.  
Clinical Outcome Parameters 
A biopsy was taken during surgery 1 hr after reperfusion for every transplant. 
Rejection was defined as any rejection treatment within 3 months after grafting and 
was proven by needle core biopsy. Treatment consisted of three doses of 
methylprednisolone (0.5 to 1.0 g/dose) in 15 patients, two of which received additional 
doses of antithymocyte globulin. Sixteen of 56 recipients received rejection treatment 
or had a positive rejection histology in the explanted graft according to the Banff 
criteria. Because of the retrospective nature of the study, no material for C4d staining 
was available.   
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Serum Collection 
Non-transfused patients received one leukocyte-poor protocollary blood transfusion 
before being placed on the transplant waiting list. After transplantation, sera were 
drawn weekly during hospitalization, monthly in the first half year, and yearly 
thereafter. After transplantectomy, sera were collected at week 0, 2, 4 and 6 and at 
month 2, 3, 4, 5, and 6. Sera were stored at -30°C and centrifugated for 10 min at 
10.000g prior to testing. Per patient, the pre-transplant serum, a post-transplant but 
pre-transplantectomy serum, and two post-transplantectomy sera drawn at week 6 
and at months 2 to 6 were analyzed.  
HLA Antibody Analysis by Luminex Single antigen assay 
Specificity of HLA class I and II IgG antibodies in recipient sera was determined using 
the LABScreen SA assay (One Lambda, Canoga Park, CA) according to the 
manufacturer’s instructions. Microbeads coated with purified HLA were incubated with 
patient serum for 30 min. After washing to remove unbound antibody, the beads were 
incubated for 30 min with anti-human IgG-conjugated phyco-erythrine. All incubations 
were performed on a gently rotating platform in the dark at room temperature. The 
LABScan 100 flow analyser (Luminex, Austin, TX) and HLA-Visual software (One 
Lambda) were used for data acquisition and analysis. All beads with a normalized 
median fluorescence intensity (MFI) value (i.e., raw MFI value of the test bead – 
MFI value of the negative control bead) more than 2000 were defined as positive. This 
cutoff point was chosen because MFI more than 2000 is associated with a positive FC 
crossmatch9,12.  
Crossmatches 
Before transplantation three complement-dependent crossmatches were performed: 
the standard NIH crossmatch, standard NIH with dithiothreitol to reduce 
IgM antibodies, and a two-color fluorescence crossmatch. Sera used for the final 
crossmatches were the pretransplant serum drawn at the time of transplantation, the 
last serum tested for anti-HLA antibodies in the quarterly screening and all relevant 
positive historical samples. A negative class I dithiothreitol crossmatch was mandatory 
for transplantation. 
Center Policy of Tissue Typing 
During the investigation period the patients and donors were typed for HLA-A, -B, -DR 
and -DQ by serology and polymerase chain reaction-sequence-specific primers. 
HLA antigens were considered unacceptable for a patient if antibodies against the 
specificity had ever been demonstrated, either at the time of transplantation or in the 
past. Mismatches from previous transplants were excluded, as were the paternally 
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inherited antigens of children of female patients. All transplants were performed 
under the auspices of Eurotransplant, which means that only HLA-A, -B and -DR 
matches were included in the allocation algorithm.  
Statistical Analysis  
Statistical analyses were performed by using Statistical Package for the Social Sciences 
software (SPSS, version 15.0 for Windows).  
Nonparametric tests were performed when indicated. A P-value less than 0.05 was 
considered to be statistically significant. The suspected risk factors for total 
HLA antibody positivity and for HLA class I and class II positivity separately, that were 
tested as independent variables in stepwise backward logistic regression were as 
follows: ‘mismatch HLA class I (0 vs. ≥1)’, ‘mismatch HLA class II (0 vs. 1 vs. ≥2)’, 
‘recipient gender (male vs. female)’, ‘donor age  (years)’, ‘recipient age (years)’, ‘acute 
rejection within 3 months (0 vs. 1)’, ‘donor type (living vs. postmortal)’, for ‘postmortal 
donor (heart-beating vs. non-heart-beating)’ and ‘time of transplantectomy (group I-II-
III)’. P-value for removal in the model of the possible independent variables was set at 
P=0.05. All interaction factors were introduced separately into the final model. 
Results 
Transplantectomy was performed in 56 first kidney graft recipients, who were all 
HLA antibody negative before transplantation based on screening by CDC, ELISA and 
flow cytometry. Their sera were now analyzed with LSA. Three of 56 recipients proved 
to possess DDA in their pretransplant serum; one patient was class I and two patients 
were class II DDA positive. They were excluded from further analysis. The patient 
characteristics of the remaining 53 recipients are given in Table 5.1.  
 
Non-DDA specificities were demonstrated in the pretransplant sera of 20 of 
53 recipients (38%). They were directed against class I in 55%, class II in 5%, and both 
class I+II in 40% of the recipients. Specificities of non-DDA in pretransplant sera could 
be explained by transfusions and pregnancies. Possession of non-DDA was not an 
indication for exclusion from the analysis. After transplantation, non-DDA were 
demonstrated in 46 of 53 recipients (87%), class I in 65%, class II in 11%, and class I+II 
in 24% of the recipients.  
 
After transplantation, 10 of 53 recipients (19%) stayed DDA negative after 
transplantation and transplantectomy. DDA positivity was demonstrated in 
43 recipients (81%) (Table 5.2). Seven of 43 recipients (16%) showed DDA before 
transplantectomy (two class I and five class II), whereas in 36 (84%) they appeared 
thereafter. After transplantectomy, 37% of the patients turned positive in the 6-week 
serum, whereas 100% were found positive in the 2 to 6 month serum. 
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Table 5.2 Post-transplant DDA in patients who underwent transplantectomy. 
DDA antibody All patients 
 
(n=53) 
Group I 
<1mo 
(n=23) 
Group II 
1-6mo 
(n=13) 
Group I 
>6mo 
(n=17) 
Total negative 10 (19%)   5 (22%)   0 (0%)   5 (29%) 
Total positive 43 (81%) 18 (78%) 13 (100%) 12 (71%) 
    Class I 37 (70%) 15 (65%) 12 (92%)   8 (47%) 
    Class II 35 (66%) 12 (52%) 12 (92%)   9 (53%) 
DDA, donor-directed antibodies 
 
HLA DDA antibodies 
HLA class I and II antibody specificities were analyzed in the 43 patients, who became 
positive after transplantation. DDA antibodies directed against class I were detected in 
23% of the recipients, against class II in 16%, and against both class I and II in 61% of 
the positive recipients. DDA after transplantectomy were directed against class I, II, 
and I+II in 25%, 14%, and 61%, respectively. The specificities of the DDA are shown in 
Table 5.3.  
DDA and rejection 
Of the 16 recipients diagnosed with acute rejection, 15 (94%) had post-transplant DDA 
versus 28 of 43 (65%) patients without rejection (P=0.12). In rejectors, DDA were 
detected before transplantectomy in four and in 11 thereafter. Three non-rejectors 
had DDA before and 25 after transplantectomy. This difference in DDA detection 
before and after transplantectomy was again not statistically significant (P=0.09). The 
antibody class of the DDA detected in rejectors and non-rejectors is explained in Table 
5.4. In rejectors, a higher incidence of combined class I+II DDA was found (P=0.16). 
Time of transplantectomy 
Time of transplantectomy ranged from 1 day to more than 10 years after 
transplantation. Differences in demographic and clinical parameters depending on 
time of transplantectomy were explored by means of non-parametric statistical tests. 
Patients were divided into 3 groups: I transplantectomy less than 1 month (n=23), 
II 1 to 6 months (n=13) and III more than 6 months (n=17). The patient characteristics 
are given in Table 5.1. Group II proved to be significantly different for HLA class II 
mismatch (P=0.02) and occurrence of acute rejection (P<0.001). There was a trend 
towards a difference in the number of non-heart-beating (NHB) donors (P=0.07). The 
number of patients becoming DDA positive in group I was 78%, in group II 100%, and in 
group III 71% (P=0.11) (Table 5.2). 
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Table 5.3 DDA positive recipients: HLA mismatch and DDA class I and II specificities. 
Recipient HLA mismatch 
A         B       DR      DQ 
Class I Class II 
1  1 0 1 0 A28 DR13 
2  0 1 1 1 B51 DR4 DQ3 
3  1 1 0 1 A66 DQ4 
4  0 1 1 0 B18 DR14 
5  1 1 0 1 A31 DQ3 
6  1 1 1 1 A2 B62 DQ3 
7  1 1 2 0 A11 B8 DR11 DR14 
8  1 1 1 1 A11 B61 DR10 DQ1 
9  0 1 1 1 B7 DR15 DQ1 
10  2 1 1 1 A1 A32 B62 DR11 DQ3 
11  0 1 1 0 B44 DR13 
12  2 1 0 1 A2 A31 DQ3 
13  1 0 1 0 None DR10 
14  2 2 1 1 A3 A24 B7 B62 DR4 DQ3 
15  1 0 0 1 A28 DQ3 
16  2 1 1 1 A29 A30 None 
17  1 1 1 1 A28 B13 DQ2 
18  1 1 1 0 A28 B8 None 
19  2 1 1 0 A11 A23 DR7 
20  1 2 1 0 None DR7 
21  1 1 1 1 None DR13 DQ1 
22  1 1 1 0 A24 None 
23  1 2 1 0 A1 B44 DR16 
24  1 1 1 1 A24 DQ2 
25  1 1 0 0 A11 B35 None 
26  1 1 1 1 None DQ1 
27  1 1 0 0 A1 B38 None 
28  0 2 0 0 B38 B44 None 
29  0 1 1 1 B57 DR7 DQ3 
30  1 1 1 0 A24 B7 DR15 
31  0 1 0 0 B35 None 
32  1 1 0 2 A23 DQ2 DQ4 
33  1 1 1 0 A24 B35 None 
34  1 1 1 1 A28 B35 None 
35  0 2 1 1 None DR16 DQ1 
36  0 2 1 1 A3 B7 DR15 DR4 DR53 
37  1 1 0 0 A3 None 
38  1 1 1 1 None DQ2 
39  0 1 1 1 None DQ3 
40  1 0 2 0 A11 DR14 
41  0 1 1 1 B57 DR15 DQ6 
42  1 1 1 1 A3 B27 DR1 DQ1 
43  1 1 1 0 A2 B57 DR10 
Recipient 1-36: DDA positive after transplantectomy; Recipient 37-43: DDA positive before 
transplantectomy; DDA, donor-directed antibodies; HLA, human leukocyte antigen 
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Table 5.4 Acute rejection in DDA positive patients before and after transplantectomy. 
 DDA 
Class I 
DDA 
Class II 
DDA 
Class I + II 
Before transplantectomy  n=7    
     Rejection  n=4 1 3 0 
     No rejection n=3 1 2 0 
After transplantectomy    
Rejection  n=11 1 3 0 
No rejection n=25 1 2 0 
DDA, donor-directed antibodies 
 
Logistic regression analysis 
To investigate the relationship between DDA positivity after transplantectomy and 
clinical parameters, such as matching grade, donor and patient characteristics, 
backward logistic regression analysis was performed. Outcome parameters were total 
DDA (class I or II or both) positivity, DDA class I positivity, and DDA class II positivity 
after transplantectomy. Outcome parameters tested for included the following: 
recipient age, recipient gender, donor age, donor type (living vs. cadaver), HLA class I 
or II mismatch, acute rejection within 3 months after transplantation, time of 
transplantectomy group I-II-III, and immunosuppressive regimen (TAC vs. CSA). 
 
With total DDA positivity as outcome parameter, the only risk factor included in the 
final model (P=0.008, ҳ2=9.76, df=1, r2=0.27) was donor age (year) (Odds ratio=1.053, 
P=0.008). This can be interpreted as follows: each 1 year increase in donor age 
increases the risk of DDA positivity with 5.3%. The positive and negative predictive 
values of the model are 70%.  
With class I DDA positivity as outcome parameter, the risk factors included in the final 
model (P<0.0001, ҳ2=23.05, df=3, r2=0.48) were donor age (Odds ratio=1.060, P=0.007) 
and donor type (NHB) (Odds ratio=32.080, P<0.0001). This means that each 1 year 
increase in donor age increases the risk of DDA positivity with 6.0% and patients 
receiving a kidney from a non-heart-beating donor are 32 times more at risk for DDA 
positivity than patients receiving a kidney from a heart-beating donor.  
With class II DDA positivity as outcome parameter, risk factors included in the final 
model (P=0.003, ҳ2=13.91, df=3, r2=0.31) were donor age (year) (Odds ratio=1.039, 
P=0.03), HLA mismatch class II (0-1 vs. ≥2) (Odds ratio=5.307, P=0.01). Thus each 1 year 
increase in donor age increases the risk of DDA positivity with 3.9% and patients 
receiving a kidney with two or more HLA class II mismatches are 5 times more at risk 
for DDA positivity than patients receiving a kidney with less than two HLA class II 
mismatches.  
The positive and negative predictive values of the models are given in Table 5.5. 
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Table 5.5 Logistic regression with total DDA, DDA class I or II positivity after transplantectomy as 
dependent variablea. 
Independent variable Odds ratio 95% Cl df P-value 
Total HLA DDA positivity     
   Donor age (yr) 1.053 (1.01-1.10) 1 0.008 
Class I DDA positivity     
   Donor age (yr) 1.060 (1.01-1.12) 1 0.007 
   Donor type (HB vs. NHB) 32.080 (3.40-571.64) 2 <0.0001 
Class II DDA positivity     
   Donor age (yr) 1.039 (1.00-1.08) 1 0.03 
   HLA mismatch class II (≥2) 5.307 (1.35-20.81) 1 0.01 
a Multivariate backward regression analysis with suspected risk factors: recipient gender (M/F), recipient age 
(years), donor age (years), HLA class I mismatch (0 vs. ≥1), HLA class II mismatch (0 vs. 1 vs. ≥2), donor type 
(living vs. hb vs. nhb), tect-group (I-II-III), acute rejection, immuno-suppressive regimen (TAC vs. CsA). 
bFinal model: P=008, chi-square=9.763, df=1, r-square=0.271, PPV=70%, NPV=70%.    
cFinal model: P<0.0001, chi-square=23.05, df=3, r-square=0.488, PPV=95%, NPV=72%.    
dFinal model: P=0.003, chi-square=13.91, df=2 r-square=0.314, PPV=75%, NPV=73%.    
Discussion 
Definition of HLA antibody specificities has become much more accurate by the use of 
increasingly sensitive antibody screening methods. After CDC and ELISA, flow 
cytometry proved to be the more sensitive method, equalled now by the Luminex 
bead-based assays12, particularly the Single antigen bead assay. Although the clinical 
relevance of DDA detected by LSA is not yet clear13, the pressure on laboratories to use 
it for clinical purposes and data presentation is growing. Testing by LSA screening 
demonstrated de novo DDA after transplantation in 81% of first transplant recipients, 
who were all DDA negative by LSA before transplantation. Antibodies were detected 
before transplantectomy in only 13% of the recipients; the majority was detected after 
transplantectomy. These findings are in contrast with several reports in the literature, 
where HLA antibodies have been shown to be associated with acute and chronic 
rejection2,14 and poor graft survival15. The results of these studies led to the hypothesis 
that detection of HLA antibodies in patients after transplantation was a useful early 
predictor of graft outcome16. The present findings could not confirm this view, which 
might be due to the selection of the patient group (transplantectomy of first graft 
patients only), the pretransplant antibody status of the recipients (DDA negative 
before transplantation by LSA) and the immunosuppressive protocol (calcineurine 
inhibitor-based). From 16 patients with rejection, 11 turned antibody-positive only 
after transplantectomy. Because only LSA DDA negative first transplant recipients were 
studied, the appearance of DDA is considered to be related to the renal transplant. 
 
DDA after transplantectomy were directed against HLA class I+II in 61%, class I only in 
25%, and class II only in 14% of the recipients. The majority of the recipients showed 
the presence of combined class I and II antibodies. The subdivision in antibody class 
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differed considerably between different studies; 32%, 21%, and 47% were found in a 
study of chronic rejection, which was performed using flow cytometric and Luminex 
methods17. In 2 studies using Elisa for HLA antibody detection, 22%, 61%, and 17%5 and 
20%, 38%, and 43%18 were found, respectively. The inclusion criteria for the patients 
were different in the papers mentioned. 
 
Of the DDA positive recipients, 98% also showed non-DDA. Non-DDA pre-transplant 
was shown in 38%, 62% demonstrated non-DDA only post-transplant. Of the recipients 
with non-DDA antibodies, 10 were female with a history of pregnancy. Two female 
recipients, who had been pregnant, showed the presence of non-DDA class I without 
specific DDA class I antibodies. Both women were proven DDA-negative after 
transplantation by LSA, the non-DDA were directed against a paternally inherited 
antigen from their children.  Because these antigens were excluded in the kidney 
donor, this shows that antibody production against paternal antigens can be (re-) 
stimulated by a nonspecific stimulus19,20. For class II, the same phenomenon was 
observed in one female recipient. In two male recipients, the non-DDA were directed 
against antigens from a previous blood transfusion.   
Mao et al. reported that 77% of recipients with failed allografts had both DDA and non-
DDA in their serum21. They concluded that the majority of these non-DDA antibodies 
were directed against “donor-specific epitopes”. The immunogenicity of a kidney graft 
is related to differences in amino acid sequences of HLA molecules between donor and 
recipient, these differences or “epitopes” are considered to be the basic units of 
immunogenicity22. In the study of Piazza et al.23, only 9% of recipients developed class I 
alloantibodies with specificity restricted to the mismatched HLA class I antigens of the 
graft, in 90% of their study population a broad HLA sensitization was found, supporting 
the idea that non-DDA are elicited together with DDA in response to a donor-specific 
epitope.    
 
The DDA appeared after transplantectomy in 84% of the positive recipients within 
6 months, 37% was demonstrable at 6 weeks. Antibody detection after approximately 
4 months was previously described for patients transplantectomised within 1 month 
after grafting11. In the present group of recipients with a median time of 
transplantectomy of 50 days (range 2-3619), the findings were similar. Removal of the 
kidney transplant itself, probably in combination with cessation of immunosuppression 
after transplantectomy, is the probable event leading to antibody detection24. 
 
Recipients were divided into three groups according to the time of transplantectomy; 
within 1 month after grafting, between 1 and 6 months, and after more than 6 months. 
The first group predominantly consists of technical failures and primary nonfunction, in 
the second acute rejection is the major reason for graft loss and in the third the 
number of acute rejections is comparable to the overall transplant group and graft 
loss, is mainly due to chronic allograft nephropathy. When the characteristics of the 
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groups are compared, HLA-DR mismatch and acute rejection episodes proved 
significantly different between the groups. The highest numbers of acute rejections 
and NHB donors were found in patients with early graft failure (groups I and II) and as 
a result early transplantectomy (less than 6 months after transplantation). In recent 
years, more NHB donors are transplanted in the Netherlands. Recipients of 
NHB donors experience more primary non-function, more rejection, and more early 
failures25-27. The number of class II mismatches is highest in patients with 
transplantectomy less than 6 months (groups I and II). It is well known that class II 
mismatches are associated with a worse graft survival28. The number of patients that 
turn DDA positive for HLA is also the highest in group II.  
 
In an attempt to determine which factors play a role in the formation of HLA class I or 
II antibodies, we performed backward regression analysis. For total DDA positivity, an 
increase in donor age was related to an increase in DDA positivity. A higher donor age 
related to DDA positivity has also been shown for a group of recipients with 
transplantectomy within 1 month, as reported previously11. Several studies have 
reported on the relation between higher donor age and increase in 
immunogenicity29,30. A mechanism called the “injury response” was suggested as 
explanation by Halloran et al.31.   
 
Factors related to DDA positivity could be different for class I and class II positivity and 
actual relationships might be obscured by the above analysis. Therefore the analysis 
was repeated for DDA class I positivity and DDA class II positivity separately.  
 
For DDA class I positivity, donor type and donor age were statistically significant in the 
final model. Particularly, recipients of NHB donor grafts had a high risk for 
DDA positivity. The effect is most probably multifactorial, NHB grafts have a longer first 
warm ischemic time, and up-regulation of major histocompatibility complex and 
shedding of antigen might be higher in those grafts, that often show primary 
nonfunction. But care should be taken in drawing firm conclusions from groups with 
small numbers, e.g. the NHB donors were older and were transplanted into older 
recipients. No significant differences in DDA positivity were noticed between recipients 
of a heart-beating and NHB graft, who failed within 6 months. Because only very few 
patients without class I mismatches were included, the factor ‘HLA class I mismatch’ 
could not be analyzed. Others investigators, however, did find such a relationship with 
class I positivity32. 
 
For class II positivity, the related independent factors were donorage (year) and class II 
mismatches (DR and DQ). In an Italian study2, no such correlation between 
DR mismatch and class II positivity was evidenced. The relation between class II 
mismatches and DDA class II positivity might be due to the fact that in our study, 
besides HLA-DR also DQ mismatches were included. It has been reported that HLA-DQ, 
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rather than HLA-DR, is targeted by the alloantibody response, proving the importance 
of HLA-DQ antibodies28,33. For DDA class II positivity, matching for class II antigens 
might be of importance especially in high risk transplants, for example, from older 
donors and NHB grafts, as they have a higher failure rate.   
 
In conclusion our hypothesis that antibodies before transplant failure, which we were 
unable to demonstrate in earlier studies, would be detectable when using more 
advanced and more sensitive methods, proved not to be valid. De novo DDA 
HLA antibodies after transplantation were demonstrated in 81% of first transplant 
recipients, who were all DDA negative by LSA before transplantation. Antibodies were 
detected before transplantectomy in only 16% of the recipients; most of them were 
detected thereafter. The frequency of class I and II antibodies was approximately the 
same; the majority of the antibodies were found combined. NHB donortype and higher 
donor age is related to DDA class I positivity, whereas worse class II match and higher 
donor age are related to antibody class II positivity. These findings may have to be 
taken into consideration in the allocation of organs of marginal donors, such as older 
or non-heart-beating kidneys. 
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Abstract 
Human leukocyte antigen (HLA)-DP is considered a target for humoral immune response in clinical 
transplantation. This study analyses the incidence of HLA-DP antibodies in renal patients. Development and 
epitope specificity of donor-specific antibodies (DSA) and non-DSA (NDSA) were examined. 
 
Pre- and post-transplant sera of 338 patients were screened for HLA-DP antibodies using the Luminex Single 
antigen assay. Positive patients, partners and/or kidney donors were HLA-DP typed by sequence specific 
oligonucleotides. Potential epitopes were mapped by comparing the amino acid sequences of HLA-DP 
hypervariable regions (HVR) A-F of recipient, partner and/or donor. Specificities in the sera were aligned to 
deduce the HVR motif responsible for the antibodies.  
 
HLA-DP antibodies were detected in 14% of the patients (48/338). Before transplantation the antibodies 
were shown in 23% (10 females and 1 male) and 77% were found after transplantation (30 in patients after 
the first, 7 after the second graft.) Specificities were never restricted to individual mismatched antigens; 
broad HLA-DP sensitization was found as a rule. A single HVR mismatch was present in 80% of the DSA and in 
79% of the NDSA. No HLA-DPA specific antibodies were found.  
 
Our findings confirm that HLA-DP antibodies are specific for epitopes shared by different HLA-DP antigens, 
indicating that only a restricted number of mismatched epitopes are recognized by the recipients immune 
system. Matching for immunogenic HLA-DP epitopes for renal transplantation seems to be functionally more 
relevant than classical matching at the allelic level. 
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Introduction 
Human leukocyte antigen (HLA)-DP is an HLA class II locus identified more than 
30 years ago as a possible stimulator of the mixed lymphocyte culture response in 
previously primed cells. It was originally named the SB locus but was renamed DP after 
the 1984 workshop1. DPB1 and DPA1 are the MHC genes encoding the DP molecule. 
HLA-DP antigens were initially typed by cellular methods, the prevalence of antibodies 
against HLA-DP antigens was shown later2,3. At present 132 HLA-DP alleles are 
described using DNA-based typing methods, mostly sequence-based typing (SBT)4,5. 
The polymorphism of HLA-DP is largely concentrated in six hypervariable regions 
(HVRs), A-F, in exon 2 of the DPB1 gene. Most DP antigens are characterized by specific 
combinations of amino acid sequences (motifs) of these six HVRs. HLA-DPA is also 
polymorphic with 27 known alleles at present. They are divided in 4 groups: 
DPA1*01-*04. The DPA polymorphism is restricted and involves less amino acids 
sequences than that of DPB. 
 
HLA-DP antigens expressed on peripheral blood cells and also on endothelial cells 
especially during rejection episodes are supposed to present a target for the humoral 
immune response in kidney transplantation6-8. Population analyses showed that 
HLA-DP mismatches between donor and recipient did not influence the outcome of 
first kidney transplants, but did have an impact on retransplants9. Epitope-based 
matching rather than allele matching should probably be the method of choice10. 
 
The contribution of HLA class II antibodies, especially HLA-DP, to graft rejection and 
graft loss has long been poorly understood, because testing for their detection on 
B-lymphocytes was hardly satisfactory. With the introduction of the solid-phase 
antibody detection assays, in particular, the Luminex Single antigen (LSA) assay, where 
HLA-DP molecules are attached to microspheres, class II DP antibodies are now 
detected easily and their clinical relevance might be assessed more accurately11.  
 
This study was designed to analyze the incidence of HLA-DP antibodies in renal 
patients before and after transplantation. Furthermore, the epitope specificity and the 
correlation between the development of donor-specific antibodies (DSA) and 
non-donor-specific antibodies (NDSA) were examined using LSA. HVRs of both patient 
and donor were determined by sequence specific oligonucleotides (SSO) to identify 
potential DSA epitopes. 
96⏐Chapter 6 
Materials and Methods 
Patients and samples 
From January 2007 until January 2009, 338 renal patients from the University Hospital 
of Maastricht were screened for the presence of HLA class II antibodies using the 
Luminex Single antigen assay (LSA). Of them, 133 are currently on the renal transplant 
waiting list, where 43 have never been transplanted and 90 are awaiting 
retransplantation. The remaining 205 were tested in the local post-transplant protocol. 
All patients presenting with HLA-DP antibodies were selected and investigated further. 
Their pre- and post-transplant sera were examined with LSA. Patient characteristics are 
given in Table 6.1.  
 
Table 6.1 Characteristics of HLA-DP antibody positive and negative patients: all (n=338), un-transplanted  
(n=43) and transplanted (n=295) patients. 
 HLA-DP ab negative patients HLA-DP ab positive patients 
All patients n=290 n=48 
Male gender 145 (50%) 19 (40%) 
Females (pregnancies) 145 (121, 83 %) 29 (22, 76%) 
No. of transplants0   32 11 
 1 180 30 
 2   67   7 
 3     6  
 4     3  
 5     2  
Nr of transfusions (mean ± SD)   
 Packed cells   4.3 ± 10.0 2.0 ± 2.5 
 Leukocyte depleted 1.7 ± 3.2   8.6 ± 12.2 
Un-transplanted n=32 n=11 
Male gender 8 (25%) 1 (9%) 
Females (pregnancies) 24 (24, 100 %) 10 (10, 100%) 
Nr of transfusions (mean ± SD)   
 Packed cells 0.7 ± 1.0 2.1 ± 3.5 
 Leukocyte depleted 1.4 ± 2.9 12.3 ± 21.5 
Transplanted n=258 n=37 
Male gender 137 (53%) 18 (49%) 
Females (pregnancies) 121 (97, 80 %) 19 (12, 63%) 
Nr of transfusions (mean ± SD)   
 Packed cells 1.8 ± 3.3 2.0 ± 2.2 
 Leukocyte depleted   4.6 ± 10.5 2.0 ± 2.2 
HLA, human leukocyte antigen 
HLA-DP antibody detection by LSA 
Antibodies against HLA-DP in recipient sera were determined using the LABScreen® SA 
class II assay (One Lambda, Canoga Park, CA) according to the manufacturer’s 
instructions. Microbeads coated with purified HLA molecules were incubated with 
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patient serum for 30 min. After washing to remove unbound antibody, the beads were 
incubated for 30 min with antihuman-IgG-conjugated phyco-erythrine. All incubations 
were performed on a gently rotating platform in the dark at room temperature. The 
LSA class II lot used contained 13 micro-beads coated with single HLA-DP alleles: 
DPB1*0101, *0201, *0301, *0401, *0402, *0501, *0901, *1001, *1101, *1301, *1401, 
*1701 and *1901. The LABScan 100 flow analyser (Luminex, Austin, TX) and 
HLA-VISUAL software (One Lambda) were used for data acquisition and analysis. All 
beads with normalized median fluorescence intensity value (i.e. raw median 
fluorescence intensity (MFI) value of the test bead – MFI value of the negative control 
bead) >2000 were considered positive. The cut-off point was established based on the 
results from previous studies12.  
HLA-DP typing by luminex SSO assay 
DNA samples of patients with HLA-DP antibodies (n=48), partners (n=8) and kidney 
donors (n=31) were typed for HLA-DP using LABType®SSO according to the 
manufacturer’s instructions. For two patients, no DNA from the partner was available 
and for six recipients DNA of the organ donor was lacking. DNA samples were isolated 
from either peripheral blood or spleen cells using the QIAamp DNA blood mini kit 
(Qiagen, Venlo, The Netherlands) and stored at -30°C.  
 
In short, 2 μl of purified genomic DNA (concentration 20 ng/μl) is polymerase chain 
reaction (PCR)-amplified using 4 μl of group-specific primer, 0.2 μl Taq polymerase 
(0.33U) and 13.8 μl amplification mix. The primer has a biotin label, which allows the 
PCR product to be detected using R-phycoerythrin-conjugated streptavidin (SAPE). 
After amplification, the PCR product is denaturated and neutralized and allowed to 
rehybridize (15 min, 60°C) to a mixture of 43 complementary sequence-specific 
oligonucleotide probes conjugated to color-coded beads. The mixture is then washed 
three times and is incubated with 50 μl of SAPE (1:50) for 5 min at 60°C. Excess SAPE is 
washed away. The LABScan 100 flow analyser (Luminex) identifies the fluorescent 
intensity of the PE on each microsphere. The assessment of the HLA-DP typing is based 
on the reaction pattern compared to patterns associated with published HLA-DP 
sequences.  
 
Twelve DNA samples previously typed for HLA-DP by the SBT method described 
previously13 were used to validate the SSO HLA-DP typing method, which represented 
the alleles: DPB1*0101, *0201, *0301, *0401, *0402, *0501, *0901, *1001, *1101, 
*1301, *1401, *1701 and *1901. The aim was to correctly identify the different 
polymorphic motifs of the six HVRs of exon 2 of all HLA-DP alleles present in the LSA 
class II lot used (Table 6.2). The results obtained were identical to SBT, albeit SSO 
included ambiguous typing results. Among those, the correct typing was always 
present, for all samples the six HVR polymorphisms were correctly identified. In case 
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an ambiguous result was obtained for patient and partner/donor-HLA-DP typing, the 
allele most frequent in Caucasians was assigned14.  
 
Table 6.2 Hypervariable regions (A-F) of exon 2 of the HLA-DPB1 alleles present  in the LSA class II assay. 
 A B C D E F 
DPB1* 8-11 33-36 55-57 65-69 76 84-87 
*0101 VYQG EEYA AAE ILEEK V DEAV 
*0201 LFQG EEFV DEE ILEEE M GGPM 
*0301 VYQL EEFV DED LLEEK V DEAV 
*0401 LFQG EEFA AAE ILEEK M GGPM 
*0402 LFQG EEFV DEE ILEEK M GGPM 
*0501 LFQG EELV EAE ILEEK M DEAV 
*0901 VHQL EEFV DED ILEEE M DEAV 
*1001 VHQL EEFV DEE ILEEE V DEAV 
*1101 VYQL QEYA AAE LLEER M DEAV 
*1301 VYQL EEYA AAE ILEEE I DEAV 
*1401 VHQL EEFV DED LLEEK V DEAV 
*1701 VHQL EEFV DED ILEEE M DEAV 
*1901 LFQG EEFV EAE ILEEE I DEAV 
HLA, human leukocyte antigen; LSA, Luminex Single antigen 
 
Donor specificity of HLA-DP antibodies 
Epitopes for possible antibody formation were mapped by comparing the HLA-DP HVR 
amino acid sequences of exon 2 of recipient, partner and/or donor, as defined by SSO 
typing. A potential mismatched epitope was defined as an amino acid sequence 
present in one of the six HVRs of partner or donor, but absent in the recipient. To 
verify the potential epitopes, LSA patterns were used (Table 6.2). The amino acid 
sequences of the HLA-DP-specificities recognized by the serum were aligned. They 
were compared in order to deduce the most likely mismatched HVR motif responsible 
for the antibodies. An example is given in Table 6.3. 
Results 
HLA-DP antibody incidence in renal patients 
Screening for HLA class II antibodies by LSA before and after transplantation was 
performed for 338 renal patients from the University hospital of Maastricht. Class II 
HLA-DP antibodies were detected in 48 (14%) of them. In 11 patients (23%), 
DP antibodies were detected before transplantation, 10 females and 1 male. In 37 of 
the positive patients (77%), the antibodies were shown after transplantation, in 30 
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after the first and in 7 after the second graft (Table 6.1). In two patients, DP antibodies 
were the only ones demonstrable; HLA-DR and -DQ antibodies were present next to DP 
in 41 (Table 6.4). Additional class I antibodies were shown in 45 patients.  
 
Table 6.3 Comparison of patient and donor hypervariable region (HVR) typing (SSO) to identify potential 
epitopes (bold) and alignment of specificities detected with LSA to verify donor-specific 
epitope (boxed).  
SSO HLA-DP HVR 
   A B C D E F 
Patient 18876 *0201 LFQG EEFV DEE ILEEE M GGPM 
 *0401 LFQG EEFA AAE ILEEK M GGPM 
Donor  *0101 VYQG EEYA AAE ILEEK V DEAV 
 *0401 LFQG EEFA AAE ILEEK M GGPM 
LSA DP HVR 
   A B C D E F 
positive beads  *1901 LFQG EEFV EAE ILEEE I DEAV 
 *0101 VYQG EEYA AAE ILEEK V DEAV 
 *1701 VHQL EEFV DED ILEEE M DEAV 
 *0301 VYQL EEFV DED LLEEK V DEAV 
 *0501 LFQG EELV EAE ILEEK M DEAV 
 *1001 VHQL EEFV DEE ILEEE V DEAV 
 *1301 VYQL EEYA AAE ILEEE I DEAV 
 *1401 VHQL EEFV DED LLEEK V DEAV 
 *0901 VHQL EEFV DED ILEEE M DEAV 
 *1101 VYQL QEYA AAE LLEER M DEAV 
negative beads *0402 LFQG EEFV DEE ILEEK M GGPM 
 *0201 LFQG EEFV DEE ILEEE M GGPM 
 *0401 LFQG EEFA AAE ILEEK M GGPM 
HLA, human leukocyte antigen; LSA, Luminex Single antigen; SSO, sequence specific oligonucleotide. 
Bold: the potential mismatched epitope, defined as an amino acid sequence present in one of the six HVRs 
of the partner or donor, but absent in the recipient  
Boxed: the mismatched DEAV motif considered to be responsible for the HLA-DP antibodies detected by LSA 
 
 
Table 6.4 Class II antibodies detected by LSA in HLA DP positive and negative patients. 
 DP ab negative patients 
(n=290) 
DP ab positive patients 
(n=48) 
DR+DQ  74 (25.5%)  27 (56%) 
DR only  48 (16.5%)  10 (21%) 
DQ only  25 (9%)  4 (8%) 
DR+DQ-negative  143 (49%)  7 (15%) 
HLA, human leukocyte antigen; LSA, Luminex Single antigen.  
 
HLA-DP typing by luminex SSO assay 
The amino acid sequences of the six HVRs of exon 2 of all HLA-DP alleles present in the 
LSA class II lot used (Table 6.2) were correctly identified by SSO in all samples. An 
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ambiguous result in patient and partner/donor-HLA-DP typing was obtained in three 
individuals (ID7 DPB1*0601, ID10 DPB1*1601 and ID11 DPB1*3601) (Table 6.6).  
Pretransplant HLA-DP antibodies   
All female patients positive for HLA-DP antibodies before transplantation had been 
pregnant. For two patients, the immunization partner was unknown and no children 
were available for typing. For the remaining eight patients, DNA of the partner was 
available for retrospective DP typing to identify the potential epitopes to which the 
antibodies were directed. Two patients proved to be DP identical with their partner, 
the remaining six were mismatched for one or two DP alleles. Patient DP typing, allelic 
and HVR mismatches are given in Table 6.5. In 5/6 DP-mismatched patients, DSA were 
detected. Additional NDSA specificities directed against a single donor-specific 
HVR mismatch were detected in three patients and against two donor-specific 
HVR mismatches in one. In one patient with four HVR mismatches, no clear motif could 
be detected. One patient had detectable NDSA only; her DP antibodies were the result 
of interlocus DRB1/DPB1 crossreactivity. The same held true for the DP antibodies of 
the two patients, who were DP identical to their partner. 
 
In the two females with unknown pregnancy immunization, two antibodies-causing 
motifs were identified. The only male patient, who presented with pretransplant 
DP antibodies, had received 66 transfusions with leukocyte-depleted blood. In his 
serum, class I antibodies were present but no additional class II DR/DQ antibodies 
were detected. No identification was possible for the antibody-causing motif.  
Post-transplant HLA-DP antibodies   
HLA-DP antibodies after transplantation were found in 37 recipients: in 30 after their 
first transplant and in 7 after the second. For 31 of them, donor-DNA was available for 
retrospective HLA-DP typing. Sixteen recipients were mismatched for two DP alleles 
with their donor, fifteen showed one allelic DP mismatch. Patient DP typing, allelic and 
HVR mismatches are given in Table 6.6.  
 
DSA were found in 26 recipients, NDSA were shown in all. DSA and NDSA were 
directed against a single donor-specific HVR in 19 patients, against 2 HVRs in 2 and 
against 3 HVRs in 1. The antibody-causing motif was donor-specific in 25, and 
non-donor-specific in 4 recipients. For eight recipients, no clear motif could be 
identified. 
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Frequency of antibody-target motifs 
A total of 47 antibody-target patterns were observed. The HVR-F (DEAV) motif was 
detected in 23 (49%) cases, HVR-C (DED/DEE) in 14 (30%), HVR-B (EEFV) in 6 (13%) and 
HVR-C (AAE), HVR-F (GGPM), HVR-D (ILEEE) and HVR-E (V) in 1 case each. In 70% 
(n=33) the antibody-target motif was donor-specific.  
Discussion 
Anti-HLA-DP antibodies have always been difficult to identify by complement-
dependent cytotoxicity (CDC). In most instances, CDC panels were not routinely typed 
for HLA-DP, and if typing was performed, the specificity of the antibodies was difficult 
to establish because they were not directed towards a single DP antigen. Furthermore, 
DP antibodies were often masked by the presence of other class II antibodies. 
Recently, microbeads coated with purified HLA-DP molecules were added to the SA 
class II assay, both in flow cytometry and luminex, which allows more precise 
identification of HLA-DP antibodies. In the present study, renal patients were screened 
for HLA-DP antibodies using a panel of 13 HLA-DP antigens: *0101, *0201, *0301, 
*0401, *0402, *0501, *0901, *1001, *1101, *1301, *1401, *1701 and *1901. Although 
over 130 HLA-DPB1 alleles have been described at present, the most frequent alleles in 
the Caucasian population are represented in this panel14. Because the polymorphism 
of HLA-DP is concentrated in six HVRs of exon 2 of the HLA-DPB1 gene and almost all 
DP antigens can be described as combinations of several different motifs at each of 
these HVRs (Table 6.2), the panel used covered all the important and most frequent 
HVRs present in the Caucasian population. The polymorphic HVR motifs of exon 2 of 
HLA-DP not represented in the panel were: VDQL at position 8-11 (DPB1*7001), 
DEV (*3201) and EEE (*8401) at position 55-57, LLEEE (*0601, 2901, 4401, 9501), 
FLEEE  (*4101), NLEEK (*6001) and FLEEK (*8301) at position 65-69 and VGPM (*1501, 
*1801, 2801, 3401, 4001, 5301, 6201, 7401) and NEAV (*2202) at position 84-87. The 
LLEEE motif was present in two donors typed as DPB1*0601 (ID 7 and ID 11, Table 6.6). 
The VGPM motif was present in one patient typed as DPB1*2801 (ID 6, Table 6.5). 
  
The SSO assay for HLA-DP typing was validated for the alleles listed in Table 6.1. In 30% 
of the validation samples, the SSO result was the same as in SBT. In 70%, SSO resulted 
in ambiguous results, always including the correct SBT-DP typing. These results were 
because of polymorphisms outside the six HVRs, for which no DNA probes were 
available in the SSO assay. Nevertheless, all polymorphic motifs of the six HVRs of exon 
2 could be correctly assigned using the SSO method. In only three cases we had to 
assign an allele that was not validated.  
 
Before the introduction of solid-phase techniques for HLA-DP antibodies detection, 
DP antibodies were studied using the monoclonal antibody immobilization of 
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leukocyte antigens (MAILA) technique. In 1990, Mueller-Eckhardt described 
DP antibodies in 9.7% of pregnancy sera using MAILA and showed a high correlation of 
HLA-DP immunization together with reactivity against HLA class I and II (DR/DQ) 
antibodies15. Using the same technique, Pfeiffer in 1995 found the overall incidence of 
HLA-DP antibodies in patients awaiting renal transplantation to be 7.3%16. Using flow-
cytometric beads, Youngs reported that 12% of patients on their renal transplant 
waiting list possessed DP antibodies. In previously transplanted patients, the 
percentage was even higher (45%)17. With the same technique, Qiu described an 
increased incidence of DP antibodies after graft rejection11. In the present study, we 
found 12% of renal patients to have DP antibodies, 23% before and 77% after 
transplantation. 
 
Although the HLA-DPA chain is also polymorphic and could potentially be the source of 
antibody reactivity, no HLA-DPA specific antibodies were found in this study. In a 
population of this size, one might expect to find DP antibodies reacting with DPA. The 
LSA class II kit used contained four beads carrying DPA*0103, eight beads coated with 
DPA1*0201 and one bead with DPA1*0401. To evaluate possible anti-DPA reactivity, 
DPA1 alleles have to be represented in different combinations with DPB1 alleles, even 
if those are not commonly encoded on the same haplotype. DPA antibodies were 
suspected in sera where the DPB specificities remained undetermined, especially in 
three patients whose sera reacted with their own DPB1 alleles (Table 6.5 ID 3, ID 12 
and ID 15); however, this was not confirmed by Single antigen analysis. The role of the 
polymorphism of DPA1 in the intensity and specificity of antigen-antibody reactivity 
with the DP-heterodimer remains to be investigated further. DPA typing of patients, 
partners and donors was not performed because no DPA antibodies were shown. 
 
Because of the weak linkage disequilibrium of HLA-DP with the classical HLA class I and 
II antigens18, even donor-recipient pairs identical for these loci have an 80% probability 
of being mismatched at DP19. However, because of the restricted DP polymorphism, 
many of these allelic mismatches will be compatible for HVR motifs and, therefore, will 
not result in anti-DP formation.  
 
For most of the patients, the immunizing HLA-DP antigens and subsequent 
HVR mismatches could be determined. In 80% the DP antibodies were donor specific. 
None of the patients developed antibodies restricted to the mismatched DP antigens, 
and broad DP sensitization was found as a rule. This finding confirm previous 
observations that DP antibodies in sera of sensitized patients are specific for epitopes 
shared by different HLA antigens17,20,21. Even though many more potential HVR 
mismatches were present, almost all the DSA (80%) and accompanying NDSA (79%) 
were directed against a single donor-specific HVR mismatch: HVR-F in 16, HVR-C in 3, 
HVR-B in 2 and HVR-E in 1. This indicates that only a small number of mismatched 
epitopes are recognized by the recipients immune system and supports the immuno-
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dominance of HVR-F and -C as also described by Duquesnoy et al.21. HVR-F and -C 
correspond to well-defined serological epitopes recognized by monoclonal 
antibodies22,23. In 35 patients homozygous for GGPM (HVR-F) 69% of the DP antibodies 
were directed against the DEAV motif at that same position. In 21 patients 
homozygous for AAE/EAE (HVR-C) 48% of the DP antibodies were directed against the 
DED/DEE motif at that same position. These findings support the findings by Laux et 
al.10 that matching for immunogenic DPB1 epitopes was functionally more relevant 
than classical matching at the allelic level9,24. 
  
As first described by Bodmer et al.22,25, DR11 has the aminoacids D and E at positions 
57 and 58 that correlate with the D and E in HVR-C (position 56-57) of 7 of the 
13 HLA-DP alleles present in the LSA assay (DPB1*0201, 0301, 0402, 0901, 1001, 1401 
and 1701). In five patients with strong anti-DR11 antibodies, the DP antibodies 
probably resulted from this inter-locus DR11-DP epitope. In two patients, who were 
HLA-DP identical to their partner and had pretransplant DP antibodies, and in one 
patient with post-transplant DP antibodies, the DP antibodies were directed against 
the DED and DEE motif of HVR-C. In another patient with pretransplant DP antibodies, 
the specificities were explained by the DEE motif of HVR-C, because the patient 
possessed the DED motif herself. In another patient, the specificities were explained by 
the DED motif of HVR-C, while the patient himself carried the DEE motif.   
 
HLA-DP as well as HLA-DQ are up-regulated upon inflammation as shown earlier8. This 
might be the reason of the clinical relevance of anti-DP antibodies in re-transplants9. 
The contribution of anti-HLA-DP antibodies to kidney graft rejection and failure has 
long been an unresolved issue. With the introduction of the SA, the presence of 
HLA-DP antibodies can be detected easily. Subsequently, it will become possible in the 
near future to assess their clinical relevance more accurately. Meanwhile, some case 
reports have recently shown that DP antibodies represent a possible risk factor for 
transplant dysfunction and failure25-27. 
 
In summary, we have shown that HLA-DPB antibodies are found in patients before and 
after kidney transplantation. Before transplantation, pregnancy is the most important 
stimulus for antibody production but also transfusions may result in DP antibody 
positivity. The majority of the DP antibodies, however, are found after transplantation, 
usually already after the first graft. No HLA-DPA specific antibodies were found in this 
study. The DP antibodies detected in sera of sensitized patients are specific for a 
number of epitopes shared by different HLA antigens. The majority of the DSA and 
accompanying NDSA found are directed against a single donor-specific HVR mismatch, 
which indicates that only a small number of mismatched epitopes are recognized by 
the recipients immune system. Our findings confirm that matching for immunogenic 
HLA-DP epitopes seems to be functionally more relevant than classical matching at the 
allelic level, whether this is only true for retransplants remains to be established. 
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Abstract 
In Luminex bead-based screening assays, color-coded microspheres coated with human leukocyte antigens 
(HLA) are used to identify both complement-binding and non-complement- binding HLA class I and II 
antibodies in recipient sera. Many laboratories rely on their specificity detection and use the information 
obtained for allocation of donor organs. A donor-specific crossmatch in the Luminex technique is for that 
reason desirable. 
 
A LumXm, in which the actual donor-HLA are coated onto specific capture beads, was tested for 88 pre- and 
post-transplant sera of 18 recipients. The results were compared with previously published flow cytometric 
crossmatch (FCXm) results for the same donor-recipient combinations. All sera were also examined by 
Luminex Single antigen (SA) tests.  
 
Class I LumXm detected 24 of 27 T-cell positive FCXm (89%) and class II 15 of 22 B-cell positive FCXm (68%). 
Sensitivity of LumXm for class I and II was 89% and 68% and specificity was 98% and 97%, respectively. 
Discrepant LumXm results were obtained in 13 sera of 9 patients (15%). In general, based on SA testing, 
FCXm showed false positive results for class I, LumXm gave false-negative and positive results for class II. The 
LumXm test was proven not to react with recipient sera containing DQ ab only, also DP detection was 
insufficient.  
 
The validity of the LumXm has been shown for class I, but its value for class II is uncertain. HLA-DR is most 
probably correctly identified, the validity for DQ and DP is doubtful. 
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Introduction 
Screening techniques of higher sensitivity than complement-dependent cytotoxicity 
(CDC) and enzyme-linked immunosorbent assay (ELISA), like the Luminex bead-based 
assays, have been introduced in the past years1,2. In these assays, color-coded 
microspheres coated with human leukocyte antigens (HLA) are used to identify HLA 
class I and II antibodies (ab) in patient sera. The tests detect both complement-binding 
and non-complement-binding HLA antibodies using anti-human immunoglobulin G 
(IgG) as second antibody. More and more laboratories rely on the detection of 
specificities demonstrated by these type of assays and use the information obtained 
for allocation of donor organs3-6.  
 
Although the clinical relevance of antibodies detected by these bead-based techniques 
is still a matter of debate7-9, the availability of a prospective crossmatch in the Luminex 
technique is highly desirable. In the United States and United Kingdom, many 
laboratories are using flow cytometric crossmatches (FCXm) to make decisions on 
organ transplantation, although, in Europe many laboratories still rely on 
CDC crossmatches. 
 
In this report, we describe a Luminex donor-specific (DS) crossmatch (LumXm), in 
which the actual donor-HLA are coated onto specific capture beads. The results of the 
LumXm were compared to flow cytometric results for the same donor-recipient 
combinations obtained previously10. 
Materials and Methods 
Patients and sera 
From 18 patients transplanted at the University Hospital of Maastricht between 1997 
and 1999, 88 pre- and post-transplant sera were tested with the Luminex Xm 
technique. The Xm at the time of transplantation was the CDCXm with and without 
dithiotreitol (DTT), as required by the organ exchange organisation. A negative class I 
CDCXm was mandatory for transplantation. All sera had been retrospectively tested by 
FCXm as described previously10. Patients and donors were typed for HLA-A/B by 
serology and for -DR/DQ by polymerase chain reaction sequence-specific primers 
(PCR-SSP). Retrospectively, all recipient and donor typings (A,B,C,DR and DQ) have 
been repeated with molecular techniques (sequence-specific oligonucleotide (SSO) 
hybridisation, Luminex) to ascertain the exact number of mismatches. If required high-
resolution typing (DRB3, DQA1, DPB1) was performed. Patient sera were stored at 
-30oC and donor lymphocytes were isolated from peripheral blood or spleen cells and 
stored in liquid nitrogen.  
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Crossmatch assay 
Xms were performed using Xm capture beads, consisting of microspheres coated with 
monoclonal antibodies against HLA class I or II, in the Luminex technology according to 
the manufacturer’s protocol (Donor Specific Antibody beads; Tepnel Lifecodes, 
Stamford, CT). Per serum, 2.2x106 donor lymphocytes were treated with 8μl of diluted 
(1:10) nonionic lymphocyte lysis buffer. The donor lysate was subsequently incubated 
for 30 min with 5μl of Xm beads to enable binding of the solubilized donor-
HLA molecules onto the beads. The mixture was washed three times with 250μl wash 
buffer using a 96-well filter plate (Millipore, Bedford, MA) in conjunction with a 
vacuum manifold. Diluted recipient serum (1:4) was added and incubated for 30 min. 
After another three washes, 50μl antihuman IgG-conjugated phycoerythrine (anti-IgG-
PE 1:10) was added and incubated for 30 min. All incubations were performed on a 
gently rotating platform in the dark at room temperature. After addition of 130μl of 
wash buffer, the LABScan100 flow cytometer (Luminex©, Austin, TX) was used for 
mean fluorescent intensity (MFI) measurement. 
Quality assurance 
In the Xm bead mixture, three negative control beads were included, whose mean 
MFI value was used as background signal. The test was considered failed if their mean 
MFI value was >500. A positive control bead (IgG) was included to check the binding of 
anti-IgG-PE, and the minimum requirement for the assay was MFI >10.000. In parallel 
with the patient sera, the coated Xm beads were incubated with biotinylated 
monoclonal antibodies against HLA class I and II, the so-called lysate control. The lysate 
control was used to indicate correct attachment of donor-HLA on the beads. Instead of 
IgG-PE, streptavidine conjugated phycoerythrine (SAPE) is used as well as a positive 
control bead to check the SAPE. A minimum MFI value for both class I and II of the 
lysate control was set at 10.000, otherwise the test was considered failed. For the 
LABScan100 flow analyser, two calibration and two control bead mixtures were run 
prior to data acquisition. 
Data analysis 
Data generated with the LABScan100 were evaluated with the LifeMatch software 
(Tepnel Lifecodes) to obtain MFI values of capture- and control beads. To define 
positivity, the median of three negative controls was subtracted from the MFI obtained 
for the testserum. The adjusted MFI values of class I and II Xm beads were compared 
with the adjusted MFI of the positive control bead. A ratio of >5% and/or MFI value of 
>1000 were considered positive.  
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Flow-cytometry donor-specific crossmatches 
The FCXm was performed as described previously10. Briefly; donor lymphocytes were 
incubated with centrifugated, heat-inactivated recipient serum to reduce non-specific 
background11,12. After three washings incubation was performed with fluorescein 
isothiocyanate (FITC)-conjugated anti-human IgG antibody (Tago, Burlingame, CA), 
PE-conjugated monoclonal mouse antihuman T-cell (CD3) and R-PE-cyanine5-
conjugated monoclonal mouse antihuman B-cell (CD19) (Dakopatts, Glostrup, 
Denmark). After washing and resuspension, lymphocytes were analyzed with a FACS 
Calibur system (Becton dickinson, San Jose, CA) using logarithmic amplification on a 
1024 channel resolution. The linear median value of FITC fluorescence was collected 
for CD3- and CD19- positive cells. A FCXm was considered positive if the ratio of 
median value of recipient serum to negative controlserum was >1.97 
(mean+3 standard deviation) for T cells and >2.99 (mean+3 standard deviation) for B 
cells, provided that the ratio of the positive control serum to negative control was 
greater than the cut off value. External proficiency testing for FCXm was performed in 
the UK NEQAS scheme (60 Xm/year) and has always proven to be adequate. 
Antibody specificity analysis by single antigen (SA) assay 
Specificity analysis of the IgG anti-HLA class I (A, B and C) and II (DR, DQ and DP) ab of 
all recipient sera was performed using the LABScreen® SA assay (One Lambda©, 
Canoga Park, CA) according to the manufacturer’s instructions. In short, microspheres 
coated with purified HLA antigens were incubated with patient serum for 30 min. After 
washing to remove unbound antibody, antihuman-IgG-conjugated PE was added. The 
LABScan100 flow analyzer (Luminex) and HLAVisual software (One Lambda) were used 
for data acquisition and analysis.  
The reactivity of three strong allosera (panel reactive antibody (PRA)>90%) was  
determined with the class I and II Single antigen (SA) bead assay. For each bead, the 
positive control value was set at the mean of the three MFI values obtained. A positive 
bead reaction was subsequently  defined as an MFI value of at least 10% of the positive 
control value for that bead. 
Statistical analysis 
Sensitivity was defined as TP/(TP+FN), specificity as TN/(TN+FP). Predictive values were 
calculated as positive predictive value = TP/(TP+FP) and negative predictive 
value=TN/(TN+FN) (True Positive (TP)=LumXm+/FCXm+, False Positive (FP)= 
LumXm+/FCXm-, True Negative (TN)=LumXm-/FCXm- and False Negative (FN)= 
LumXm-/FCXm+). 
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Results 
Luminex bead-based crossmatches were performed for 88 longitudinal pre- and post-
transplantsera of 18 patients transplanted in Maastricht between 1997-1999. All sera 
had been crossmatched for T- and B-cells by FCXm as described previously10. A positive 
LumXm was found for class I in 25 sera, for class II in 17. For 2 sera no reliable results 
were obtained, all other sera showed negative LumXm. 
LumXm versus FCXm 
Class I LumXm detected 24 of 27 T-cell positive FCXm (89%) and class II 15 of 22 B-cell 
positive FCXm (68%) (Table 7.1). LumXm MFI values showed time curves comparable 
to the curves obtained by FCXm ratios. In Figures 7.1 and 7.2, some examples of class I 
and II LumXms are shown.  
 
Table 7.1 Comparison of donor specific LumXm with T- and B-cell FCXm. 
 LumXm positive LumXm negative N* sens/spec PPV/NPV 
FCXmT-cell pos 24 3 
FCXmT-cell neg 1 58 
86 89%/98% 96/95 
FCXmB-cell pos 15 7 
FCXmB-cell neg 2 62 
86 68%/97% 88/90 
* 2 LumXm failed due to high background values. PPV = positive predictive value, NPV = negative predictive 
value 
 
Results are compared to the corresponding FCXm obtained previously, for LumXm, the 
MFI values and for FCXm, the ratios are plotted against time. Figures 7.1A, 7.1B and 
7.1C show the class I Xm results of three recipients. All have concordant negative as 
well as positive LumXm/FCXm results. In Figures 7.2A and 7.2B, recipients are shown 
with concordant positive and negative class II LumXm/FCXm results. In Figure 7.2C, a 
patient with discordant results is depicted, some FCXm values (indicated by *) are 
positive, while the corresponding LumXm values are negative.  
 
Compared to FCXm, sensitivity of LumXm was 89% for class I and 68% for class II and 
specificity was 98% and 97% respectively. The positive predictive value of LumXm was 
96% for class I and 88% for class II and the negative predictive values were 95 and 90%, 
respectively. 
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Figure 7.1 Examples of 3 donor-recipient class I LumXm compared to T-cell FCXm. 
 Adjusted MFI values (=MFI - median negative control) for LumXm and  the ratios (=median 
value of recipient serum/negative control serum) for FCXm are plotted against time. The first 
measuring point was the time of transplantation, the others are follow-up dates.   
 Cut off point for positivity of T-cell FCXm was 1.97, and for LumXm 1000 MFI. 
 F means failure of the graft. 
 
Specificity analysis  
The sera used for the crossmatches were examined for presence and specificity of 
HLA antibodies by the SA bead assay. For class I, all 24 LumXm+/FCXm+ sera showed 
class I DS ab, whereas the 58 LumXm-/FCXm- sera showed no ab (n=27), non-DS ab 
(n=30) or a weak DS ab (n=1). The weak antibody was directed against A1. For class II, 
all 15 LumXm+/FCXm+ sera showed class II DS ab. The 62 LumXm-/FCXm- sera showed 
no ab (n=41), non-DS (n=19) or DS (n=2). The DS ab were both weak anti-DQ 
antibodies. 
Discrepant LumXm vs FCXm results were obtained in 13 sera of nine patients. For 
class I, a LumXm-/FCXm+ was shown in three patients: two had non-DS ab and one had 
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no ab at all. One patient presented as LumXm+/FCXm- and SA showed the presence of 
weak B51 DS ab. 
For class II, a total of nine discrepant LumXm results was obtained in five patients: 
three patients with seven LumXm-/FCXm+ proved to possess DP ab (n=2) or DQ ab 
(n=1). The DQ and one DP ab were DS and the other DP ab was non-DS. The other two 
patients with a LumXm+/FCXm- result were negative for HLA ab by the SA bead assay. 
With the SA bead assay as “gold standard”, the sensitivity of LumXm was 96% for class 
I and 65% for class II, the specificity was 100% and 97%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Examples of 3 donor-recipient class II LumXm compared to B-cell FCXm. 
 Adjusted MFI values (=MFI - median negative control) for LumXm and the ratios (=median 
value of recipient serum/negative control serum) for FCXm are plotted against time. The first 
measuring point was the time of transplantation, the others are follow-up dates. 
 Cut off point for positivity of B-cell FCXm was 2.99, and for LumXm 1000 MFI. 
 F means failure of the graft.  
 In 2c a patient with discordant results is shown; the positive FCXm values marked * have 
negative corresponding LumXm values. 
           FCXm T/B ratio,             LumXm MFI, F failure, Tx transplantation, * discordant LumXm / 
FCXm results 
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Detection of HLA-DQ and -DP antibodies in selected sera 
The results obtained questioned the ability of the LumXm beads to correctly capture 
class II HLA-DQ and HLA-DP molecules, which might result in failure to detect class II 
DQ and DP ab. Additional tests were performed to determine whether the LumXm test 
detected DQ or DP ab in selected sera without other class II ab. For HLA-DQ, five sera 
were selected without DR or DP ab, as proven by SA testing, specificities included were 
HLA-DQ2,4,5,7,8 and 9. The sera were tested against eight donor cells, carrying at least 
one of the relevant DQ specificities. All DQ LumXm failed to react with beads prepared 
from the selected donors (Table 7.2). 
 
Table 7.2 Specific HLA-DQ antibodies in the LumXm assay. 
Panel cell   
  
ab specificity 
SA DQA1 DQB1 
LumXm 
 
1 
2 
3 
4 
5 
6 
7 
8 
DQ2 
DQ2 
DQ5 
DQ6+DQ9 
DQ9 
DQ5 
DQ5 
DQ4 
 0101  0501 
 0101  0501 
 0101  0501 
 0102  0302 
 0102  0302 
 0101  0505 
 0101  0201 
 0501  04 
0201 0501 
0201 0501 
0201 0501 
0303 0602 
0303 0602 
0301 0501 
0202 0501 
0201 0402 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
 
For HLA-DP, five sera were selected, which showed only DP ab in the SA test. 
DP specificities included DP1,3,4,5,13,17 and 19. The sera were tested against five 
different donor cells, carrying at least one of the DP specificities mentioned. Two out 
of five DP LumXm were positive with donors possessing the relevant DP specificity and 
the other three failed to react (Table 7.3). 
 
Table 7.3 Specific HLA-DP antibodies in the LumXm assay. 
ab specificity Panel cell LumXm   
  SA DPA1 DPB1  
1 
2 
3 
4 
5 
DP3 
DP5 
DP1+DP13 
DP17 
DP19 
0103 
0103 0202 
0201 0401 
0103 0201 
n.t. 
0301 0401 
0401 0501 
0101 1301 
0402 1701 
0201 1901 
neg 
pos 
pos 
neg 
neg 
Specific DQ (a) and DP (b) sera were tested with selected panel cells with known high resolution HLA-DQ and 
DP types. 
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Discussion 
The aim of the present study was to compare class I and II LumXm using donor-HLA 
antigens coated on microparticle beads, to our standard FCXm, with donor T- and 
B-cells as the HLA target. The results from both tests were compared. Class I results 
showed good correlation with FCXm results in 18 recipient-donor combinations, the 
LumXm was found to have approximately the same sensitivity and specificity as the 
FCXm (89%/95%). However, for class II, the sensitivity was found to be 68%, with a 
specificity of 97%. Compared to the SA bead assay, the sensitivity of the LumXm was 
96% for class I and 65% for class II and the specificity was 100% and 97%, respectively. 
Overall there were more discrepant results found in class II, mostly negative results 
where positive ones were expected. 
 
Negative LumXm for class I, discrepant with FCXm, was obtained in three recipients, 
two had non-DS ab and one had no HLA ab at all. In one discrepant positive LumXm, 
the presence of weak DS B51 ab was shown. FCXm seemed to provide false-positive 
Xm results, while LumXm was positive only when DS HLA ab were present.  
For class II, discrepant-negative LumXm were shown for three recipients, two proved 
to possess DS DQ and DP ab and one had non-DS DP ab. Two recipients had discrepant-
positive LumXm, they were negative for HLA ab by the SA bead assay. Thus, LumXm 
missed DS ab in two recipients and was false positive in two others. In general, for 
class I, FCXm showed false- positive results, while for class II, more false-negative and 
positive results were noticed for LumXm. 
 
A closer look at the class II data suggested that test results were obtained as expected 
when the target molecule was DR, which was the case in most of the donor-recipient 
combinations used. When, however, DQ or DP was the target, the LumXm was found 
negative. Additional LumXm tests with specific sera that contained solely DQ or DP ab 
(as determined by SA analysis of the sera) yielded test results that were false negative. 
Five HLA-DQ-specific sera did not react in eight LumXm, with beads prepared from 
eight donors selected for the relevant DQ antigens (Table 7.2). In the same way, five 
HLA-DP-specific sera gave positive results in two LumXm, but failed to react with beads 
prepared from three donor cells bearing the corresponding DP antigens (Table 7.3). 
The two positive DP sera showed high MFI values in the SA bead assay, suggesting that 
the ab titer might play a role in the binding as fluorescence values in the SA bead assay 
are correlated with ab strength and titer9. Because all DQ and most of the DP sera did 
not show binding of the antibody to the bead, DQ and DP antigens are most probably 
not captured by the LumXm beads. Another explanation could be that their molecular 
structure has changed in the binding process, thus preventing antibody binding. 
Discrepancies in the results of Luminex Xm beads and results of SA testing may also be 
because of the fact that the basis for attachment of the HLA molecules to the beads 
differs between the 2 assays. 
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Both FCXm and LumXm may produce false-positive and false-negative results. 
 
False-positive FCXm results have been described due to the presence of IgG autoab, 
non-HLA ab or monoclonal ab, Fc-receptors, complement receptors or other 
immunoglobulins on the cell surface13,14. The percentage of false positive FCXm in our 
study is very low (3.5% for T-cell FCXm and 2.3% for B-cell FCXm) compared with some 
publications15, even though no pretreatment of lymphocytes with pronase was 
performed to reduce non-specific background16-18. The explanation for the low rate of 
false-positive FCXm in this study could be 1) the comparison of the FCXm outcome 
with a  very sensitive technique,  the SA bead assay, and 2) the specific FCXm protocol 
used, including centrifugation11 and heat-inactivation12 of the sera. 
 
In bead-based immuno-assays, binding of HLA molecules to beads may modify the 
structure of the molecule and the accessibility of epitopes. Impaired binding of 
HLA antibodies may subsequently result in false positive or negative reactions8,19. It is 
possible that the so-called lysate control, used as a check for the correct attachment of 
HLA class I and II molecules, to the beads, does not reflect correctly the binding of all 
class I and II antigens. 
 
An attempt to reduce the cell concentration of the lymphocyte population, necessary 
to provide the donor antigens for the capture beads, also revealed problems in class II 
binding, although class I seemed to be unaffected. 
 
One of the major advantages of the solid-phase approach for both screening and 
crossmatching is that a clear distinction can be made between class I and class II ab 
and that no viable cells are necessary. The objective measurement of MFI values by a 
flow analyser in stead of subjective microscope readings is also an advantage, as is the 
multiplexing capacity of the LumXm, which enables performance of 96 different 
LumXm at the same time. The assay is performed within 3 h, which makes it adequate 
for prospective crossmatching for deceased donor organ transplantation in 
24 h services. 
 
The LumXm assay in its present form, does not distinguish between complement-
binding and non-complement-binding DS ab. The use of different types of labelled 
second ab as IgG subclasses or IgM might extend the test to more specific ab classes20. 
In this respect, the clinical relevance of complement binding ab has been described 
extensively, the role of non-complement-binding HLA ab in kidney transplantation is 
less clear21. 
 
In conclusion, with the DS LumXm described here, a crossmatch assay is available that 
is performed in the same technique that many laboratories nowadays use for ab 
detection in transplant candidates. At this moment, the validity of the LumXm has 
been shown for class I, but its value for class II is uncertain. HLA DR is most probably 
correctly identified and the validity for DQ and DP is doubtful.   
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Abstract 
The clinical significance of the presence of donor-specific anti-human leukocyte antigen (HLA) antibodies 
prior to renal transplantation detected solely by solid-phase techniques remains unclear. 
 
This study was designed to determine the clinical relevance of the recently introduced bead-based Luminex 
donor-specific crossmatch (LumXm). A group of 165 patients transplanted between 1997 and 2001 were 
tested. 
 
Out of 165 recipients transplanted with a negative complement-dependent cytotoxicity (CDC) crossmatch, 
32 proved to have a positive Luminex crossmatch. Sixteen were positive for class I, 15 were positive for 
class II, 1 was both class I and II positive and 133 recipients were negative. 
 
Acute rejection (AR)-free survival for all recipients was 77%, and there was no difference in AR-free survival 
between LumXm-positive and LumXm-negative recipients. Overall graft survival after a median follow-up 
time of 8 years was 56%. Recipients with a positive class I LumXm had worse long-term graft survival 
(P=0.006). In recipients with a positive class I LumXm 5-year graft survival was 41% vs. 70% in negative 
patients and 10-year graft survival was 27% vs. 56%. Positivity for class II LumXm was not a significant risk 
factor for graft failure (P=0.7).    
 
In conclusion, pretransplant DSA detected by the LumXm had no impact on AR episodes. Class II LumXm-
positivity proved no significant risk factor for graft failure, but the value of the class II LumXm is 
questionable. A positive class I LumXm resulted in worse long-term graft survival compared to a negative 
one. 
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Introduction 
The presence of preformed cytotoxic donor-specific anti-human leukocyte antigen 
(HLA) antibodies (DSA) in recipient serum prior to renal transplantation is the 
predominant risk factor for irreversible hyperacute allograft rejection and subsequent 
graft loss. For that reason, prospective complement-dependent cytotoxicity 
crossmatches (CDCXms) before renal transplantation have been performed routinely 
for over forty years1. About 20 years ago, a more sensitive technique, the flow 
cytometric crossmatch (FCXm), was introduced. Many centres, mainly in the United 
States and the UK, strongly advocate the use of this technique2, while others regard it 
as a test that prevents recipients to obtain grafts that would potentially function well3.  
 
For CDC and FC, a crossmatch is available in the same technique that laboratories use 
for routine antibody detection. The CDCXm and the FCXm are cell-based assays 
differing in sensitivity, but comparable in specificity and both methods have 
disadvantages. CDCXm interpretation is complicated because non-graft damaging 
autoreactive immunoglobuline M (IgM)-antibodies as well as alloantibodies are 
detected. CDCXm and FCXm are subject to interference by non-HLA antibodies that 
bind to lymphocytes and by therapeutic antibody present in the recipient. 
Differentiation of antibodies specific for class I and class II requires removal of 
class I-specific antibodies. For these reasons, many laboratories are now using solid-
phase techniques, in particular the recently introduced bead-based assay4-6 that offers 
the advantage of greater sensitivity and specificity for routine antibody screening. For 
the first time now, a crossmatch has become available using the same bead-based 
technique. In an earlier study7, we evaluated this new crossmatch technique, the 
Luminex donor-specific crossmatch (LumXm). LumXm results of a selected group of 
patients were compared with FCXm results and the outcome of Luminex Single antigen 
(LSA) screening. The LumXm proved to be valid for class I DSA detection but of limited 
value for the detection of class II DSA.  
 
The aim of the present study was to evaluate the clinical significance of the donor-
specific LumXm in a group of renal transplant recipients, who were all transplanted 
with a negative CDCXm over a 4-year period. 
Materials and Methods 
Patients 
Two hundred and thirty-eight consecutive ABO-compatible renal transplantations with 
a negative CDCXm were performed between January 1997 and January 2001 at the 
University hospital of Maastricht. Follow-up was continued up to May 2008. From 165 
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of these donor-recipient pairs, sufficient donor lymphocytes were available to 
retrospectively perform donor-specific LumXm with the sera drawn at the time of the 
transplantation. Pretransplant characteristics of the patients included in the study are 
given in Table 8.1. The pretransplant characteristics from the 73 patients without 
available donor lymphocytes were comparable to those of the patients included in the 
study. 
 
Table 8.1 Patient characteristics.  
Parameter All recipients 
n=165 
LumXm pos 
n=32 
LumXm neg 
n=133 
Median recipient age, years (range) 54 (16-77) 57 (19-75) 53 (16-77) 
Male gender 103 (62%) 24 (75%) 79 (59%) 
Female recipients with pregnancies 45/62 6/8 39/54 
Donor type (L/HB/non-HB) 23/85/57 4/18/10 19/67/47 
Median donor age, years (range) 49 (6-74) 50 (11-73) 49 (6-74) 
HLA-A mismatch 0/1/2 (%) 31/48/21 25/60/15 33/45/22 
HLA-B mismatch 0/1/2 (%) 22/67/11 22/66/12 23/67/10 
HLA-DR mismatch 0/1/2 (%) 30/65/5 41/53/6 28/68/4 
Median day of follow-up time 2852 2522 2887 
Acute rejection within 6 months 38 (23%) 6 (19%) 32 (24%) 
Delayed graft function 61 (37%) 14 (44%) 47 (35%) 
First Tx/ReTx 134/31 25/7 109/24 
CDC PRA current ≥6% 17 (10%) 8 (25%)* 9 (7%)* 
Cold ischemia time (h), mean ± sd 22.3 ±10.5 22.7 ±10.1 22.2 ±10.7 
First warm ischemia time (min), mean ± sd 14.2 ±24.0 9.4 ±17.0 15.4 ±25.4 
Nr of transfusions, mean ± sd 7 ±14 12 ±24 5 ±10 
* Non-parametric test for differences between LumXm positive and negative recipients (P=0.002) 
 
Immunosuppression 
The immunosuppressive regimen was calcineurine inhibitor-based drug therapy in 
combination with prednisolone for all recipients. Calcineurine inhibitor was 
cyclosporine (CSA) in 8 and tacrolimus (TAC) in 157. Additional immunosupression 
consisted of azathioprine in 1 recipient, mycophenolate mofetil in 74 and rapamycine 
in 14. Five recipients participated in a multicenter clinical trial, and therefore, they 
received induction therapy with interleukine-2-receptor antagonist. CSA levels were 
determined in whole blood by enzyme monoclonal immuno test (Dade Behring, 
Newark, DE) or high-performance liquid chromatography-MS/MS. In the first 3 months 
after transplantation, target CsA trough levels were 0.10 to 0.15 mg/l, afterwards 
decreasing to 0.05 to 0.10 mg/l. TAC trough levels were measured in whole blood by 
ImX (Abbott, Abbott Park, IL) or high performance liquid chromatography-MS/MS, 
target levels were 15 to 20ng/ml for weeks 1 and 2 and 10 to 15ng/ml for weeks 3 and 
4, thereafter tapering at 5 to 7ng/ml. 
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Clinical outcome parameters 
A biopsy was taken during surgery 1 h after reperfusion for every transplant. Acute 
rejection (AR) was defined as any rejection treatment within 6 months after grafting. 
All rejection episodes were proven by needle core biopsy. No fresh-frozen material for 
C4d staining was available because of the retrospective design of the study. 
AR treatment for vascular rejection consisted of a 10-day course of rabbit 
antithymocyte globulin or three doses of methylprednisolone (0.5-1.0 g/dose) in case 
of tubulointerstitial rejection. Delayed graft function (DGF) was defined as the need for 
dialysis in the first week after transplantation. Graft failure was defined as loss of 
kidney function (return to renal replacement therapy or retransplantation) but also 
included death with functioning graft. All patients were followed up until date of graft 
failure, date of death or May 2008.  
Centre policy of tissue typing 
During the investigation period all patients and donors were typed for HLA-A, -B, -DR 
and -DQ by serology and polymerase chain reaction with sequence specific primers 
(PCR-SSP). All recipient sera were screened before transplantation for presence of anti-
HLA class I and II antibodies by CDC using the two-colour fluorescence technique on 
unseparated peripheral blood lymphocytes (PBLs). Reading was performed with an 
automated Leitz inverted fluorescence microscope. HLA antigens were considered 
unacceptable for a patient if antibodies against the specificity had ever been 
demonstrated, either at the time of transplantation or in the past. Mismatches from 
previous transplants were excluded, as were the paternally inherited antigens of 
children of female patients. All transplants were performed under the auspices of 
Eurotransplant, which means that only HLA-A, -B and -DR matches were included in 
the allocation algorithm.  
Prospective CDC and FCXm Crossmatches 
Before transplantation, CDCXms were performed using unseparated PBLs: the 
standard national institute of health (NIH) crossmatch with and without dithiothreitol 
(DTT) to reduce IgM antibodies. Sera used for the final crossmatch were the 
pretransplant serum drawn at the time of transplantation, the last serum tested for 
anti-HLA antibodies in the quarterly screening and all relevant positive historical 
samples. A negative class I DTT-Xm for current as well as historical sera was mandatory 
for transplantation. T- and B-cell FCXm from current and historical sera are performed 
for all transplantations according to the technique described by Scornik et al.8 with 
slight modifications, that is centrifugation9 and heat inactivation of the sera10 to reduce 
the number of false positive results. The result of the FCXm is not considered in the 
decision regarding transplantation. A positive FCXm result therefore is no reason for 
exclusion from this study.  
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Retrospective LumXms 
Donor-specific LumXm of 165 recipients transplanted with a negative CDCXm were 
performed according to the manufacturer’s (DSA, Tepnel Lifecodes, Stamford, USA) 
recommendations as described previously7. The sera used for LumXm were the same 
pretransplant sera as used for the original CDCXM. In short, a lysate prepared with 
donor lymphocytes was incubated for 30 min with capture beads to enable binding of 
the solubilized donor-HLA molecules onto the beads. The mixture was washed three 
times with wash buffer using a 96-well filter plate (Millipore, Bedford, MA) in 
conjunction with a vacuum manifold. Diluted recipient serum was added and 
incubated for 30 min. After another three washes, anti-human immunoglobulin G 
(IgG)-conjugated phycoerythrine (1:10) was added and incubated for 30 min. All 
incubations were performed on a gently rotating platform in the dark at room 
temperature. After addition of wash buffer, the LABScan100 flow cytometer 
(Luminex©) was used for mean fluorescent intensity (MFI) measurement of capture 
and control beads. To define positivity, the median MFI value of the three negative 
controls was subtracted from the MFI value of the capture bead. This adjusted MFI was 
then compared with the adjusted MFI of the positive control bead. A ratio of ≥5% 
and/or an adjusted MFI value of ≥1000 for the capture bead were considered to be 
positive. 
 
For antibody specificity analysis by the LSA assay, the reactivity of three strong allosera 
was determined. For each bead, the positive control value was set at the mean of the 
three MFI values obtained. A positive bead reaction was subsequently defined as an 
MFI value of at least 10% of the positive control value for that bead. 
Statistical analysis 
All statistical analyses were performed by using Statistical Package for the Social 
Sciences software (SPSS, Cary, NC). Groups were compared with parametric 
(independent samples Student’s t-test) and non-parametric tests (Pearson chi-square 
test, Fisher’s exact test, Kruskal-Wallis test). A P-value of ≤0.05 was considered to be 
statistically significant. Kaplan-Meier survival analysis was used to analyze differences 
in rejection-free survival and graft survival (log-rank statistic). Rejection-free survival 
and graft survival were also analyzed with the proportional hazards regression analysis 
(Cox regression) using stepwise backward elimination techniques for all suspected risk 
factors. With rejection as outcome parameter, the suspected risk factors tested for in 
the basic model included crossmatch outcome of current serum: “class I and II LumXm 
(neg vs. pos)” and “T- and B-cell FCXm (neg vs. pos)”; patient characteristics: “age of 
recipient (years)”, “gender recipient (male vs female)”, “immunosuppressive regimen 
(TAC vs. CsA )”, “CDC PRA% current serum (non-immunized <6% vs immunized ≥6%)”; 
donor characteristics: “age of donor (years)”, “donor type (living vs post mortal) and 
(heartbeating vs. non-heartbeating)” and transplant characteristics: “transplant 
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number (first transplant vs re-transplantation)”, “mismatch class I HLA-A, B (0 vs. ≥1)”, 
“mismatch class II HLA-DR (0 vs. ≥1)”, “cold ischemia time (hours)”. With graft survival 
as outcome parameter “acute rejection within 6 months (no vs. yes)” and “delayed 
graft function (immediate graft function vs. delayed graft function)” were included as 
suspected risk factors to the model.   
Results 
Luminex donor-specific crossmatches 
Donor lymphocytes and pretransplant patient sera of 165 renal transplant recipients 
transplanted between 1997 and 2001 with a negative CDCXm were available for 
retrospective LumXm. Out of 165 recipients, 32 (19%) were found to have a positive 
LumXm. Sixteen recipients had a positive class I LumXm, 15 were positive for class II 
and 1 recipient was positive for both class I and II. The remaining 133 recipients were 
negative. No statistically significant differences in patient characteristics were 
observed between the LumXm positive and LumXm negative recipients (Table 8.1), 
with the exception of a higher incidence of immunization in the positive group (25%) 
compared to the negative one (7%) (P=0.002).   
 
Comparing FCXm with LumXm results showed that the number of positive LumXm was 
clearly higher than the number of positive FCXm. Of 17 class I LumXm-positive 
recipients, 3 were T-cell FCXm positive, while 14 were T-cell FCXm negative. Three 
T-cell FCXm-positive recipients were class I LumXm negative. Sixteen recipients were 
class II LumXm positive, 2 of them had a positive B-cell FCXm, while 14 patients were 
B-cell FCXm negative. Four B-cell FCXm-positive recipients were class II LumXm 
negative (Table 8.2). 
 
All LumXm positive sera were examined by LSA. DSA were found in 5 out of 17 class I 
and 5 out of 16 class II LumXm positive sera. 
 
Table 8.2 Comparison of donor-specific class I and II LumXm and FCXm results. 
                             LumXm class I 
  pos neg  
T-cell FCXm pos   3     4 ҳ2=10.62  P=0.02 
 neg 14 145  
                             LumXm class II 
  pos neg  
B-cell FCXm pos   2     4 ҳ2=3.98  P=0.11 
 neg 14 145  
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Acute rejection-free survival 
AR-free survival for all patients was 77%. Kaplan-Meier and Cox-regression analyses 
did not reveal statistically significant differences between the LumXm-positive and the 
LumXm-negative recipients (Table 8.3). AR-free survival was 81% for recipients with a 
positive class I LumXm and 76% for class I negative patients (log-rank χ2=0.31, df=1, 
P=0.6; Figure 8.1). Eighty-two per cent of the class II-positive recipients had AR-free 
survival vs 76% of the negative ones (log-rank χ2=0.20, df=1, P=0.7; Figure 8.2).  
 
Table 8.3 Cox regression analysis of acute-rejection free survival: associated risk factors and effect of 
LumXm result (n=165). 
Independent variable Odds Ratio 95% CI df P-value 
Class I     
     Recipient age (years) 0.98 0.96-1.00 1   0.06 
     Positive class I LumXm 0.52 0.15-1.80 1 0.3 
Class II     
     FcXm B cell (pos vs neg) 3.36 1.19-9.46 1   0.05 
     Positive class II LumXm 0.71 0.21-2.36 1 0.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Rejection-free survival according to LumXm class I positivity of 165 recipients transplanted 
with a negative CDCXm between January 1997 and January 2001. Kaplan-Meier curve of acute 
rejection-free survival for LumXm class I negative (solid line) and LumXm class I positive 
(dotted line) recipients. log rank ҳ2=0.3 df=1 P=0.6 
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None of the 165 recipients experienced hyperacute rejection. Of 17 recipients with a 
positive class I LumXm, 3 (18%) were treated for biopsy proven AR within 6 months 
after grafting compared to 32 of 148 (22%) of recipients with a negative class I LumXm 
(χ2=0.14, P=0.7). Three of 16 (19%) recipients with a positive class II LumXm had AR 
compared with 32 of 149 (21%) with a negative LumXm (χ2=0.06, P=0.8; Table 8.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Rejection-free survival according to LumXm class II positivity of 165 recipients transplanted 
with a negative CDCXm between January 1997 and January 2001. Kaplan-Meier curve of acute 
rejection-free survival for LumXm class II negative (solid line) and LumXm class II positive 
(dotted line) recipients. log rank ҳ2=0.2 df=1 P=0.7 
 
 
Table 8.4 Biopsy proven acute rejection in LumXm positive and LumXm negative recipients. 
 LumXm class I  
 pos (n=17) neg (n=148)  
Acute rejection   3   32 ҳ2=0.14  P=0.7 
No rejection 14 116  
 LumXm class II  
 pos (n=16) neg (n=149)  
Acute rejection   3   32 ҳ2=0.06  P=0.8 
No rejection 13 117  
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Graft survival 
Overall graft survival after a median follow-up period of 8 years was 56%. Kaplan-
Meier analysis showed a statistically significant difference in graft survival between 
class I LumXm- positive and class I LumXm-negative recipients (log-rank χ2=7.43, df=1, 
P=0.006; Figure 8.3). Five-year graft survival in recipients with a positive class I LumXm 
was 41% vs. 70% in class I-negative recipients, and 10-year graft survival was 
27% vs. 56%. In multivariate Cox regression analysis, significant risk factors for graft 
failure were a positive class I LumXm [odds ratio (OR) =2.47, P=0.005] and HLA-B 
mismatch (≥1 vs. 0) (OR=2.56, P=0.009; Table 8.5). For class II LumXm positivity, there 
was no difference in graft survival (log-rank χ20.14, df=1, P=0.7; Figure 8.4). Five-year 
graft survival in recipients with a positive class II LumXm was 88% vs. 64% in recipients 
with a negative class II LumXm, and 10-year graft survival was 50% vs. 53%. LumXm 
class II positivity was not a significant risk factor for graft failure in multivariate Cox 
regression analysis (OR=0.69, P=0.6; Table 8.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 Graft survival according to LumXm class I positivity of 165 recipients transplanted with a 
negative CDCXm between January 1997 and January 2001. Kaplan-Meier curve of graft survival 
for LumXm class I negative (solid line) and LumXm class I positive (dotted line) recipients. log 
rank ҳ2=7.4 df=1 P=0.006 
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Table 8.5 Cox regression analysis of graft survival: associated risk factors and effect of LumXm result 
(n=165). 
Independent variable Odds Ratio 95% CI df P-value 
Class I     
     Positive class I LumXm 2.47 1.32-4.62 1  0.005 
     ≥1 HLA-B mismatch 2.56 1.27-5.17 1  0.009 
Class II      
     Positive class II LumXm 0.69 0.29-1.61 1  0.4 
     Recipient age (years) 1.02 1.00-1.04 1  0.04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 Graft survival according to LumXm class II positivity of 165 recipients transplanted with a 
negative CDCXm between January 1997 and January 2001. Kaplan-Meier curve of graft survival 
for LumXm class II negative (solid line) and LumXm class II positive (dotted line) recipients. log 
rank ҳ2=0.1 df=1 P=0.7 
 
Discussion 
Within Eurotransplant, the standard prospective crossmatch is the CDCXm, which 
detects antibodies that activate complement and are thus responsible for tissue injury. 
In many countries, the more sensitive FCXm is used, which detects both complement-
activating and non-complement-activating antibodies. The widespread use is based on 
studies showing worse graft survival in T-cell FCXm-positive regraft recipients11,12. The 
clinical relevance of a positive B-cell FCXm13,14 is still a matter of debate15 as is the 
positive FCXm for primary transplant recipients16. A previous study from our centre 
showed T-cell FCXm not to be superior to the classical CDCXm with regard to clinical 
outcome in renal transplant recipients, both retransplanted as well as sensitized first 
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transplants3. These findings were considered to be the result of the specific 
pretransplant antibody screening protocol and the general centre policy on obtaining 
all relevant patient information on immunization. Nevertheless, FCXms were adopted 
in our centre and are performed for living-related and -unrelated transplants as well as 
for postmortal transplants. At this moment their results are only taken into account for 
living related and unrelated transplants.  
Recently, we evaluated a new bead-based solid-phase crossmatch, the LumXm, in 
which the actual donor-HLA antigens are coated onto specific capture beads7. LumXm 
results of a selected group of recipients were compared with results obtained by the 
LSA assay. Sensitivity of the LumXm was 96% for class I and 65% for class II, and 
specificity was 100% and 97%, respectively. The LumXm proved to be valid for class I 
DSA detection, and the value for class II DSA was however uncertain; HLA-DR 
antibodies were most probably correctly identified, and the detection of HLA-DQ and 
-DP was doubtful or absent. The present study was undertaken to evaluate the clinical 
significance of the LumXm in a group of consecutive CDCXm negative transplant 
recipients. 
 
Little is known about the clinical relevance of pretransplant DSA detected by solid-
phase but not by cell-based techniques. Some authors claim higher AR rates and worse 
graft survival in recipients with DSA detected by solid-phase assays in the crossmatch-
negative pre-transplant sera17-20. In a previous paper, we reported on LSA screening for 
HLA antibody and the effect of donor-specific antibodies found in a group of highly 
sensitized patients (PRA>85%) transplanted with a negative CDCXm within the 
Eurotransplant Acceptable Mismatch program21. We concluded that DSA detected by 
the LSA assay in the peak historical sera of this patient group may be related to a 
higher incidence of AR episodes. When analysis was performed on the LSA results of 
the current sera, however, DSA-positive and -negative recipients had comparable 
AR-free survival. Long-term graft survival was not affected by DSA detected by LSA in 
both peak and current sera. 
 
Nineteen per cent of the recipients transplanted between 1997 and 2001 with a 
negative CDCXm presented with a positive LumXm. In the LumXm-positive group, more 
patients were sensitized than in the negative group. Neither Kaplan-Meier nor 
Cox regression analysis showed a statistical difference in AR-free survival between 
recipients with a positive and a negative LumXm. At a median follow-up time of 
8 years, however, Kaplan-Meier and Cox regression analyses of graft survival showed a 
statistically significant difference in graft survival between class I-positive and 
class I-negative recipients. For class II, such a difference was not observed. These data 
are concordant with the findings of Gupta et al., who showed AR rates in DSA-positive 
recipients detected by LSA, to be similar to those in negative recipients. However, 
DSA positivity proved to be associated with an increased risk of long-term graft 
failure22. 
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All LumXm-positive sera were examined by LSA. DSA were found in 5 out of 17 class I  
and 5 out of 16 class II LumXm positive sera. The discrepancies between LumXm and 
LSA can be explained by the difference in preparation of the beads used in both 
techniques. For the LumXm, the actual donor-HLA antigens are coated onto the 
crossmatch beads. The Single antigen beads are coated with purified HLA antigens 
cultured in cell lines. Thus, the density of antigens expressed on the respective beads 
may differ, resulting in a difference in sensitivity. Also, binding of HLA molecules to 
beads may modify the structure of the antigens, especially in the case of the LSA, 
where the molecules are purified and the peptide is dislodged from the groove of the 
molecule. This modification of structure may have an effect on epitope accessibility 
and subsequent on antibody binding.  
 
From the 12 graft losses in the class I LumXm-positive group, 5 occurred within 
2 months after grafting. Three of the five recipients died shortly after transplantation; 
one recipient died with a functioning graft due to cardiac arrest, one graft never 
functioned (rejection was excluded by biopsy) and the recipient died of myocardial 
ischemia and one died as a result of haemorrhage caused by an infection of the graft. 
The two remaining recipients underwent transplantectomy; one lost his graft the day 
after transplantation due to technical problems and the other graft never functioned 
and was removed two months after transplantation (repeated biopsies did not show 
rejection). The remaining seven graft losses in the class I LumXm positive-group 
occurred late after grafting. Two recipients died with functioning grafts. Five recipients 
lost their graft because of chronic allograft nephropathy while on immunosuppression. 
In the class I LumXm-negative group, 14 of 61 graft losses were because of chronic 
allograft nephropathy while on immunosuppression. Thus, the incidence of 
immunological failures in the class I LumXm-positive group (42%) is nearly twice as 
high as that in the class I LumXm negative group (23%). Because of small numbers; this 
difference in AR rate between the class I LumXm-positive and the class I LumXm-
negative recipients did not reach statistical significance. 
  
The class I LumXm proved to be more sensitive than the T-cell FCXm. Fourteen patients 
were class I LumXm positive with a negative T-cell FCXm, while only 3 class I LumXm- 
positive recipients had a positive T-cell FCXm. The graft survival in both groups was 
significantly worse compared with recipients with a negative class I LumXm. Three 
patients were class I LumXm negative but showed a positive T-cell FCXm; their graft 
survival was comparable to that of 145 class I LumXm/T-cell FCXm-negative recipients 
(data not shown). We assumed that the three recipients with class I LumXm neg/T-cell 
FCXm positive results probably possessed non-HLA antibodies.  
 
The contribution of preformed anti-HLA class II antibodies to graft rejection and graft 
loss was long poorly understood. Testing against B cells for their detection was less 
than satisfactory. The B-cell FCXm proved to be technically difficult, and interpretation 
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of the results was not easy due to lack of specificity23. A positive B-cell FCXm can result 
from the presence of anti-HLA class II antibodies, weak anti-HLA class I antibodies and 
autoreactive or non-HLA antibodies. Therapeutic antibodies, Fc-receptors and 
immunoglobulins on the surface of the B cell may also yield false-positive B-cell FCXm 
results. With the introduction of solid-phase techniques, class II antibodies are 
detected easily and their impact on AR and graft survival assessed more accurately. 
Using this Luminex technique, Eng et al. demonstrated that only one third of positive 
B-cell FCXm are caused by class II antibodies and were associated with late graft loss24. 
Class II antibodies represent a significant risk factor for transplant dysfunction and 
failure as described by several authors25-27. The lack of association between a positive 
class II LumXm and graft survival in our present study is most probably because of the 
fact that the LumXm in its present form only detects HLA-DR antibodies and some but 
not all HLA-DQ and –DP antibodies7. 
 
In conclusion, the class I LumXm proved to be more sensitive than the FCXm, and 
14 patients were LumXm positive while FCXm negative. LumXm class II positivity was 
no significant risk factor for graft failure, but one should bear in mind that the class II 
LumXm in its present form does not detect all class II anti-HLA antibodies. 
Pretransplant donor-specific anti-HLA class I antibodies detected by LumXm have no 
impact on AR episodes; however, a positive class I LumXm results in worse long-term 
graft survival compared to a negative one. Considering the improved patient survival 
after transplantation and the late occurrence of graft failure in class I LumXm-positive 
recipients, for every patient, the balance between transplantation with a kidney after a 
class I LumXm-positive result or waiting for a class I LumXm-negative donor kidney has 
to be determined. 
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General discussion 
Renal transplantation and histocompatibility 
Antibodies to human leukocyte antigens develop as a result of pregnancy, blood 
transfusion or transplantation. The presence of donor-specific anti-HLA antibodies 
(DSA) in a kidney transplant patient is strongly associated with acute antibody-
mediated rejection. Therefore pretransplant crossmatches are performed to identify 
patients at risk of losing their graft due to hyperacute rejection1. The method used in 
histocompatibility laboratories for over half a century has been the CDC crossmatch2. 
Transplant immunologists try to establish very precisely the pretransplant immune 
status of a kidney recipient in order to be able to choose the right graft for a potential 
transplant recipient and to avoid positive crossmatches at the time of transplant. As 
described in Chapters 1 and 2, screening for preformed DSA has evolved from the 
relatively insensitive complement-dependent cytotoxicity to more sensitive solid-
phase assays, where purified HLA antigens attached to beads are used as antibody 
detection target3. For that reason the Luminex bead based Single antigen assay is of 
the utmost importance in describing the HLA antibody profile of a future transplant 
recipient. Despite the development of increasingly effective immunosuppressive drugs 
chronic allograft nephropathy, presently known as chronic transplant dysfunction, 
remains a major barrier to long-term renal graft survival4. The identification of the 
factors responsible for the development of chronic allograft nephropathy is important, 
since this will provide a basis for the establishment of interventions that may arrest its 
progression. Evidence suggests that the humoral immune response plays an important 
role in the development of chronic transplant dysfunction, and for that reason several 
authors recommend antibody monitoring after transplantation5,6. The detection of 
HLA antibodies and especially the determination of their specificity remains an 
important goal of histocompatibility testing.  
Solid-phase antibody detection techniques: Luminex technology 
As mentioned before the solid phase techniques, in particular the Luminex Single 
antigen assay allows accurate identification of HLA class I and II antibodies at a much 
more sensitive and specific level than conventional CDC and according to some authors 
even FC. The main advantages are that the assay detects complement-binding as well 
as non-complement-binding IgG HLA antibodies and that class I and class II 
HLA antibodies can be clearly discriminated7. Analysis of complex antibody profiles in 
highly sensitized patients is made possible, thereby allowing definition of acceptable 
and non-acceptable mismatches. Also so-called virtual crossmatching is within reach8. 
However, the highest level of sensitivity in antibody detection does not necessarily 
translate into clinical relevance of the antibodies detected. Whether or not low 
antibody levels have a deleterious impact on the graft depends also on the 
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immunoglobulin (sub) class, the ability to bind complement and the avidity of the 
antibody.   
 
The sensitivity of the Single antigen assay depends on the cut-off point used to define 
positive and negative bead reactions. This cut-off point has to be defined by the user 
and therefore may differ considerably between laboratories. Many cut-off points have 
been described in the literature for the assay, ranging from 500-6000 median 
fluorescence intensity (MFI) value9-14. For our first study on pretransplant DSA 
detected by the Single antigen assay (described in Chapter 3 of this thesis), the cut-off 
point for positivity was established by testing three positive control sera (PRA >90%) 
with Single antigen beads for both class I and II. For every single bead in the assay, the 
positive control value was set at the mean MFI value of these sera. A positive bead 
reaction was subsequently defined as an MFI value of at least 10% of the positive 
control value for that specific bead, which correlated with a cut-off point for positivity 
of approximately 1000 MFI. In our later studies on post-transplant DSA (chapters 4, 5, 
6), an MFI value of 2000 was used as cut-off point for positivity, being the value 
corresponding most closely to a positive flow-cytometry crossmatch in our hands. This 
cut-off point is not necessarily the same for tests produced by different manufacturers. 
In a recent quality assurance-testing program by the Australian National Association of 
Testing Authorities, the results of Single antigen assays were compared between 
laboratories and different vendors. The MFI values and bead rankings sorted by MFI 
were reproducible between laboratories using products from the same vendor, which 
was not the case when using products from different vendors15.  
 
Results of Single antigen assays may be influenced by different amounts of antigen or 
immunogenic epitope on the SA bead. Also the configuration may be altered and not 
represent the one found on intact cells. The presence of IgM antibodies in the serum 
may hinder the binding of IgG antibodies to the SA beads, which can be overcome by 
the addition of DTT to the test16. In a study by Kosmoliaptis, the addition of DTT to 
patient sera markedly increased (doubled) the antibody binding to HLA class I and/or 
class II specificities in 18% of the sera. In a cohort of highly sensitized patients, 
treatment of sera with DTT enhanced antibody-binding levels in 93% of the tested 
sera17. To reduce variation in antibody definition caused by day to day testing or 
measurement on different platforms, and to compare results between different 
laboratories, another unit of fluorescence has been introduced. The MESF (molecules 
of equivalent soluble fluorochrome) value, are converted from MFI values to 
accurately compare quantitative fluorescence intensities18,19. Another approach to 
overcome this problem is the expression of the MFI value as a percentage of maximum 
binding as determined by a monoclonal antibody for each HLA specificity20. This allows 
correcting for variation in antigen density on Single antigen beads between different 
lots of the SA assay. A variant of this approach was used for the cut-off determination 
in chapter 3.    
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For clinical purposes, it was considered desirable to define a cut-off value for those 
HLA antibodies that were acceptable or not acceptable for a patient waiting for a renal 
transplant. This cut-off point should include all HLA antibodies that were detected in 
the CDC screening and were considered relevant. To clarify how the results of the 
regular CDC screening compared to the results obtained with the Single antigen assay, 
we tested well-known HLA typing sera in both techniques. As described in Chapter 2, 
more than 100 sera for which CDC specificity and reaction strength were well defined, 
have been tested with Single antigens class I and II. For each serum the main 
CDC specificity and extra specificities if present, were categorized according to the 
MFI value obtained. For class I 99% of all CDC specificities (main plus extra) had an 
MFI value of >4000, for class II this was 92%. The reason for the latter lower 
percentage is that the Single antigen class II assay contains multiple beads coated with 
the same serological class II specificity, but not necessarily the same subtype 
specificity. For the analysis, the mean MFI value of all specific beads (regardless of 
subtype) was used. Based on the results of the studies previously performed and those 
from the typing sera, the cut-off point for positivity of the Single antigen assay was set 
at 4000 MFI or higher for clinical transplant purposes in our centre. We feel confident 
that in this way all specificities detected by the classical CDC screening are covered and 
listed as non-acceptable antigens for a future transplant recipient. As a consequence of 
this policy, specificities with an MFI value of >4000, not detected in CDC, are also 
considered unacceptable for a patient.  
Clinical relevance of pre-transplant HLA antibodies 
We have shown that in patients transplanted with a negative CDC crossmatch in the 
Eurotransplant AM program, the presence of DSA detected only by the Single antigen 
assay, was associated with a higher incidence of treatable acute rejection within the 
first 6 months post-transplant, but was not related to poorer graft survival when 
compared to patients without DSA (chapter 3). Currently all patients transplanted in 
the AM program in the Netherlands have been tested by Luminex Single antigens and 
the preliminary data of this nationwide study, confirm our results on graft survival. 
About 50% of patients have DSA in their pre-transplant serum by Single antigens, but 
the DSA do not effect graft survival. No data on acute rejections were available for this 
study (personal communication Prof. I. Doxiadis, Eurotransplant)  
 
In the past three years, several studies investigated the effect of low strength 
pre-transplant DSA detected by the Single antigen assay on acute rejection rate and 
graft survival. The study designs and the cut-off points used for determining positive 
bead reactions differed considerably between studies. All included large consecutive 
series of patients with different PRA values and different pre-transplant protocols. In 
some studies correlations with acute rejection were found21-23, and some showed DSA 
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to be correlated to graft survival21,22,24. The different results may be explained by the 
fact, that in our study, only highly sensitized recipients (>85%) were included, who had 
been extensively screened in CDC and ELISA. Their sensitization history was well 
known, as were their acceptable and non-acceptable antigens.  
 
Increased sensitivity results in a larger number of specific HLA antibodies identified in a 
patient’s serum. When those antibodies are listed as non-acceptable mismatches, as is 
customary within Eurotransplant, it prolongs the waiting time and leads to a higher 
percentage of sensitized recipients. This clearly has implications for organ allocation, 
because sensitized recipients receive extra transplant points. As long as no consensus 
on the cut-off point for Single antigen positivity exists, patients from different centres 
will be put on the waiting list with incomparable antibody statuses. The present 
uncertainty on the relevance of antibodies detected by the Single antigen assay 
influences the allocation program for the whole Eurotransplant organization. The 
number of highly sensitized patients will rise, which may have a clear impact on the 
Eurotransplant AM program. That this threat is considered real, is revealed by the 
recent implementation of Eurotransplant (also based on the results of our study 
presented in Chapter 3) that recipients with antibodies detected by Luminex Single 
antigen only, are not considered for the AM program25. 
Solid-phase crossmatch: Luminex crossmatch  
European histocompatibility standards (EFI) require the use of crossmatch methods of 
similar or greater sensitivity than those used in screening to define the presence of 
antibodies. For that reason the availability of a prospective crossmatch in the Luminex 
technique is highly desirable. It has the added advantages that no viable cells are 
needed for the crossmatch, is specific for HLA antibodies and reading is easy and 
automated. Chapter 7 is the first report ever on the use of a Luminex Crossmatch 
(DSA™, donor specific antibody detection, Tepnel). The results obtained were 
compared with results from flow cytometric crossmatches. Sensitivity and specificity of 
the Luminex crossmatch for class I were 89% and 98% and for class II 68% and 97%. 
After all sera were tested with the Single antigen assay from One Lambda, to define 
the DSA in each serum, the sensitivity of the Luminex crossmatch proved to be higher 
for class I (96%) than class II (65%). The Luminex crossmatch did not detect any 
HLA-DQ antibodies, HLA-DP antibody detection was insufficient, only HLA-DR seemed 
to be correctly identified. Recently Caro-Oleas compared results of the Single antigen 
assay to the Luminex crossmatch in sera that were well defined by CDC. The sensitivity 
of the Single antigen assay was found to be higher than that of the Luminex 
crossmatch for both class I and II, regardless of the fact that crossmatch and screening 
assay were from the same vendor26. This study also confirmed our finding that the 
Luminex crossmatch does not identify HLA-DQ antibodies. We therefore feel that the 
test in its present form is not suitable for use in a clinical setting. 
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The clinical significance of the Luminex crossmatch was evaluated over a 4-year period, 
as described in Chapter 8. The Luminex crossmatch was performed for consecutive 
renal transplant recipients, who have all been transplanted on the basis of a negative 
CDC crossmatch. A positive class I Luminex crossmatch with the current pre-transplant 
serum had no impact on acute rejection episodes, but resulted in worse long-term 
graft survival compared to a negative class I Luminex crossmatch. The class II Luminex 
crossmatch had no effect on acute rejection or graft survival, probably because the 
test proved not to detect HLA-DQ and –DP antibodies. Recently a second report on the 
clinical relevance of the Luminex crossmatch in 37 selected recipients with 
pre-transplant HLA antibodies, was published this year. No relationship with graft 
survival was shown, the maximum follow-up time was only 3 years. A clear relationship 
between the class I Luminex crossmatch and antibody-mediated acute rejection was 
established if they combined the results of the class I Luminex crossmatch with the 
results of the SA test. Antibody mediated acute rejection was found in 80% of the 
patients with a positive class I Luminex crossmatch and an MFI value >900 in the Single 
antigen test (test spec 96%)27. The conclusion of our studies still remains that the 
Luminex crossmatch for class II has to be improved, at least for DQ antibodies. 
Pre-transplant donor-specific anti-HLA class I antibodies detected by the Luminex 
crossmatch have no impact on acute rejection episodes; however, a positive class I 
Luminex crossmatch results in worse long-term graft survival compared to a negative 
one. Considering the improved patient survival after transplantation and the late 
occurrence of graft failure in class I Luminex crossmatch-positive recipients, for every 
patient, the balance between transplantation with a kidney after a class I positive 
crossmatch result or waiting for a class I negative crossmatch donor kidney has to be 
determined. 
Clinical relevance of post-transplant HLA antibodies  
Presence of HLA antibodies has been described before failure28, and their detection is 
considered to be useful in predicting graft failure29. There is however no consensus on 
antibody positivity shown by the Single antigen assay, the time of appearance of DSA 
nor the class of DSA detected. 
 
The frequency and nature of “de novo” HLA DSA after kidney transplantation detected 
by Single antigen was analyzed in Chapter 4. The presence of DSA was monitored from 
the time of transplantation up to 14 years thereafter. All patients were DSA negative 
by Single antigen before transplantation, had a negative CDC crossmatch, at least 1 
year of renal function and were tested 5-12 times (average 8) during follow-up. Post-
transplant DSA were detected frequently (25%). Slightly more class II than I was 
detected, and class II antibodies were mainly against HLA-DQ. Only persistent class II 
DSA, that were present more than one year after transplantation, turned out to result 
in worse clinical outcome. Its presence was associated with graft survival, but did not 
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necessarily lead to immediate loss of graft function. Most of the DSA found were 
persistent throughout the follow-up period, but a new finding was that in a number of 
patients the DSA were present only for a short period of time. These so-called 
“transient” DSA were characterized by lower MFI values than the persistent ones and 
were not related to graft survival. We concluded from the study that the detection of 
DSA posttransplant in a single serum sample, has to be interpreted with caution and 
may not necessarily justify the use of therapeutic interventions. Furthermore, the fact 
that only the presence of class II DSA was found to be predictive of graft failure after 
adjusting for a number of clinical variables, is concordant with recent publications on 
the importance and relevance of class II HLA antibodies30-33. The high number of 
patients with anti-DQ antibodies was remarkable. In this respect it would be desirable 
if within Eurotransplant, histocompatibilty laboratories would be obliged to report on 
HLA-DQ typing of potential donors to the transplant recipient centres.  
 
Although this study was unique in terms of number of consecutive patients with a long 
follow-up and multiple sera tested, a drawback of our study is the fact that patients 
included in this study did not have their yearly follow-up consultation in our centre, 
and therefore many samples are missing. Also because of the retrospective nature of 
the study no biopsies from the time of failure were available. Therefore, it is difficult to 
identify the specific reasons for graft failure. This study allows the identification of 
patients with an increased risk of (immunological) graft failure for future randomized 
controlled trials to target immunologic failure by specific interventions. 
 
After transplantation DSA may be undetectable in the circulation because they are 
absorbed by the graft. This was demonstrated by the fact that these antibodies are 
eluted from rejected transplants34,35 and the appearance of previously undetectable 
antibodies by CDC following transplantectomy36. Testing for HLA antibodies in 
re-transplant candidates, who still have their graft in situ, is therefore of limited value. 
The study in Chapter 5 was designed to test whether antibodies before transplant 
failure and transplantectomy would be detectable using the Single antigen assay. Time 
of DSA appearance was monitored in a group of 53 first renal transplant recipients, 
who lost their graft at different time points after transplantation (median 50 days 
post-transplant). 81% became DSA positive after transplantation, 16% before and 84% 
after transplantectomy. Logistic regression analysis showed that DSA positivity for class 
I was related to higher donor age and donor type (non-heart-beating), class II to higher 
donor age and class II mismatch. Looking at the time of transplantectomy, patients 
who lost their graft between 1-6 months all became DSA positive and showed a higher 
number of class II mismatches and acute rejections.  
 
Remarkably, the majority of the DSA were found several months after 
transplantectomy. Although there still is discussion on the clinical utility of 
transplantectomy versus leaving the rejected graft in place37, in our centre failed grafts 
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are removed and immunosuppression is cessated, because continuation of 
immunosuppressive drugs after return to dialysis is not tolerated due to side effects. It 
remains to be elucidated whether the antibodies found circulating after 
transplantectomy, are antibodies that were previously absorbed by the graft or were 
formed after the transplantectomy due to the cessation of immunosuppression and/or 
as a result of the fact that the vascular patch of the anastomosis was still in situ38. In 
general patients are tested for the presence of HLA antibodies only when they are on 
the ET waiting list, for transplantectomized patients this means that they are 
monitored only if considered for re-transplantation. Based on our results we propose 
that patients after transplantectomy are monitored for the presence of antibodies for 
at least 6 months. In our local protocol, sera are collected after a transplantectomy 
and monitored for antibodies at regular intervals until 6 months later. For recipients 
that receive a kidney donor offer before they have been monitored for half a year, 
prospective pretransplant crossmatches have to be performed with all historically 
relevant sera as well as a serum drawn at the time of the crossmatch.  
 
In the transplantectomy study, the recipients of a NHB donor had a higher risk of DSA 
positivity. Combined with the fact that kidneys from non-heart-beating donors 
experience an increased incidence of primary non-function compared to kidney 
transplantation from heart-beating donor, this may point to a more stringent 
acceptance of NHB donors. This has to be balanced against the fact that even 
transplantation with NHB donors has been shown to result in increased patient 
survival compared to remaining on dialysis and the waiting list39.  
 
A recent study by Marrari et al. on patients with late transplantectomy (mean 6.6 
years), found a higher incidence of DSA before transplantectomy but the same overall 
incidence of DSA after transplantation40. They compared their results to ours and 
hypothesised that in their study, the transplant had been in situ for a longer period of 
time, thus serving as a continuous source of donor antigens, which had expanded the 
antibody repertoire. However in our study, late and early graft removal resulted in 
comparable percentages of DSA. In our study recipients with pre-transplant DSA 
detected by FC or SA, were excluded from the study, in contrast to the study of Marrari 
et al.  
Conclusion 
In this thesis we have mainly focussed on the detection and relevance of 
HLA antibodies in renal transplantation by newer antibody screening and crossmatch 
techniques. Throughout the literature available on Single antigen testing, there are 
reports of authors that support the idea that the Single antigen assay is superior to all 
other tests and that CDC has become obsolete. Specificity and sensitivity are usually 
reported, however data on clinical relevance are scarce. It has even been suggested 
146⏐Chapter 9 
that the Single antigen assay is too sensitive to use in a clinical setting. Therefore we 
addressed some of these items. We studied the relationship between Single antigen 
and CDC results and together with the results of our clinical studies we defined a 
cut-off point of 4000 MFI for clinical transplant purposes. DSA by the Single antigen 
assay proved not to influence graft survival in highly sensitized AM patients. In 
post-transplant screening DSA are often seen, and unexpectedly a substantial portion 
of these DSA proved to be transient. Transient DSA had no effect on graft survival in 
contrast to persistent DSA, if they were class II and present beyond 1 year after 
transplantation. DSA were particularly shown to be present after failure and 
transplantectomy, and were related to specific donor, recipient and transplant 
parameters. The Single antigen assay also allows the detection of class II HLA-DP 
antibodies, which provides a possibility of studying their impact in renal 
transplantation. A positive class I Luminex crossmatch is related to graft failure, 
although not in the first years after transplantation. The class II Luminex crossmatch 
needs further development, especially for HLA-DQ and -DP, to become clinically 
relevant. The data presented in this thesis point to the importance of pre- end 
post-transplant detection of HLA antibodies and their identification in renal 
transplantation. 
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Summary 
The immune system protects the individual against pathogens and consists of different 
types of cells that mediate an immune response that is either non-specific innate or 
antigen-specific acquired. The latter, also known as the adaptive immune response, is 
triggered when antigen-receptors on lymphocytes recognize antigen presented in the 
context of MHC molecules. HLA molecules are highly polymorphic and as a 
consequence, they are able to bind a variety of antigens and present them to the 
immune system. The response that follows is cellular or humoral. Cellular responses 
occur when T-cells recognize foreign antigens presented by an HLA molecule on APC’s. 
The humoral immune response is initiated by B-cells and leads to the production of 
antibodies against the foreign antigen.  
 
As discussed in Chapter 1 the recognition of donor-HLA molecules by the recipient’s 
immune system generates an immune response that in renal transplantation, may lead 
to allograft rejection. The relevance of compatibility for ABO and HLA in rejection has 
been known for decades. Most of the immunosuppressive reagents used nowadays 
target the cellular rejection response; humoral rejection however is still a matter of 
concern. In this thesis, we focus our attention on the humoral or antibody-mediated 
immune response in renal transplantation. Already before transplantation contact with 
foreign HLA molecules through blood transfusion or pregnancy may lead to the 
development of HLA antibodies. It is obvious that transplantation itself is a major 
trigger for antibody formation. There is abundant evidence that preformed 
HLA antibodies have a deleterious effect on renal graft outcome as reflected by 
increased rejection rates and lower graft survival in sensitized recipients. Several 
immunological procedures in the field of histocompatibility are in use to detect the 
presence of HLA antibodies, thereby decreasing the rejection rate and increasing graft 
survival. Some of these procedures are screening for HLA antibodies before 
transplantation, matching the HLA antigens of recipient and final donor and 
performance of different cross-matches before the donor-kidney is transplanted. 
There is a high correlation between the degree of HLA matching and sensitization. 
Antibodies produced after renal transplantation constitute a risk factor for acute and 
chronic rejection. A poor HLA match decreases the chances of finding a second cross-
match-negative donor and prolongs the waiting time for re-transplantation. Preformed 
cytotoxic donor-specific HLA antibodies cause hyperacute rejection, leading to loss of 
graft function within minutes to hours after reperfusion. CDC-crossmatches of patient 
sera and donor cells to identify donor-specific antibodies, are routinely performed 
before transplantation and hyperacute rejection has thus become a rare event in renal 
transplantation. To prevent positive pretransplant crossmatches, all sera from 
recipients on the waiting list are tested for the presence and specificity of 
HLA antibodies. The specificities detected in the serum are considered non-acceptable 
mismatches. 
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Our understanding of sensitization in renal patients, the clinical relevance of 
HLA antibodies and the available antibody detection and crossmatching techniques 
have evolved considerably during the last 40 years. In Chapter 2, the different 
techniques for antibody detection that have been used over the years are described, 
with special emphasis on the recently introduced bead-based antibody detection 
technology. This Luminex Single antigen technique uses beads coated with purified 
HLA molecules, as its target for antibody detection. It is shown to be more sensitive 
and specific in detecting HLA antibodies than the CDC and ELISA assays. Interpretation 
has become an important factor in discriminating clinically relevant from clinically non-
relevant antibodies. The cut-off point for positivity of the Luminex Single antigen assay 
has to be defined by its user and for that reason may differ considerably between 
laboratories. To clarify how the results of the assay compare to those of the CDC assay, 
we have tested 103 HLA typing sera with well-known CDC specificities and 
CDC reaction strength in the Luminex Single antigen class I and II assay. For each serum 
the main CDC specificity and, if present, the extra specificities, were categorized 
according to their MFI value. Altogether 99% of all class I CDC specificities had an MFI 
value of 4000 or more, as did 93% of all class II CDC specificities when tested with the 
Luminex Single antigen assay. Based on the results, it was decided in our centre, that 
the cut-off point for positivity of the Luminex Single antigen assay would be 4000 MFI 
for clinical transplant purposes. With this cut-off point all specificities detected by CDC 
are covered and considered as non-acceptable antigens for a transplant recipient.   
 
In Chapter 3, the clinical relevance of preformed DSA detected by the Luminex Single 
antigen assay, is studied in a group of highly sensitized recipients transplanted in the 
AM program. Recipients with a sensitization of 85% or more panelreactive antibodies 
(PRA) are highly sensitized (HS) and have a lower chance of receiving a kidney donor. 
For this type of recipients, desensitization protocols have been designed with the 
intention to remove their HLA antibodies in order to increase their probability of 
finding a crossmatch-negative donor. Within Eurotransplant (ET) a special program was 
developed, the Acceptable Mismatch (AM) program, to facilitate renal transplantation 
in HS recipients. For highly sensitized recipients (current or historical sensitization 85% 
PRA or more), acceptable HLA mismatches, i.e. antigens to which the recipients had 
never made antibodies, are determined. The patients are entered on a special waiting 
list that gives them priority to blood-group-compatible donors that are HLA-A, -B and 
-DR matched with their own HLA antigens, including the AM antigens. Up till now, the 
standard technique for the determination of the AM antigens was based on the 
CDC technique, the same assay in which the pre-transplant crossmatch was 
performed. From 34 AM patients, 27 were transplanted with 1-5 mismatches and 7 
with 0 mismatches, for all 34 patients the pre-transplant and peak sera were retested 
with LSA. From the mismatched patients 13 proved to possess pre-transplant DSA 
detected by Luminex Single antigen assay, while 14 did not. No DSA were found in the 
0 mismatched group as expected. Comparison of the DSA-positive and DSA-negative 
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patients in the mismatched group revealed a trend towards earlier and more frequent 
rejection episodes in DSA positive patients (P=0.08). No detrimental effect of DSA on 
graft survival was observed. This single centre study showed that in the AM program, 
DDA detected by LSA and not by less sensitive methods, may be related to acute 
rejection episodes but are not detrimental to long-term graft outcome. These findings 
question the indiscriminate use of more sensitive screening techniques for the 
allocation of organs, more specifically the interpretation of the findings. 
 
Chapter 4 describes the prevalence, time of appearance, and HLA class of DSA in a 
consecutive group of patients transplanted between 1995 and 1999. All 140 renal 
recipients had no pre-transplant DSA, at least one year of renal function and an 
extensive follow-up period of up to 14 years. Multiple serum samples (n=1107) of all 
patients were tested for “de novo” DSA with the Luminex Single antigen assay. The 
presence of DSA after transplantation and before graft failure was shown in 224 serum 
samples of 35 recipients. In 17 patients DSA were shown that were present only for a 
short period of time and did not reappear, so-called “transient” DSA. Median 
fluorescence values (MFI) in the Single antigen assay differed considerably for 
persistent and transient DSA, the median values being 12.000 and 3.000 respectively. 
In multivariate analysis the presence of class II DSA after the first year post-transplant 
proved to be the only independent risk factor for graft failure (OR=3.2). For transient 
DSA patients no difference was found between class I and II positivity, both had the 
same risk of graft failure as DSA negative recipients. From this study, we concluded 
that class II DSA positivity was predictive of graft failure if appearing after the first year 
post-transplant. The presence of “transient” DSA did not affect graft failure. Persistent 
DSA was shown to have four times higher MFI values; nevertheless many DSA positive 
patients had grafts with stable function.  
 
In Chapter 5 the appearance of DSA was analyzed in relation to patient and graft 
characteristics in a group of patients who lost their graft at different time points after 
transplantation. Pre- and post-transplant sera of 56 CDC-negative first transplant 
patients were screened for HLA class I and II DSA by the Luminex Single antigen assay. 
Three out of 56 patients proved DSA positive before transplantation. 81% of the 
remaining 53 patients became DSA class I and/or II positive; 16% before and 84% after 
transplantectomy. Class I antibodies were produced in 84% and class II in 77% of the 
recipients. Based on the time of transplantectomy the recipients were divided into 
3 groups: those who lost their graft (1) within one month, (2) between one and six 
months and (3) after more than six months. The groups proved to be significantly 
different for HLA class II mismatch and acute rejection. All recipients in group 2 were 
DSA positive. Median time of DSA appearance was four months after 
transplantectomy. Logistic regression analysis showed that DSA positivity for class I 
was related to higher donor age and donor type (non-heart-beating), class II to higher 
donor age and class II mismatch. Donor-directed HLA antibodies after transplantation 
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were demonstrated in 81% of first transplant recipients. The majority of the antibodies 
were found after transplantectomy. These findings should be taken into consideration 
in allocating organs of marginal donors, such as older or non-heart-beating kidneys. 
 
The major advantage of the Luminex Single antigen assay is that it allows accurate 
evaluation of sera containing complex mixtures of antibodies. Class I and class II 
antibodies are clearly discriminated. Furthermore, antibodies directed against 
HLA-DRB3, 4, 5, HLA-DQ and HLA-DP are discriminated from reactivity against HLA-DR, 
which was difficult or even impossible using the former standard techniques. HLA-DP is 
considered a target for the humoral immune response in clinical transplantation. In 
Chapter 6, the incidence, time of development and epitope-specificity of HLA-DP 
antibodies in renal patients are examined, Pre- and post-transplant sera of 
338 patients were screened for HLA-DP antibodies using the Luminex Single antigen 
assay. Patients with DP antibodies, their partners and/or kidney donors were HLA-DP 
typed by SSO. Potential epitopes were mapped by comparing the amino acid 
sequences of HLA-DP hypervariable regions (HVR) A-F of recipient, partner and/or 
donor. Specificities in the sera were aligned to deduce the HVR motif responsible for 
the antibodies. DP antibodies were detected in 48 out of 338 patients (14%). Before 
transplantation, 23% (10 females and one male) was found positive, 77% after 
transplantation (30 after the first, 7 after the second graft). Specificities were never 
restricted to individual mismatched antigens; broad HLA-DP sensitization was found as 
a rule. A single HVR mismatch was present in 80% of the DSA and in 79% of the non-
DSA. Our findings confirm that HLA-DP antibodies are specific for epitopes shared by 
different HLA-DP antigens, indicating that only a restricted number of mismatched 
epitopes are recognized by the recipient’s immune system. These results suggest that 
matching for immunogenic HLA-DP epitopes for renal transplantation is possibly more 
relevant than classical matching at the allelic level.  
 
Chapter 7 reports on the Luminex Crossmatch and compares the results obtained with 
those from flow-cytometric crossmatches. In Luminex bead-based screening assays, 
color-coded microspheres coated with HLA antigens are used to identify both 
complement-binding and non-complement-binding HLA class I and II antibodies in 
recipient sera. Many laboratories rely on all specificities detected and use that 
information for allocation of donor organs. A donor-specific (DS) crossmatch in the 
Luminex technique is therefore desirable. The Luminex DS crossmatch (LumXm), in 
which the actual donor-HLA antigens are coated onto specific capture beads, was 
tested for 88 pre- and post-transplant sera of 18 recipients. The results were compared 
to previously published flow cytometric crossmatch (FCXm) results for the same donor-
recipient combinations. All sera were also examined by the Luminex Single antigen (SA) 
assays. Class I LumXm detected 24/27 T-cell positive FCXm (89%) and class II 15/22 B-
cell positive FCXm (68%). Sensitivity of LumXm for class I and II was 89% and 68% 
respectively, specificity 98% and 97%. Discrepant LumXm results were obtained in 13 
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sera of 9 patients (15%). In general, based on LSA testing, FCXm showed false positive 
results for class I, LumXm gave false negative and positive results for class II. The 
LumXm test was proven not to react with recipient sera containing DQ antibodies only, 
also DP detection was insufficient. The validity of the LumXm has been shown for class 
I, but its value for class II is uncertain. HLA-DR is most probably correctly identified, 
-DQ and -DP are not.    
 
In Chapter 8, the clinical significance of the Luminex Crossmatch is evaluated over a 
4-year period in a group of renal recipients, transplanted on the basis of a negative 
CDC crossmatch. The clinical significance of the presence of donor-specific anti-HLA 
antibodies prior to renal transplantation detected solely by solid-phase techniques 
remains unclear. A group of 165 patients transplanted between 1997 and 2001, with a 
negative CDC crossmatch, was tested. 32/165 recipients proved to have a positive 
LumXm. Sixteen were positive for class I, 15 for class II, one was both class I and II 
positive and 133 recipients were negative. Acute rejection-free survival for all 
recipients was 77%, there was no difference in acute rejection-free survival between 
LumXm-positive and -negative recipients. Overall graft survival after a median follow-
up time of 8 years was 56%. Recipients with a positive class I LumXm had worse long-
term graft survival (P=0.006), 5-year graft survival was 41% vs. 70% in negative 
patients, and 10-year graft survival was 27% vs. 56%. Positivity for class II LumXm was 
not a significant risk factor for graft failure (P=0.7), however, as stated in chapter 7, the 
value of the class II crossmatch is questionable. In conclusion pre-transplant donor-
specific anti-HLA antibodies detected by the LumXm, had no impact on acute rejection 
episodes. A positive class I LumXm resulted in worse long-term graft survival.  
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Samenvatting 
Het immuunsysteem beschermt ons tegen pathogenen en is opgebouwd uit een 
netwerk van cellen, die betrokken zijn bij de niet-specifieke of bij de antigeen-
specifieke immuunrespons. De eerste is aangeboren, de tweede verworven. Deze 
laatste ook wel adaptieve immuunrespons genoemd, wordt geactiveerd als antigenen 
in combinatie met MHC moleculen herkend worden door antigeen-receptoren op 
lymfocyten. HLA moleculen zijn buitengewoon polymorf en daardoor in staat een grote 
verscheidenheid aan antigenen aan zich te binden en aldus te presenteren aan het 
immuunsysteem. De immuunrespons die daarop volgt, kan cellulair of humoraal zijn. 
Een cellulaire respons treedt op als lichaamsvreemde antigenen gepresenteerd 
worden aan T-cellen door HLA moleculen, die aanwezig zijn op APC’s. De humorale 
respons wordt geïnitieerd door B-cellen en leidt tot de productie van antistoffen tegen 
het lichaamsvreemde antigeen. 
 
In Hoofdstuk 1 wordt besproken hoe, bij niertransplantatie, de herkenning van 
lichaamsvreemde donor-HLA moleculen door het immuunsysteem van de ontvanger 
een immuunrespons opwekt, die kan leiden tot afstoting van de transplantaatnier. Het 
is al geruime tijd bekend dat compatibiliteit voor zowel ABO als voor HLA een 
belangrijke rol speelt bij het afstotingsproces na niertransplantatie. Het merendeel van 
de anti-afstotingsmedicatie na transplantatie is bedoeld om cellulaire afstoting te 
voorkomen, tegen humorale afstoting bestaat geen afdoende medicatie. Dit 
proefschrift gaat over de humorale of antistof-gemedieerde, immuunrespons na 
niertransplantatie. Contact met lichaamsvreemde HLA moleculen, door bloed-
transfusie of zwangerschap, kan leiden tot de ontwikkeling van HLA antilichamen. 
Maar met name transplantatie brengt vaak antistofvorming op gang. Er is een 
overvloed aan bewijs voorhanden, dat laat zien dat HLA antistoffen die al aanwezig zijn 
vóór de transplantatie, een negatief effect hebben op de overleving van het 
transplantaat; ontvangers met antistoffen hebben vaker afstotingsverschijnselen en 
hebben een lagere transplantaatoverleving. Weefseltyperingslaboratoria gebruiken 
een aantal immunologische procedures om HLA antistoffen vóór en na transplantatie 
op te sporen, en zo de kans op afstoting te voorkomen en de transplantaatoverleving 
te vergroten. Zulke procedures zijn bijvoorbeeld het onderzoeken van patiëntensera 
op HLA antistoffen vóór transplantatie, het matchen van de HLA antigenen van donor 
en ontvanger en het uitvoeren van verschillende kruisproeven tussen donor en 
ontvanger voordat de uiteindelijke transplantatie plaatsvindt. Er bestaat een duidelijke 
correlatie tussen de mate van HLA match van donor en ontvanger en de kans op 
vorming van HLA antistoffen na transplantatie. HLA antistoffen die gevormd worden na 
transplantatie, vormen een risico voor het optreden van acute en chronische afstoting. 
Een initiële geringe HLA match verhoogt de kans op de vorming van HLA antistoffen en 
verlaagt daarmee de kans op het vinden van een geschikte volgende donor. Het wordt 
moeilijker een kruisproef-negatieve donor te vinden en dat verlengd de wachttijd voor 
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retransplantatie. Cytotoxische donorspecifieke HLA antistoffen aanwezig vóór 
transplantatie kunnen leiden tot hyperacute afstoting en daaropvolgend verlies van 
transplantaatfunctie. Daarom worden CDC kruisproeven met patiëntensera en 
donorcellen uitgevoerd, voordat de transplantatie doorgang kan vinden. Om positieve 
kruisproeven te voorkomen, worden alle ontvangers op de wachtlijst getest op de 
aanwezigheid van HLA antistoffen. De HLA antigenen waartegen eventuele antistoffen 
zijn gericht worden geregistreerd als niet-acceptabele mismatches voor de patiënt.  
 
Onze kennis over de klinische relevantie van HLA antistoffen bij nierpatiënten en de 
methodes voor het opsporen ervan, hebben de laatste 40 jaar een duidelijke evolutie 
doorgemaakt. In Hoofdstuk 2 worden de verschillende technieken, die gebruikt zijn of 
nog steeds gebruikt worden, beschreven. Speciale aandacht wordt besteed aan de 
recent geïntroduceerde Luminex techniek, waarbij beads met daaraan HLA moleculen 
gekoppeld, worden gebruikt om antistoffen aan te tonen. Deze techniek is gevoeliger 
en specifieker dan de al langer in gebruik zijnde CDC en ELISA testen. De interpretatie 
van de Luminex resultaten is een belangrijke factor geworden bij het onderscheid 
tussen klinisch relevante en irrelevante antistoffen. Een probleem is het cut-off point 
voor positiviteit dat gedefinieerd moet worden door de gebruiker zelf, daardoor kan 
variëren van het ene laboratorium tot de andere. Om de resultaten verkregen met 
deze techniek te vergelijken met de resultaten verkregen met de CDC techniek, 
werden 103 cytotoxische HLA typeersera (uitvoerig bekend in CDC), getest door middel 
van Luminex SA. Voor elke serum werden de belangrijkste CDC specificiteiten 
gerangschikt op MFI waarde verkregen met SA. De MFI waarde van 99% van alle 
klasse I en 93% van de klasse II CDC specificiteiten was groter dan 4000. Daarom werd 
in ons transplantatiecentrum de cut-off voor positiviteit vastgelegd op 4000 MFI. 
 
In Hoofdstuk 3 wordt de klinische relevantie van donorspecifieke antistoffen voor 
transplantatie, die alleen aantoonbaar zijn met Luminex SA, onderzocht bij patiënten 
getransplanteerd in het AM programma. Binnen Eurotransplant werd het AM 
programma ontwikkeld om de transplantatiekans van deze hooggeïmmuniseerde 
patiënten te vergroten. Ontvangers met een huidige of historische PRA hoger dan 85% 
worden met hun zogenoemde acceptabele mismatches, dit zijn HLA antigenen 
waartegen de ontvanger nooit antistoffen heeft gevormd, op een speciale wachtlijst 
gezet. Wanneer een ABO compatibele donor, waarvan de HLA-A, -B en –DR antigenen 
overeenkomen met hun eigen en/of AM antigenen, beschikbaar is, krijgen de AM 
patienten voorrang bij de allocatie van die donor. Tot nu toe was de CDC, die ook 
gebruikt wordt voor de pretransplantatie kruisproeven, de standaard techniek voor 
het bepalen van AM antigenen. Van de in totaal 34 patiënten getransplanteerd binnen 
het AM programma in Maastricht, werden er 27 getransplanteerd met 1 tot 5 en 7 met 
0 mismatches. Het pretransplantatie serum en historisch piekserum van deze 
patiënten werden hertest met Luminex SA. Van de 27 patiënten die getransplanteerd 
werden met 1-5 mismatches, werden bij 13 patienten DSA gevonden en bij 14 niet. 
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Zoals verwacht werden er geen DSA gevonden bij de patiënten die getransplanteerd 
waren zonder mismatch. In de gemismatchte groep hadden de patiënten met DSA een 
trend tot vroegere en frequentere afstotingsverschijnselen (P=0.08). DSA bleek echter 
geen nadelig effect te hebben op transplantaatoverleving. Uit deze studie blijkt dat bij 
patienten in het AM programma, DSA gedetecteerd met Luminex SA en niet met 
minder gevoelige technieken, gerelateerd zouden kunnen zijn aan afstotings-
verschijnselen, maar dat zij de lange termijn transplantaatoverleving niet beïnvloeden. 
Deze bevindingen stellen vraagtekens bij onbedachtzaam gebruik van gevoelige 
screeningsmethodes en de interpretatie ervan bij orgaanallocatie. 
 
Hoofdstuk 4 beschrijft het vóórkomen van DSA, het tijdstip van verschijnen en de HLA 
klasse ervan in een groep van 140 patiënten getransplanteerd in Maastricht tussen 
1995 en 1999. De 140 ontvangers hadden geen HLA antistoffen vóór transplantatie, 
hun nier functioneerde tenminste 1 jaar en de follow-up tijd bedroeg tot 14 jaar. 
Meerdere sera (n=1107) van de patiënten werden getest op de ontwikkeling van “de 
novo” (nieuwgevormde) DSA met behulp van Luminex SA. De aanwezigheid van DSA 
na transplantatie en voor transplantaatfalen werd aangetoond in 224 sera van 35 
patiënten. In 17 van deze patiënten was het DSA slechts korte tijd aantoonbaar 
(“transient” DSA). De MFI values van transient DSA waren aanzienlijk lager (3000 MFI) 
dan die van persisterende DSA (12000 MFI). Multivariaat analyse toonde aan dat de 
aanwezigheid van klasse II DSA na het eerste jaar posttransplantatie, de enige 
onafhankelijke risicofactor was voor falen van het transplantaat (OR=3.2). Patiënten 
met transient klasse I of klasse II DSA hadden een risico op transplantaatfalen 
vergelijkbaar met dat van patiënten zonder DSA. Uit deze studie concludeerden wij, 
dat klasse II DSA, ontstaan of reeds aanwezig na het eerste jaar posttransplantatie, 
voorspellend zijn voor transplantaatfalen. De aanwezigheid van transient DSA had 
geen invloed op falen. De MFI waardes van persisterend DSA waren 4 maal hoger dan 
die van transient DSA, maar desondanks hadden veel patiënten een stabiele 
transplantaatfunctie in aanwezigheid van DSA.  
 
In Hoofdstuk 5 wordt het verschijnen van DSA geanalyseerd aan de hand van patiënt- 
en transplantaatkenmerken in een groep patiënten, die een transplantectomie 
ondergingen. Pre- en posttransplantatie sera van 56 patiënten, die een eerste nier 
ontvingen en geen CDC detecteerbare antistoffen hadden, werden opnieuw getest 
met Luminex SA. Drie van hen toonden DSA voor transplantatie, 43 patiënten 
ontwikkelden DSA na transplantatie. Van de 43 DSA positieve patiënten werden de 
DSA in 16% voor en in 84% na transplantectomie gevonden. Klasse I HLA antistoffen 
waren aanwezig in 84% en klasse II HLA antistoffen in 77%. De ontvangers werden 
onderverdeeld in 3 groepen op basis van het tijdstip waarop ze hun transplantectomie 
ondergingen: binnen 1 maand na transplantatie (1), tussen 1 en 6 maanden (2) en na 
meer dan 6 maanden (3). De 3 groepen verschilden significant wat betreft HLA klasse II 
mismatch en acute afstoting. Bij alle ontvangers in groep 2 werden DSA gevonden. DSA 
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verschenen gemiddeld vier maanden na transplantectomie. Uit logistische regressie 
analyse bleek dat positiviteit voor klasse I gerelateerd was aan hogere donorleeftijd en 
donortype (NHB), en positiviteit voor klasse II aan hogere donorleeftijd en klasse II 
mismatch. DSA na transplantatie werden gedetecteerd bij 81% van de ontvangers van 
een eerste nier. Het merendeel van de antistoffen werd pas aangetoond na 
transplantectomie. Met deze bevindingen zou rekening gehouden moeten worden bij 
de allocatie van nieren van marginale donoren, zoals oudere donoren en NHB 
donoren.  
 
Het belangrijkste voordeel van Luminex SA is, dat het een nauwkeurige evaluatie 
toelaat van sera, die een complex mengsel van antistoffen bevatten. Klasse I en klasse 
II antistoffen kunnen duidelijk van elkaar onderscheiden worden. Zelfs antistoffen 
gericht tegen HLA-DRB3,4,5, HLA-DQ en HLA-DP kunnen onderscheiden worden van 
antistoffen gericht tegen HLA-DR, iets wat voorheen met de standaard technieken op 
zijn minst moeilijk zoniet onmogelijk was. Ook HLA-DP is een mogelijk doelwit voor de 
humorale immuunrespons bij klinische transplantatie. In Hoofdstuk 6 worden de 
incidentie, het tijdstip van verschijnen en de epitoop-specificiteit van HLA-DP 
antistoffen bij nierpatiënten onderzocht. Pre- en posttransplantatie sera van 
338 patiënten werden getest op de aanwezigheid van antistoffen gericht tegen HLA-DP 
met behulp van SA. Patiënten met DP antistoffen werden getypeerd voor HLA-DP met 
behulp van SSO, evenals hun partners en/of nierdonoren. De aminozuursequenties van 
de HVR A-F van HLA-DP van patiënt, partner en/of donor werden met elkaar 
vergeleken om potentiële epitopen voor antistofvorming te bepalen. De in sera 
gevonden HLA-DP specificiteiten werden vergeleken om de HVR verantwoordelijk voor 
de antistofvorming af te leiden. 48 van de 338 (14%) patiënten hadden DP antistoffen, 
23% van de antistoffen werd gevonden voor transplantatie, 77% erna. De gevonden 
specificiteiten waren nooit uitsluitend gericht tegen de gemismatchte DP antigenen. 
80% van de DSA en 79% van de NDSA werden veroorzaakt door 1 enkele HVR 
mismatch. Dit lijkt erop te wijzen dat slechts een beperkt aantal van de gemismatchte 
epitopen herkend worden door het immuunsysteem van de ontvanger. Deze 
resultaten tonen aan dat bij niertransplantatie, matchen voor immunogene HLA-DP 
epitopen, mogelijk relevanter is dan klassiek matchen op allel niveau.  
 
Hoofdstuk 7 beschrijft de Luminex kruisproef en de resultaten ervan worden 
vergeleken met die verkregen met behulp van flow cytometrische kruisproeven. De 
Luminex techniek maakt gebruik van kleurgecodeerde microbeads met daarop HLA 
antigenen gehecht, om complement-bindende en niet-complement-bindende HLA 
klasse I en II antistoffen aan te tonen in patiëntensera. Veel laboratoria gebruiken deze 
techniek om sera te screenen en houden rekening met de verkregen informatie bij de 
allocatie van donornieren. Een kruisproef in dezelfde techniek is daarom wenselijk. De 
LumXm, waarbij de HLA antigenen van de donor aan beads gekoppeld worden, werd 
getest met behulp van 88 pre- en posttransplantatiesera van 18 patiënten. De 
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resultaten werden vergeleken met resultaten van flow cytometrische kruisproeven 
uitgevoerd met dezelfde patiëntensera en donorcellen. De sera werden eveneens 
getest met SA. Een positieve klasse I LumXm werd gevonden bij 24 van de 27 (89%) 
T-cel positieve FCXm en een positieve klasse II LumXm bij 15 van de 22 (68%) B-cel 
positieve FcXm. De sensitiviteit van de LumXm bedroeg 89% voor klasse I en 68% voor 
klasse II, de specificiteit voor klasse I was 98% en voor klasse II 97%. In 13 sera (15%) 
van 9 patiënten werd een discrepantie tussen de FCXm en LumXm resultaten 
gevonden. Wanneer de SA screeningsresultaten van de sera erbij betrokken werden, 
kon geconcludeerd worden dat de FcXm vals positieve resultaten opleverde voor 
klasse I en de LumXm vals negatieve en vals positieve resultaten voor klasse II. De 
LumXm toonde geen HLA-DQ antistoffen aan en ook de detectie van HLA-DP 
antistoffen was onvoldoende. Samenvattend waren de resultaten van de klasse I 
LumXm bevredigend, maar die van de klasse II LumXm twijfelachtig; antistoffen tegen 
HLA-DR werden aangetoond, antistoffen tegen HLA-DQ en –DP niet.  
 
In Hoofdstuk 8 wordt de klinische relevantie van de LumXm geëvalueerd in een groep 
nierpatiënten getransplanteerd met een negatieve CDC kruisproef over een periode 
van 4 jaar. De klinische betekenis van pretransplantatie DSA, die alleen aantoonbaar is 
met behulp van gevoelige solid-phase technieken is nog steeds onduidelijk. De 
pretransplantatiesera van 165 patiënten getransplanteerd op basis van een negatieve 
CDC kruisproef tussen 1997 en 2001, werden getest met de LumXm. 32 van de 165 
patiënten hadden een positive LumXm; 16 klasse I, 15 klasse II en een klasse I en II. 133 
patienten hadden een negatieve LumXm. Acute rejectie-vrije overleving in de hele 
groep was 77%, er was geen verschil tussen patiënten met een positieve of negatieve 
LumXm. De transplantaatoverleving bedroeg 56% na 8 jaar (mediaan). Patiënten met 
een positieve klasse I LumXm hadden een slechtere transplantaatoverleving (P=0.006); 
de 5-jaars transplantaatoverleving in patiënten met een positive klasse I LumXm 
bedroeg 41%, die in patiënten met een negatieve klasse II LumXm 70%. De 10-jaars 
transplantaatoverleving bedroeg 27 versus 56%. Een positieve klasse II LumXm leek 
geen risicofactor voor transplantaatfalen (P=0.7), hierbij dient echter rekening 
gehouden te worden met het feit dat de waarde van de klasse II LumXm twijfelachtig 
is. DSA aanwezig voor transplantatie, en alleen aantoonbaar met LumXm, hebben geen 
invloed op afstoting. Een positieve klasse I LumXm resulteert in een slechtere lange 
termijn transplantaatoverleving.    
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Abbreviations 
AHG  anti-human globulin 
AM  acceptable mismatch (es) 
APC  antigen-presenting cell 
AR  acute rejection 
ATG  anti-thymocyte globulin 
AZA  azathioprine 
B1  immature B-cell 
B2  mature B-cell 
Β2m  Β2 microglobulin 
BCR  B-cell receptor 
CD  cluster of differentiation 
CDC  complement-dependent cytotoxicity 
CI  confidence interval 
CIT  cold ischemia time 
CNI  calcineurine inhibitors 
DCB  donation after cardiac death 
DDA  donor-directed antibody 
DGF  delayed graft function 
DNA  deoxyribonucleic acid 
DSA  donor-specific antibody 
DTT  dithiotreitol 
EBV  Epstein-Barr virus 
EFI  European Federation for Immunogenetics 
ELISA  enzyme-linked immunosorbent assay 
ESDP  Eurotransplant Senior DR-compatible program 
ESP  Eurotransplant Senior program 
ET  Eurotransplant 
FITC  fluorescein isothiocyanate 
HB  heart-beating 
HLA  human leukocyte antigen 
HS  highly sensitized 
HVR  hypervariable region 
Ig  immunoglobulin 
IL2  interleukine-2 
LSA  Luminex Single antigen assay 
MESF  molecules of equivalent soluble fluorophores 
MFI  median fluorescence intensity 
MHC  major histocompatibility complex 
MICA  MHC class I chain-related molecules 
MMF  mycophenolate mofetil 
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NAM  non-acceptable mismatch (es) 
NDSA  non-DSA 
NHB  non-heart-beating 
NIH  National Institute of Health 
NK   natural killer  
OR  odds ratio 
PBL  peripheral blood lymphocyte 
PCR  polymerase chain reaction 
PE  phyco-erythrin 
PRA  panel reactive antibody 
PRED  prednisone 
RAPA  rapamycine 
RT  room temperature 
SAPE  phyco-erythrin-conjugated streptavidin 
SBT  sequence based typing 
SSOP  sequence specific oligonucleotide probes 
SSP  sequence specific primers 
TCR  T-cell receptor 
TX  renal transplantation 
Xm  crossmatch 
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Dankwoord 
Promoveren doe je niet alleen. Vele mensen hebben me bij mij promotieonderzoek 
met raad en daad bijgestaan. Op deze plaats wil ik iedereen die direct of indirect zijn 
steentje heeft bijgedragen aan de totstandkoming van dit boekje bedanken, een aantal 
mensen in het bijzonder. 
 
Allereerst mijn promotor, Prof. dr. Ella van den Berg-Loonen. Beste Ella, jij hebt een 
nieuwe wending aan mijn loopbaan en leven gegeven door me in 2007 voor te stellen 
samen een promotieonderzoek te starten. Het is bewonderenswaardig dat je dit 
project hebt aangevat na je carrière bij de afdeling Weefseltypering. Bedankt voor de 
vele uren die we bij jou thuis, met vers gebak binnen handbereik, samen met Maarten 
hebben doorgebracht. Ik apprecieer je efficiënte manier van werken enorm en na onze 
overlegmomenten had ik telkens weer frisse moed om er tegen aan te gaan. Ik sta nog 
steeds versteld van hoe snel je mijn versie van een manuscript leesbaarder en 
helderder wist te maken. Jouw toewijding voor en kennis van de transplantatie-
immunologie waren een bron van motivatie en inspiratie voor mij. Ik zal je nooit 
genoeg kunnen bedanken voor alles wat je voor me gedaan hebt. 
 
Mijn co-promotor, Dr. Maarten Christiaans. Maarten, steeds weer vond je ondanks je 
overvolle agenda tijd voor me. Al had je honderd en één andere dingen aan je hoofd, 
steeds gaf je me het gevoel dat mijn onderzoek het belangrijkste was. Je schijnbaar 
onuitputtelijk bron van enthousiasme en energie werkte aanstekelijk. Je bent niet 
alleen een goede nefroloog maar hebt ook nog eens een bewonderenswaardige kennis 
van statistiek en weefseltypering. Zonder jouw inzet, oog voor detail en 
onvoorwaardelijke steun was dit proefschrift er niet geweest. Hartelijk dank voor alles. 
 
Vervolgens gaat mijn dank uit naar de leden van de beoordelingscommissie, Prof. dr. 
J.P. van Hooff (voorzitter), Prof. dr. C.A. Bruggeman, Prof. dr. I.I.N. Doxiadis, Dr. M. 
Emonds en Prof. dr. L.W.E. van Heurn, voor hun bereidwilligheid mijn manuscript te 
beoordelen.  
 
Van de afdeling weefseltypering (transplantatie-immunologie) wil ik het secretariaat 
bedanken. Diana, voor alle hulp bij de lay-out en inzending van manuscripten, en 
Mieke, voor het nauwkeurig voorbereiden van afspraken en congressen, het 
inschrijven van literatuur in endnote en het opzoeken van patiëntenstatussen. Het 
afdelingshoofd, Prof. dr. Marcel Tilanus, die in de afrondingsfase mijn tweede 
promotor is geworden, wil ik bedanken voor zijn bijdrage aan de voorbereiding op de 
verdediging. Alle (oud-)collega’s wil ik bedanken voor de gezellige momenten en 
prettige samenwerking. In het bijzonder Christel, die in de loop der jaren een vriendin 
geworden is en me door heel wat moeilijke momenten geholpen heeft. 
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Van de afdeling Nefrologie, wil ik de secretaresses Anke en Etienne, en Monique, de 
onderzoeksassistente, bedanken voor het zoeken en doornemen van groene lijsten en 
het uiterst nauwkeurig vervolledigen van patiëntengegevens. En uiteraard Tiny, voor 
het verzorgen van de lay-out van dit boekje. Zonder jouw toewijding, oog voor detail 
en goede raad was dit boekje nooit zo mooi geworden.  
 
Mijn familie, vrienden en kennissen, bedankt voor jullie belangstelling de afgelopen 
jaren. In het bijzonder mijn zus Pascale, die mij op mijn grote dag bijstaat als paranimf. 
En mijn ouders, aan wie ik dit proefschrift opdraag. Zonder jullie betrokkenheid, steun, 
vertrouwen en liefde zou ik mijn ambities niet hebben kunnen waarmaken. 
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Curriculum Vitae 
Evy Veronicque Anne-Marie Billen was born on January 7, 1980 in Hasselt. After she 
finished secondary school (Humaniora Virga Jesse, Hasselt) in 1998, she studied 
Biology at the University of Hasselt for one year. Subsequently, she continued with 
biomedical sciences at the faculty of Medicine of the Universities of Hasselt and 
Leuven and graduated in 2003. Her study was completed with a training period at the 
Centre of Fertility of the University hospital in Leuven, where she investigated 
prostate-specific antigen in sperm. After graduation she worked as a senior research 
technician at the Tissue Typing Laboratory of the University Hospital Maastricht. In 
October 2007 she started her PhD project under the supervision of Prof. dr. P.M. van 
den Berg-Loonen and Dr. M.H.L. Christiaans, later joined by Prof. dr. M. Tilanus. The 
study focused on the presence and detection of HLA antibodies and their relevance for 
patients undergoing kidney transplantation. The results are described in this thesis. 
